AU2008223066A1 - Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders - Google Patents

Description

WO 2008/109437 PCT/US2008/055495 COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS This invention was made with government support under Grant No. AG028561 and Grant No. NS044998 awarded by the "National Institute of Health." The U.S. government has certain rights in the invention. 5 FIELD OF INVENTION The invention relates to compositions and methods for treatment of patients with seizure-related disorders, especially epilepsy. BACKGROUND OF INVENTION Epilepsy is a common but devastating disorder that affects millions of people 10 worldwide. Epilepsy is a chronic neurological condition characterized by transient but recurring excessive or abnormal disruptions to neural activity. These disruptions can be manifested as motor, convulsion, sensory or psychic symptoms, particularly in the form of seizures and loss of consciousness. Epilepsy syndromes have been classified into more than 40 distinct types based 15 upon characteristic symptoms, types of seizure, cause, age of onset and EEG patterns. These include, but are not limited to, absence epilepsy, psychomotor epilepsy, temporal lobe epilepsy, frontal lobe epilepsy, occipital lobe epilepsy, parietal lobe epilepsy, Lennox Gastaut syndrome, Rasmussen's encephalitis, childhood absence epilepsy, Ramsay Hunt Syndrome type II, benign epilepsy syndrome, benign infantile encephalopathy, benign 20 neonatal convulsions, early myoclonic encephalopathy, progressive epilepsy and infantile epilepsy. Seizure sufferers are frequently limited in the kinds of activities they may participate in. Seizures can prevent people from driving, working or otherwise participating in much of what society has to offer. Some sufferers have serious seizures so frequently 25 that they are effectively incapacitated. Furthermore, these are often progressive and can be associated with degenerative disorders and conditions. Over time, seizures often become more frequent and more serious, and in particularly severe cases, are likely to lead to deterioration of other brain functions as well as physical impairments. Although a number of anti-convulsive therapies have been developed for the 30 control of epilepsy and other disorders involving seizures, seizures remain uncontrolled in approximately one-third of patients with epilepsy, for example, and treatment failures are 1 WO 2008/109437 PCT/US2008/055495 common (Loscher, W. and Schmidt, D., 2002, Epilepsy Res. 50:3-16). Of even greater importance is that patients often become refractory to a drug over time. In addition, many anti-seizure agents cause unwanted side effects, neurotoxicities, and drug interactions. Accordingly, a continuing need exists for pharmaceutical compositions that treat or prevent 5 conditions involving seizures such as epilepsy, and its associated symptoms with minimal side effects. SUMMARY OF INVENTION The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these 10 compounds as an active component for treating Seizure-Related Disorders, including Epilepsy. The invention provides a composition comprising a pyridazine compound in a therapeutically effective amount for treating a Seizure-Related Disorder in a subject. In particular, the invention provides a composition comprising a pyridazine compound in a 15 therapeutically effective amount for treating Epilepsy in a subject. The compositions of the invention generally comprise a pyridazine compound in a pharmaceutically acceptable carrier, excipient, or vehicle. In aspects, a pharmaceutical composition of the invention comprises a therapeutically effective amount of a pyridazine compound to provide a beneficial effect, 20 in particular a sustained beneficial effect following treatment. In other aspects, a pharmaceutical composition comprises a pyridazine compound with a favorable pharmacological profile which makes the compounds particularly suitable in patients with enhanced need of safety and tolerability such as pediatric patients and/or patients subject to long term treatment. 25 The invention further provides methods for preparing a composition of the invention. In an aspect, the invention provides a method of preparing a pharmaceutical composition comprising a pyridazine compound adapted for use in a disorder disclosed herein. A method can comprise mixing one or more pyridazine compound and optionally a pharmaceutically acceptable carrier, excipient, or vehicle. A pharmaceutically acceptable 30 carrier, excipient, or vehicle may be selected that is effective to physically stabilize the pyridazine compound(s). After compositions have been prepared, they can be placed in an 2 WO 2008/109437 PCT/US2008/055495 appropriate container and labeled for treatment of an indicated condition. For administration of a composition of the invention, such labeling would include amount, frequency, and method of administration. In some aspects, the invention provides methods to make commercially available 5 pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium) suppositories, sterile injectable solutions, and/or sterile packaged powders, which contain a pyridazine compound adapted for use in a disorder disclosed herein. The invention also contemplates the use of one or more pyridazine compound or 10 method of the invention to prevent and/or ameliorate disorder severity, disorder symptoms, and/or reduce periodicity of recurrence of a disorder disclosed herein. Therefore, the invention contemplates the prevention and treatment, in a subject, of a disorder disclosed herein, using a pyridazine compound or a composition of the invention. In particular, the invention provides a method for treating a disorder disclosed 15 herein in a subject comprising administering to the subject a therapeutically effective amount of one or more pyridazine compound or a composition of the invention. A method of the invention can be used therapeutically or prophylactically in a subject susceptible to or having a predisposition to a disorder disclosed herein. In an aspect, the invention provides a method for the prevention and/or intervention 20 of a disorder disclosed herein in a subject comprising administration of at least one pyridazine compound or composition of the invention to the subject. The invention provides a method of treating a disorder disclosed herein comprising administering at least one pyridazine compound or a composition of the invention to a subject in need thereof to thereby produce beneficial effects, in particular sustained 25 beneficial effects following treatment. In an embodiment, the compound or composition is administered orally or systemically. In an aspect, the invention provides a method for ameliorating progression of a disorder or obtaining a less severe stage of a disorder disclosed herein in a subject suffering from such disorder comprising administering a therapeutically effective amount of one or 30 more pyridazine compound or a composition of the invention. 3 WO 2008/109437 PCT/US2008/055495 The invention relates to a method of delaying the progression of a disorder disclosed herein comprising administering a therapeutically effective amount of one or more pyridazine compound or a composition of the invention. The invention also relates to a method of increasing survival of a subject suffering 5 from a disorder disclosed herein comprising administering a therapeutically effective amount of one or more pyridazine compound or a composition of the invention. In an embodiment, the invention relates to a method of improving the lifespan of a subject suffering from a disorder disclosed herein comprising administering a therapeutically effective amount of one or more pyridazine compound or a composition of 10 the invention. In particular embodiments of the invention, the compositions and methods are useful in the prevention, palliation, and/or treatment of Seizure-Related Disorders (e.g. seizures, conduction disturbances, and electroconvulsive disorders) and their manifestations irrespective of the origin of the condition in a subject. 15 The invention provides methods for the prevention, palliation and/or treatment of epilepsy in a pediatric patient comprising inhibiting glial activation. In a particular aspect, the invention provides methods for the prevention, palliation and/or treatment of epilepsy in a pediatric patient comprising reducing pro-inflammatory cytokines (e.g. IL-3 and S100B) following early-life seizures. 20 A treatment method of the invention may be sustained over several days, weeks, months or years thereby having a major beneficial impact on the severity of a disorder or and its complications. The invention also contemplates the use of one or more pyridazine compound as a medicament or for the preparation of a medicament for preventing and/or treating a 25 disorder disclosed herein. The invention additionally provides uses of a pharmaceutical composition of the invention as a medicament or in the preparation of medicaments for the prevention and/or treatment of a disorder disclosed herein. In aspects of the invention, the medicaments provide beneficial effects, preferably sustained beneficial effects following treatment. A 30 medicament may be in a form suitable for consumption by a subject, for example, a pill, tablet, caplet, soft and hard gelatin capsule, lozenge, sachet, cachet, vegicap, liquid drop, 4 WO 2008/109437 PCT/US2008/055495 elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium) suppository, sterile injectable solution, and/or sterile packaged powder. A composition or method of the invention may be administered to a healthy subject or a subject suffering from a disorder disclosed herein. Accordingly, in an embodiment, a 5 pyridazine compound or a composition of the invention is to be administered before or after the onset of symptoms in a subject. The invention also provides a kit comprising a pyridazine compound or a pharmaceutical composition of the invention in kit form. In an aspect, the invention provides a kit comprising one or more pyridazine compound or composition of the 10 invention, a container, and instructions for use in treating and/or preventing a disorder disclosed herein. These and other aspects, features, and advantages of the present invention should be apparent to those skilled in the art from the following detailed description. DESCRIPTION OF THE FIGURES 15 Figure 1. (A) Latency to seizure onset; (B), survival and; (C, D), quantification of neuronal injury following kainic acid (KA)-induced seizures in the immature and adult rat. (A) Latency of seizure onset (minutes ± SEM) on postnatal day (P)15 (KA-PBS) is reduced compared to adult (P45) seizures (PBS-KA). Early-life seizures increase susceptibility to seizures in adulthood shown by reduced latency of seizures in the 'two hit' (P15 and P45) 20 seizure group (KA-KA) compared to the adult seizure (PBS-KA) group. (B) Kaplan-Meier survival curves over 40-day recovery following administration of KA or vehicle (PBS) on P15 are significantly different (log Rank Test, p < 0.05). Survival is significantly decreased in the KA-KA group following the second hit of KA. (C) Representative photomicrograph demonstrating Fluoro-Jade B (FJB) fluorescent dead and dying neurons (green) 25 counterstained with DAPI in the CA1 field of the hippocampus of a 'two-hit (KA-KA) animal. (D) Quantification of FJB-fluorescence after 40-day recovery in the hippocampus of control (PBS-PBS) and KA-PBS groups shows no evidence of injury. 'Two-hit' (KA KA) animals show greater injury compared to adult animals first exposed to KA (PBS KA). (E) Regions of interest for cell counts in axial sections of the hippocampus. Digital 30 images of CA1, CA2, CA3, dentate gyrus (DG), and polymorph dentate gyrus (PoDG) were obtained at low power (lOX). Each image was analyzed for positive staining, and 5 WO 2008/109437 PCT/US2008/055495 results added to represent total hippocampal staining. ***p < 0.001; **p < 0.01 vs PBSPBS by ANOVA. Scale bars, (C) 100 p m; (E) 200 p m. Figure 2. KA-induced seizures increase hippocampal proinflammatory cytokine protein levels after 24-hour recovery. (A) Significant increases in IL-I were present in 5 both newborns (P15 KA) and adults (P45 KA). No intergroup differences were found for IL-6 or TNF-a (B, C). (D) S1OOB levels were significantly increased compared to controls following seizures both in newborns and adults. P values determined by ANOVA. Figure 3. (A) KA-induced seizures in newborns result in impairment in hippocampal-linked-task. Serial measurement of spontaneous alternation of rats in Y-maze 10 after early-life seizures (KA-PBS) shows reduction compared to controls (PBS-PBS) over 40-day recovery. (B-F) KA-induced seizures on P15 result in prolonged increase in hippocampal expression of GFAP on P55. Representative photomicrographs illustrating GFAP immunostaining in the CA1 field of the hippocampus of controls (B, PBS-PBS), early-life seizures (C, KA-PBS), adult seizures (D, PBS-KA), and 'two-hit' (E, KA-KA) 15 animals. Morphology of GFAP-positive astrocytes in the CA1 of KA-PBS, PBS-KA and KA-KA groups resembles activated glia compared controls (PBS-PBS). (F) Quantification of GFAP-immunoreactive cells in combined regions of the hippocampi in the four groups. All three KA-treated groups showed a significant increase in GFAP expression compared to controls. (G-K) KA-induced seizures on P15 result in prolonged increase in 20 hippocampal expression of S1OOB over 40-day recovery. (G-J) Representative photomicrographs illustrating S1OOB immunostaining in the CA1 field of the hippocampus of PBS-PBS (G), KA-PBS (H), PBS-KA (I), and KA-KA (J) animals. (K) Quantification of SlOOB-immunoreactive cells in combined regions of the hippocampi in the four groups. All three KA-treated groups showed a significant increase in S1OOB expression compared 25 to controls. Counterstain is hematoxylin. Insets (B-E; G-J) represent higher magnification photomicrographs of CAl. ***p < 0.001 vs PBS-PBS; **p < 0.01 vs PBS-PBS by ANOVA. Scale bars, (B) 200 pm; Inset (B) 100 pm. Figure 4. KA-induced microglial activation in adult animals is enhanced by early life seizures. (A-D) Representative photomicrographs illustrating Ibal immunostaining in 30 the CA1 field of the hippocampus of PBS-PBS (A), KA-PBS (B), PBS-KA (C) and KA KA (D) animals. Insets (A-D) are higher magnification photomicrographs of CA1. (E) 6 WO 2008/109437 PCT/US2008/055495 Quantification of Ibal-immunoreactive cells in combined regions of the hippocampi in the four groups shows no long-term increase in microglial activation following early-life seizures (KA-PBS). The 'two-hit' (KA-KA) group showed significantly greater microglial activation compared to the adult seizure group (PBS-KA). Values in both groups were 5 increased compared to controls (PBS-PBS). ***p < 0.001 vs PBSPBS; **p < 0.01 vs PBS PBS by ANOVA. Scale bars (A) 200 p m; Insets (A-D) 100 p m. Figure 5. Hippocampal factor H (FH) and clusterin levels following KA exposure. (A) Western blot micrographs and relative quantification of FH blot density demonstrate no significant changes in FH protein levels 24-hr following KA-induced seizures in 10 newborns and adults. (B) Representative photomicrograph of FH immunostaining in the CA1 field of the hippocampus of 'two-hit' (KA-KA) animals on P55. (B inset) Photomicrograph showing a FH-immunoreactive astrocyte. (C) Quantification of FH immunoreactive cells on P55 in combined regions of the hippocampi in the long-term recovery groups shows no significant intergroup differences. (D) Western blot micrographs 15 and relative quantification of clusterin blot density show a significant increase in hippocampal clusterin protein levels 24-hr following seizures on P15 and P45. (E-G) Representative photomicrographs demonstrating clusterin immunostaining in the CA1 field of the hippocampus of long-term recovery groups, controls (E inset, PBS-PBS), early-life seizures (E, KA-PBS), adult seizures (F, PBS-KA; Inset, higher power view of clusterin 20 immunoreactive cells in CAl), and 'two-hit' (G, KA-KA) animals. (H) Quantification of clusterin-immunoreactive cells on P55 in combined regions of the hippocampi in the long term recovery groups shows a significant increase in the 'two-hit' (KA-KA) group compared to the adult seizure (PBS-KA) animals. (I, J) Representative photomicrographs demonstrating that NeuN-positive cells do not co-stain with clusterin. (I) NeuN (gray) and 25 clusterin, (red) do not co-label. (J) Immunofluorescent detection shows a similar pattern of NeuN (green) and clusterin (red). (K) Immunofluorescent double-labeling with GFAP (green) and clusterin (red) shows that clusterin-positive cells are not astrocytes. Clusterin positive cells are Ibal-immunoreactive (L), suggesting that these cells are microglia. (H) ***p < 0.001 vs PBS-PBS by ANOVA. (B) Scale bars (B,F,G) 200 pm; (E, J) 100 pm; 30 (I,L) 50 pm. 7 WO 2008/109437 PCT/US2008/055495 Figure 6. KA-induced seizures in P45 animals result in an increase in glial-specific glutamate transporters, GLAST and GLT-1. (A-C) Representative photomicrographs illustrating GLAST immunostaining in the field CA1 of the hippocampus of PBS-PBS (A inset), KA-PBS (A), PBSKA (B) and KA-KA (C) animals. Inset (C) shows higher power 5 view of GLAST-immunoreactive cells in CA1. (D) Quantification of GLAST immunoreactive cells on P55 in combined regions of the hippocampi in the long-term recovery groups demonstrates increased expression in PBS-KA and KA-KA compared to controls (PBS-PBS). PBS-KA and KA-KA are not significantly different from each other. GLT-1 results were similar to GLAST (data not shown). **p < 0.01 vs PBS-PBS; *p < 10 0.05 vs PBS-PBS by ANOVA. Scale bars 200 pm; (Inset C) 100 pm. Figure 7. (A) Timeline of Minozac (Mzc) administration and Y-maze testing. Following intraperitoneal (ip) administration of either PBS or kainic acid (KA) on P15, animals were treated with Mzc (5 mg/kg, ip) or Saline diluent (Sal), at 3 hr and 9 hr recovery. One cohort of animals from each group (PBS-Sal, KA-Sal and KA-Mzc) was 15 sacrificed at 12 hr for assessment of changes in hippocampal pro-inflammatory cytokines. Remaining animals were allowed to recover for 30 days (P45). In these groups, Y-maze testing for hippocampal-dependent behavior was initiated at weaning age (P21, 6 day recovery) and continued until sacrifice. (B) Serial measurement of spontaneous alternation in Y-maze after early-life seizures shows protection by Mzc over 30 day recovery. ***p < 20 0.001 vs KA-Sal by ANOVA. Figure 8. Effect of Minozac (Mzc) on acute increase in proinflammatory cytokines following KA-induced seizures on P15 (A-D) and glial activation after 30 day recovery (E L). (A) Administration of Mzc following early-life seizures suppressed the acute increase in IL-1 seen in untreated animals (KA-Sal). Similar results were seen for IL-6 (B), TNF-a 25 (C), and S100B (D). Tissues for brain homogenates were collected at 12 hr following KA injection. (E-L) Minozac (Mzc) suppresses long-term glial activation response to KA induced early-life seizures after 30 day recovery from KA exposure on P15. (E-G) Representative photomicrographs of GFAP immunostaining in the CA1 field of control (E, PBS-Sal), early-life seizure (F, KA-Sal) and Mzc-treated (G, KA-Mzc) animals. (H) 30 Quantification of GFAP-positive cells in the hippocampus shows Mzc-treated animals (KA-Mzc) have significantly less glial activation compared to untreated animals (KA-Sal). 8 WO 2008/109437 PCT/US2008/055495 (I-L) Representative photomicrographs of S100B immunostaining in the CA1 field of PBS Sal (I), KA-Sal (J) and KA-Mzc (K) animals. (L) Quantification of S100B-immunopositve cells show that Mzc suppressed the increased S100B expression seen in KA-Sal. Data (D) expressed as % Control ± SEM. Data (H, L) are % immuno-positive cells ± SEM. *p < 5 0.05 vs KA-Sal, **p < 0.01 vs KA-Sal; ***p < 0.001 vs KA-Sal by ANOVA. Scale bars (E) 200 pm; (Insets F,G,J,K) 100 pm. Figure 9. Proposed schema for the role of astrocyte and microglial activation in enhanced seizure susceptibility. Summary of effects of kainate administration on postnatal (P) day 15 (A), and P45 (B) including 'two-hits' (P15 and 45) (B). On P15, a transient 10 increase in proinflammatory cytokines is followed by microglial activation and sustained (40 day) astrocyte activation. A similar pattern of cytokine and microglial activation occurs on P45 when astrocyte glutamate transporters also increase. Importantly, the 'two-hit' group exposed to kainate on P15 and P45 show enhanced microglial activation (B, green dashed line). 15 Figure 10 depicts a production scheme for synthesis of 2-(4-(4-methyl-6 phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine dihydrochloride salt (MW01-9-034WH, also referred to herein as "Minozac"). Reagents and conditions: (a) N2-4, EtOH, reflux, (b) CuCl 2 , CH 3 CN, reflux, (c) POCl 3 , CH 3 CN, reflux, (d) 1-(2-pyrimidyl) piperazine, water, reflux, (e) HCl, isopropanol. 20 DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Numerical ranges recited herein by endpoints include all numbers and fractions subsumed within that range (e.g. I to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also 25 to be understood that all numbers and fractions thereof are presumed to be modified by the term "about." The term "about" means plus or minus 0.1 to 50%, 5-50%, or 10-40%, preferably 10-20%, more preferably 10% or 15%, of the number to which reference is being made. Further, it is to be understood that "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition 30 comprising "a compound" includes a mixture of two or more compounds. 9 WO 2008/109437 PCT/US2008/055495 As used herein the terms "administering" and "administration" refer to a process by which a therapeutically effective amount of a compound or composition contemplated herein is delivered to a subject for prevention and/or treatment purposes. Compositions are administered in accordance with good medical practices taking into account the subject's 5 clinical condition, the site and method of administration, dosage, patient age, sex, body weight, and other factors known to physicians. The term "treating" refers to reversing, alleviating, or inhibiting the progress of a disorder, or one or more symptoms of such disorder, to which such term applies. Depending on the condition of the subject, the term also refers to preventing a disorder, 10 and includes preventing the onset of a disorder, or preventing the symptoms associated with a disorder. A treatment may be either performed in an acute or chronic way. The term also refers to reducing the severity of a disorder or symptoms associated with such disorder prior to affliction with the disorder. Such prevention or reduction of the severity of a disorder prior to affliction refers to administration of a compound or composition of the 15 present invention to a subject that is not at the time of administration afflicted with the disorder. "Preventing" also refers to preventing the recurrence of a disorder or of one or more symptoms associated with such disorder. "Treatment" and "therapeutically," refer to the act of treating, as "treating" is defined above. The purpose of prevention and intervention is to combat the disorder and includes the administration of an active 20 compound to prevent or delay the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disorder. In aspects of the invention where the disorder is epileptogenesis, in particular epilepsy, treatment may comprise (i) partial or complete reversal of epileptogenesis, (ii) prevention of, or decrease or slowing of the rate of epileptogenesis, (iii) inhibition or 25 slowing of the rate of biochemical processes which take place during epileptogenesis; and/or (iv) prevention, slowing, halting and/or reversing the process of epileptogenesis. The terms "subject", "individual", or "patient" are used interchangeably herein and refer to an animal preferably a warm-blooded animal such as a mammal. Mammal includes without limitation any members of the Mammalia. A mammal, as a subject or patient in the 30 present disclosure, can be from the family of Primates, Carnivora, Proboscidea, Perissodactyla, Artiodactyla, Rodentia, and Lagomorpha. In a particular embodiment, the 10 WO 2008/109437 PCT/US2008/055495 mammal is a human. In other embodiments, animals can be treated; the animals can be vertebrates, including both birds and mammals. In aspects of the invention, the terms include domestic animals bred for food or as pets, including equines, bovines, sheep, poultry, fish, porcines, canines, felines, and zoo animals, goats, apes (e.g. gorilla or 5 chimpanzee), and rodents such as rats and mice. In aspects of the invention, the terms refer to organisms to be treated by the methods of the present invention. In the context of particular aspects of the invention, the term "subject" generally refers to an individual who will receive or who has received treatment (e.g., administration of a pyridazine compound(s) or compositions) for a disorder 10 disclosed herein. Typical subjects for treatment include persons afflicted with or suspected of having or being pre-disposed to a disorder disclosed herein, or persons susceptible to, suffering from or that have suffered a disorder disclosed herein. A subject may or may not have a genetic predisposition for a disorder disclosed herein, such as Epilepsy. In certain aspects 15 of the invention the subject is a pediatric patient. In certain aspects, a subject may be a healthy subject. As utilized herein, the term "healthy subject" means a subject, in particular a mammal, having no diagnosed disorder, infirmity, or ailment disclosed herein. As used herein, the terms "co-administration", "combination treatment", and 20 "administering in combination" refer to the administration of one or more pyridazine compound and additional therapeutic agent or therapies to a subject. In aspects, the administration of two or more agents/therapies is concurrent. In other aspects, a first agent/therapy is administered prior to a second agent/therapy. In this aspect, each component may be administered separately, but sufficiently close in time to provide the 25 desired effect, in particular a beneficial, additive, or synergistic effect. The formulations, routes of administration and the appropriate dosage for co-administration can be readily determined by one skilled in the art. In some embodiments, when agents/therapies are co administered, the respective agents/therapies are administered at lower dosages than appropriate for their administration alone. Thus, co-administration is especially desirable in 30 embodiments where the co-administration of the agents/therapies lowers the requisite dosage of a known potentially harmful (e.g., toxic) agent(s). 11 WO 2008/109437 PCT/US2008/055495 A "beneficial effect" refers to an effect of a pyridazine compound or a composition of the invention, including favorable pharmacological and/or therapeutic effects, and improved biological activity. In aspects of the invention, the beneficial effects include without limitation enhanced stability, a longer half life, and/or enhanced uptake. In other 5 aspects the beneficial effects include one or more of the following: (a) reduction or amelioration of neuronal dysfunction or injury following early-life seizures; (b) reduction or suppression of pro-inflammatory cytokines; (c) reduction in astrocyte activation; (d) reduction in GFAP immunoreactive cells; (e) reduction in microglial activation and (f) reduction in glial activation and impairment of hippocampal-dependent behavior. A 10 beneficial effect can be a statistically significant effect in terms of statistical analysis of an effect of a pyridazine compound or a composition of the invention, versus the effects without the compound or composition that is not within the scope of the invention. Statistically significant" or "significantly different" effects or levels may represent levels that are higher or lower than a standard. In aspects of the invention, the difference may be 15 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or 50 times higher or lower compared with the effect obtained without a pyridazine compound or a composition of the invention. In aspects, the beneficial effect is a "sustained beneficial effect" where the beneficial effect is sustained for a prolonged period of time after termination of treatment. A treatment can be sustained over several days, weeks, months or years thereby having a 20 major beneficial impact on the severity of the disorder and its complications. In aspects of the invention, a beneficial effect may be sustained for a prolonged period of at least about 1 to 3 days, 2 to 4 weeks, 2 to 5 weeks, 3 to 5 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 10 weeks, 2 to 12 weeks, 2 to 14 weeks, 2 to 16 weeks, 2 to 20 weeks, 2 to 24 weeks, 2 weeks to 12 months, 2 weeks to 18 months, 2 weeks to 24 months, or several years following 25 treatment. The period of time a beneficial effect is sustained may correlate with the duration and timing of the treatment. A subject may be treated continuously for about or at least about 1 to 3 days, 1 week, 2 to 4 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 10 weeks, 2 to 12 weeks, 2 to 14 weeks, 2 to 16 weeks, 2 weeks to 6 months, 2 weeks to 12 months, 2 weeks to 18 months, or several years, periodically or continuously. 30 The term "pharmaceutically acceptable carrier, excipient, or vehicle" refers to a medium which does not interfere with the effectiveness or activity of an active ingredient 12 WO 2008/109437 PCT/US2008/055495 and which is not toxic to the hosts to which it is administered. A carrier, excipient, or vehicle includes diluents, binders, adhesives, lubricants, disintegrates, bulking agents, wetting or emulsifying agents, pH buffering agents, and miscellaneous materials such as absorbants that may be needed in order to prepare a particular composition. Examples of 5 carriers etc. include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The use of such media and agents for an active substance is well known in the art. "Therapeutically effective amount" relates to the amount or dose of an active pyridazine compound or composition of the invention that will lead to one or more desired 10 effects, in particular, one or more beneficial effects, more particularly therapeutic effects. A therapeutically effective amount of a substance can vary according to factors such as the disorder state, age, sex, and weight of the subject, and the ability of the substance to elicit a desired response in the subject. A dosage regimen may be adjusted to provide the optimum therapeutic response (e.g. sustained beneficial effects). For example, several divided doses 15 may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. Generally, when treating a CNS disorder, an effective amount of compound or composition is that amount sufficient to pass across the blood-brain barrier of the subject to interact with relevant receptor sites in the brain of the subject. 20 A "pyridazine compound" refers to a compound of the formula I, II, III, IV, or V, or a compound depicted in Table 1, 2, 3, 4, or 5, in particular Table 2, 3, 4, or 5. In aspects of the invention a pyridazine compound refers to a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl. In some aspects the term includes the structures disclosed in US Patent Application Serial Numbers 20030176437 and 25 20060073472. In aspects, a pyridazine compound that demonstrates beneficial effects, in particular statistically significant beneficial effects is selected for use in the present invention. In aspects of the invention, a compound of the following formula Ia or lb is employed. 13 WO 2008/109437 PCT/US2008/055495 R1 R RN RR2 1 2 3 R 3 NR3 R 4 R 6 R 4 R 6 R 5 R 5 Ia Ib wherein R , R , and R are independently substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, 5 acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, or carboxamide; R 7 is substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, 10 aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, or carboxamide or R may be absent and 4 5 6 there is a double bond between N at position 1 and C at position 6; R , R , and R are 1 2 1 7 2 3 15 independently hydrogen, alkyl, alkoxy, halo, or nitro; or R and R , R and R , or R and R may form a heteroaryl or heterocyclic ring; or an isomer or a pharmaceutically acceptable salt thereof. In an aspect, a compound of the Formula Ta or Tb is employed wherein: (a) RI is optionally substituted halo, hydroxyl, alkyl, alkenyl, alkoxy, cyano, amino, cycloalkyl, 20 sulfonyl, sulfinyl, sulfenyl, thioaryl, thioalkyl, carbonyl, silyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, -SR20 wherein R20 is optionally substituted alkyl, carbonyl, carboxyl, carbamoyl, aryl, heterocylic, or heteroaryl; (b) R2 is optionally substituted halo, hydroxyl, alkyl, alkenyl, alkoxy, carbonyl, carboxyl, phenyl, benzyl, amino, aryl, cyano, -COH, piperazinyl, alcohol, piperidinyl, morpholinyl, or naphthyl;(c) R3 is optionally 25 substituted hydrogen, halo, hydroxyl, alkyl, alkenyl, alkoxy, phenyl, piperazinyl, 14 WO 2008/109437 PCT/US2008/055495 piperidinyl, pyrrolidinyl, morpholinyl, thiol, sulfenyl, sulfonyl, sulfinyl, or nitro; (d) R 4 is hydrogen, halo, or nitro; (e) R 5 is optionally substituted hydrogen, halo, alkoxy, or amido;(f) R 7 is substituted or unsubstituted hydrogen halo, hydroxyl, alkyl, alkenyl, alkoxy, carboxy, morpholino, imidazolyl, piperazinyl, piperidinyl, pyrrolidinyl, 5 morpholinyl or R 7 is absent and there is a double bond between N at position 1 and C at 1 2 1 7 2 3 position 6; and/or (g) R and R , R and R or R and R may form a substituted or unsubstituted heteroaryl or heterocyclic ring. In another aspect of the invention a compound of the Formula Ta or lb is employed wherein R is CI or Br, -NH 2 , alkyl, -CN, =S, silyl, sulfonyl, thioalkyl, thioaryl, 10 piperazinyl, piperidinyl, morpholinyl, pyrrolyl, or pyrrolidinyl, which may be optionally substituted with halo, =0, alkoxy, alkenyl, alkyl, substituted alkyl, -CN, -SR wherein R2 is optionally substituted methyl, ethyl, phenyl, heterocylic, or heteroaryl, or -CO substituted with phenyl or substituted phenyl. In another aspect of the invention a compound of the Formula Ta or Tb is employed 15 wherein R2 is carbonyl, piperazinyl, morpholinyl, sulfonyl, sulfinyl, sulfenyl, or phenyl, CN, -COH, -CH 2 OH, -OCH 2

CH

3 , or alkyl which may be optionally substituted with alkyl, alkoxy, amino, halo, phenyl, substituted phenyl, benzyl, hydroxyl, amino, piperidinyl, or morpholinyl. In another aspect of the invention a compound of the Formula Ta or Tb is employed 20 wherein R 3 is piperazinyl; substituted piperzinyl; alkyl which may optionally be substituted with amino; phenyl; substituted phenyl; amino which may be optionally substituted with alkyl or alkylamine (e.g., NHCOOC(CH 3

)

3 ), carboxyl, or substituted carboxyl; hydroxyl; or nitro. In another aspect of the invention a compound of the Formula Ta or Tb is employed 25 wherein R 4 is nitro or hydrogen. In another aspect of the invention a compound of the Formula Ta or Tb is employed wherein R 5 is hydrogen, halo, -OCH 2

CH

2

CH

2

NHCOOC(CH

3

)

3 , or -OCH 3 . In another aspect of the invention a compound of the Formula Ta or Tb is employed wherein R 7 is alkyl, morpholinyl, benzyl, imidazolyl, -CH 2

COOCH

2

CH

3 , 30 CH 2

C=COOCH

2

CH

3 , CH 2

CH

2

CH

2

SO

2 OH, CH 2

CH

2

CH

2

SO

3 -, CH 2

CH

2

CH

2

CH

2

PO(OH)

2 , or CH 2

CH

2

CH

2

PO(OH)

2 . 15 WO 2008/109437 PCT/US2008/055495 In another aspect of the invention a compound of the Formula Ta or lb is employed wherein R 7 is absent and there is a double bond between N at position 1 and C at position 6. 1 2 3 In a further aspect, a compound of the Formula Ta is employed wherein R , R , R , 5 and R 7 are independently substituted aliphatic, lower alkyl substituted amino, lower alkyl substituted halogen, cycloaliphatic, or substituted cycloaliphatic. In a still further aspect of the invention a compound of the Formula Ta or Tb is employed wherein R is a piperazinyl which may be substituted (e.g., with a pyrimidinyl moiety); halo; amino which may be substituted; cyano; - SR wherein R is alkyl or aryl 10 (e.g. phenyl) which may be substituted (e.g., halo); substituted alkyl [e.g., alkyl substituted with halogen, such as CH(Br) 2 ]; morpholinyl; pyrrolyl which may be substituted; hydroxyl; -OR28 wherein R is alkyl; -C= CHR wherein R is alkyl; or pyrrolidinyl. In a still further aspect of the invention a compound of the Formula Ta or Tb is employed wherein R2 is hydrogen; morpholinyl; piperazinyl which may be substituted 15 (e.g., with a pyrimidinyl moiety); phenyl; alkyl; alkoxy (e.g. CH(OCH 3

)

2 ); substituted alkyl; substituted aryl (e.g., phenyl); cyano; or hydroxyl. In another aspect of the invention a compound of the Formula Tb is employed wherein R is pyridinyl, and R2 is an N-substituted piperzinyl. In another embodiment a compound of the Formula Tb is employed wherein R, is 20 amino substituted with alkyl or cycloalkyl and R 2 is pyridinyl. In a still further aspect of the invention a compound of the Formula Ta or Tb is employed wherein R 3 is hydrogen; hydroxyl; alkyl which may be substituted (e.g., halo); amino which may be substituted; -COR wherein R is hydrogen, hydroxyl, alkoxy (e.g.

-OCH

3 ); or, aryl (e.g. phenyl) which may be substituted (e.g., alkyl). 25 In a still further aspect of the invention a compound of the Formula Ta or Tb is employed wherein R 4 is hydrogen or halo; R 5 is hydrogen or halo; R 6 is hydrogen or halo. In a still further aspect of the invention a compound of the Formula Ta is employed wherein R 7 is hydrogen; alkyl which may be substituted (e.g. with phenyl);

-CH

2

CH

2 COOR wherein R is alkyl, -CH 2 C=COOR wherein R is alkyl, 30 CH 2

CH

2

CH

2

S(O)

2 0H, morpholinyl, benzyl, imidazolyl, or [CH 2 ]nPO(OH) 2 wherein n is 1 to 6, in particular 3 or 4. 16 WO 2008/109437 PCT/US2008/055495 In a still further aspect of the invention a compound of the Formula Ta or Tb is employed wherein R and R2 form a piperidinyl ring which may optionally be substituted with a carboxyl. In a still further aspect of the invention a compound of the Formula Ta is employed 5 wherein R and R 7 form a pyrimidinyl ring which may optionally be substituted with alkyl, aryl, halo, or hydroxyl. In a particular aspect, a compound of the formula Ta or Tb is employed wherein R is -NR 3 4

R

35 wherein R 3 4 is hydrogen or alkyl, and R 35 is hydrogen, alkyl, carbonyl, aryl, amino, cycloalkane, heterocylic, or heteroaryl which may be substituted. In embodiments 10 R 35 may comprise or be selected from the group consisting of hydrogen, C 1

-C

6 alkyl (e.g. methyl or ethyl) which may be substituted with optionally substituted hydroxyl, alkyl, amino, carbonyl, carboxyl, morpholinyl, isoquinolinyl, or an amino which may be substituted with one or more of optionally substituted alkyl, benzyl, carboxyl, alcohol group, heteroaryl or heterocyclic, a propanol group, phenyl which may be optionally 15 substituted with halo, benzyl which may be substituted with alkoxy, cyclohexyl, piperidinyl which may be substituted with optionally substituted phenyl, pyrrolidinyl or pyrrolidinylalkyl which may be substituted with alkyl, -COOR wherein R8 is alkyl which may be substituted, or [CH 2 ]m-piperidinyl wherein m is 1 to 4, in particular 1 to 3 and the piperidinyl is optionally substituted with optionally substituted alkyl, phenyl, or benzyl. 20 In embodiments, R 35 is -R 4 4

R

45 wherein R 44 is -NH[CH 2 ]wNH wherein w is 1 to 4, in particular 2 or 3, and R 45 is piperazinyl substituted with pyrimidinyl which may be substituted, in particular substituted with alkyl. In embodiments, R is -R46R47 wherein R46 is -[CH 2 ]wN(CH 3 ) wherein w is 1 to 4, in particular 2 or 3, and R 47 is piperazinyl substituted with pyrimidinyl which may be 25 substituted, in particular substituted with alkyl. In an aspect of the invention, a compound of the Formula Ta or Tb is employed wherein R is halo, especially chloro or bromo, R2 is alkyl which may be substituted, in particular substituted with alkoxy (e.g., methoxy, dimethoxy), substituted aryl which may be substituted with alkyl, alkoxy, (e.g., benzyl, methoxy phenyl), halo (e.g. bromo or 30 chloro), or carbonyl, a substituted or unsubstituted saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g., piperidinyl, and piperazinyl] 17 WO 2008/109437 PCT/US2008/055495 or a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl], in particular a substituted morpholinyl, piperazinyl,or piperazinyl substituted with a heteroaryl in particular an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in 5 particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, especially pyrimidinyl, and optionally R , 4 5 6 7 R , R , R , and R 7 are hydrogen. In another aspect of the invention, a compound of the Formula Ta is employed wherein R is halo especially chloro or bromo, and R 3 is a substituted or unsubstituted 10 saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g., piperidinyl, and piperazinyl] or a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl], in particular a substituted morpholinyl, piperazinyl,or piperazinyl substituted with alkyl or a heteroaryl in particular an unsaturated 5 to 6 membered heteromonocyclyl group 15 containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, especially pyrimidinyl, or R2 is a substituted amino, in particular amino substituted with alkyl or substituted alkyl, in particular alkyl substituted with alkoxy carbonyl, and optionally R 2 , 4 5 6 7 R , R , R , and R 7 are hydrogen. 20 In further aspect R is halo, especially bromo or chloro, and R2 and R3 form an unsaturated ring, in particular phenyl, R 5 is a heteroaryl, in particular a substituted or unsubstituted unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, especially imidazolyl, and optionally R 4 , R 6 and R 7 are hydrogen. 25 In a further aspect, R is halo, especially bromo or chloro, and R 4 is nitro, and optionally R 2 , R 3 , R 5 , R 6 , and R 7 are hydrogen. In a further aspect, the invention employs a compound of the Formula Ta wherein R is a thiol substituted with alkyl (thioalkyl); substituted alkyl, in particular alkyl substituted with a substituted or unsubstituted saturated 3 to 6-membered heteromonocylic 30 group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl] or a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 18 WO 2008/109437 PCT/US2008/055495 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl], especially a substituted morpholinyl or piperidinyl; aryl; substituted aryl; carboxyl which may be substituted with substituted or unsubstituted aryl; optionally R 2 is alkyl, in particular lower alkyl; optionally R 3 is alkyl, in particular lower alkyl or nitro; optionally R 5 is alkoxy; 5 optionally R 7 is alkyl; and optionally R 4 , R , and R 6 , are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 1 2 53 wherein R is =S, and optionally R is alkyl, in particular lower alkyl, R 5 is alkoxy, and R , 4 6 7 R , R and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 10 wherein R is sulfonyl which may be substituted with substituted or unsubstituted aryl, in 2 3 4 5 6 7 particular substituted phenyl, and optionally R is alkyl and R , R , R , R , and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed wherein R 1 is substituted or unsubstituted alkyl or alkynyl, in particular alkyl substituted 15 with aryl, substituted aryl, halo, cyano, or alkynyl substituted with alkyl; and optionally R2 73 4 5 6 is alkyl, R 7 is alkyl, and R , R , R , and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 1 2 3 4 5 6 7 wherein R is cyano and R is aryl or alkyl, and optionally R , R , R , R , and R are hydrogen. 20 In a further aspect of the invention, a compound of the Formula Ta is employed wherein one or both of R and R2 are a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl], especially a substituted morpholinyl, and optionally R , R 4 , R , R 6 , and R 7 are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 25 wherein R is a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl], which may be substituted with substituted or 2 3 4 5 6 7 unsubstituted carboxyl; R is alkyl or halo, and optionally R , R , R , R6, and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 30 wherein R is hydroxyl; R2 is alkyl or substituted alkyl or R3 is a saturated 3 to 6 membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g. piperidinyl, and 19 WO 2008/109437 PCT/US2008/055495 piperazinyl] which may optionally be substituted with a heteroaryl [e.g., pyrimidinyl], and 2 34 5 6 7 the other of R or R is hydrogen, and optionally R 4 , R , R 6 , and R 7 are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed wherein R is a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 5 nitrogen atoms [e.g., piperidinyl and piperazinyl] which may be substituted with carboxyl or carboxyl substituted with alkyl or alkoxy or with purinyl or substituted purinyl; R2 is 3 4 5 6 7 alkyl or substituted alkyl, in particular alkylaryl, and optionally R , R , R , R , and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 10 wherein RI is =0, and R2 is alkyl, alkylaryl, cyano, alkoxy, or substituted alkoxy, and optionally R 3 , R 4 , R 5 , R 6 , and R 7 are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed 1 2 3 4 5 wherein R is alkoxy, R is alkyl, substituted alkyl, or alkoxy, and optionally R , R , R , 6 7 R , and R are hydrogen. 15 In a further aspect of the invention, a compound of the Formula Ta is employed wherein R and R2 form a heterocyclic, in particular a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms, in particular a 6-membered ring comprising 1 or 2 nitrogen atoms [e.g., piperidinyl and piperazinyl] which may be substituted for example with alkyl, halo, carboxyl, or alkoxy carbonyl, and optionally R , 20 R 4, R, R6, and R 7 are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed wherein R and R 7 form a heteroaryl, in particular an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, 23 4 5 6 7 25 pyrazinyl, or pyridazinyl, R 2 is hydrogen or alkyl, and R , R , R , R , and R are hydrogen. In a further aspect of the invention, a compound of the Formula Ta is employed wherein R is silyl which may be substituted, in particular substituted with alkyl, R2 is alkyl, and R , R 4, R , R 6, and R are hydrogen. In some aspects, one or more of the following compounds are not within the scope 30 of a pyridazine compound of the formula Ta or Tb employed in the present invention: 20 WO 2008/109437 PCT/US2008/055495 a) a compound wherein when R 1 is =0, R 3 is -COOCH 3 , CH=CHCOOCH 3 , -CH=CHC(=O)-phenyl, -CH=CH(C(=O)OCH 3

)

2 , -S-phenyl,

-CH=CH(COCH

3

)(COOCH

3 ), CH=CH(COOCH 2

CH

3

)

2 , -phenyl-COOCH 3 , -CH=CHCO-phenyl, -CH 2 CH(Cl)(CH 2 OH), -methylphenyl, R 7 is hydrogen 1 2 4 5 6 5 or -CH 2

OCH

3 , and R , R , R , R and R are hydrogen; b) a compound wherein when Rl is =0, R2 is cyano, R3 is -C(=O)OCH 3 , and 3 4 5 6 R , R , R , and R are hydrogen; 1 2 3 c) a compound wherein when R is =0, R is -methylthiophene or benzyl, R , 4 5 6 7 R , R , R , and R are hydrogen; 10 d) a compound wherein when RI is =0, R2 is methyl, R is hydrogen, hydroxyl, chloro, or bromo, R 7 is hydrogen or ethylmorpholinyl, and R , 4 6 R4, and R are hydrogen; e) a compound wherein when R2 is methyl, R is chloro, bromo, or hydrogen,

R

7 is hydrogen or -CH 2

CH

2 -morpholinyl, and Rl, R3, R4, and R6 are 15 hydrogen; f) a compound wherein when R is piperazinyl, piperazinyl substituted with pyridinyl, phenyl, or methyl, R 2 is hydrogen or methyl, and R 3 , R 4 , R 5 , and R6 are hydrogen; g) a compound wherein when R 1 is chloro or bromo, R2 is C 1

-C

3 alkyl, phenyl, 20 amino, benzyl, morpholinyl, chloro, -C(=O)NH 2 , -NH 2 , CI-C 3 alkylphenyl, 3 4 5 6

-CH(CH

3

)

2 , -CH 2

CH(CH

3

)

2 , -benzylchloro, and R , R , R and R are hydrogen; h) a compound wherein when R is chloro or bromo, R 3 is hydroxyl, chloro, 2 4 5 6 bromo, CI-C 3 alkyl, phenyl, or -N(CH 3

)

2 , and R2, R , R and R are 25 hydrogen; i) a compound wherein when R is chloro, R2 is methyl, R 5 is hydroxyl, and 3 4 6 R , R , and R are hydrogen; 1 2 3 4 5 6 j) a compound wherein when R is chloro, R , R , R , R and R are hydrogen; k) a compound wherein when R is hydroxyl, R 2 is CI-C 4 alkyl, and R , R 4 , R 5 30 and R 6 are hydrogen; 21 WO 2008/109437 PCT/US2008/055495 1) a compound wherein when R is -CI-C 4 alkoxy, or CI-C 4 alkoxy substituted with -N(CH 3

)

2 , morpholinyl, or piperidinyl substituted with benzyl, R2 is 3 4 5 6 7 hydrogen or methyl, R , R , R and R are hydrogen, R is absent, hydrogen, or methyl; 5 m) a compound wherein when R is -SH, -SCH 3 , or -SCH 2

C(=O)CH

3 , R2 is hydrogen or methyl, and R , R 4 , R 5 and R 6 are hydrogen; n) a compound wherein when R is =S, R2 is hydrogen or methyl, R 7 is methyl 3 4 6 or benzyl, and R , R , and R are hydrogen; o) a compound wherein when R is =S, R2 is methyl and R is chloro or R7 is 3 4 6 10 methyl, and R , R , and R are hydrogen; p) a compound wherein when R is hydroxyl, R 2 is hydrogen, methyl, or butyl, 3 4 5 6 and R , R , R and R are hydrogen; q) a compound wherein when R is methoxy, R 2 , R 3 , R 4 , R 5 and R 6 are hydrogen; 15 r) a compound wherein when R is CI-C 2 alkoxy or C 1

-C

4 alkoxy substituted with morpholinyl, -N(CH 3

)

2 , or piperidinyl substituted with benzyl, R2 is 3 4 5 6 methyl, and R , R , R and R are hydrogen; 2 3 4 5 6 s) a compound wherein R2, R , R , R and R 6 are hydrogen; t) a compound wherein R 1 is cyano or cyano substituted with -C(OCH 2

CH

3

)

2 , 20 -CH(OH)(CH 3 ), -Si(CH 2

CH

3

)

2 , cyclohexol, -CH 2 0-trimethyldiphenylsilyl 3 4 5 6 or cyclohexyl substituted with hydroxyl, and R , R , R and R are hydrogen; u) a compound wherein R is cyano substituted with -CH(OH)(CH 3

)

2 , -Si(CH 2

CH

3

)

2 , morpholinyl, trimethyldiphenylsilyl, or -CH(OCH 2

CH

3

)

2 , R2 25 is methyl, and R 3 , R 4 , R 5 and R 6 are hydrogen; 7 2 3 4 v) a compound wherein R is oxy, and R is hydrogen or methyl, and R, R, R and R6 are hydrogen; 1 2 3 4 5 6 w) a compound wherein R is methyl, and R , R , R , R and R are hydrogen; 2 1 3 4 5 6 x) a compound wherein R is methyl, and R , R , R , R and R are hydrogen; 1 32 4 5 30 y) a compound wherein R is methoxycarbonyl, R 3 is hydrogen, and R , R , R and R6 are hydrogen; 22 WO 2008/109437 PCT/US2008/055495 z) a compound wherein R is -NH 2 , R2 is methyl, chlorophenyl, methoxyphenyl, ethylphenyl, ethylmethoxyphenyl, propylphenyl, or 4 5 6 7

-CH(CH

3

)

2 , R , R and R are hydrogen, and R is absent or

-CH

2

CH

2

CH

2 COOH; 5 aa) a compound wherein RI is -OR29 wherein R29 is ethylmorpholinyl or 2 3 4 5 6

-CH

2

CH

2

N(CH

3

)

2 and R , R , R , R and R 6 are hydrogen; 1 3 3 4 5 6 bb) a compound wherein R is -NH 2 , R is -NH 2 , and R , R , R and R are hydrogen; cc) a compound wherein R is -NH 2 , R and R6 are methoxy, and R3 and R4 10 are hydrogen; 1 3 4 5 6 dd) a compound wherein R is -NH 2 , R is methyl and R , R and R are hydrogen; 1 5 3 4 6 ee) a compound wherein R is -NH 2 , R is chloro, and R , R and R are hydrogen; 15 ff) a compound wherein R is -NH-chlorophenyl, and R2 and R3 form a phenyl 4 5 6 group, and R , R and R are hydrogen; gg) a compound wherein R is -NH 2 , R4 and R is methoxy, and R 2, R3 and R6 are hydrogen; hh) a compound wherein R1 is -NH 2 , R2 is ethylmethoxyphenyl, R7 is 3 4 6 20 carboxyethyl or carboxypropyl, and R , R and R are hydrogen; ii) a compound wherein R is -NHR wherein R is ethylmorpholinyl, ethylmorpholinyl substituted with =O, -CH 2

CH

2

OCH

3 ,

-CH

2

CH

2

CH

2

CH

2

CH

2

CH

2

CH

2

CH

3 , -CH 2

CH

2

CH

2

CH

2 OH, -CH 2

CH

2 OH, or

-CH

2

CH

2

OCH

3 , R2 is hydrogen, methyl, ethyl, -CHO, -CH 2 OH, -COOH, 25 chloro, -CH 2

CH

2

NH

2 , -NO 2 , -C=N, -C(=O)OCH 2

CH

3 , or -C(=O)NH 2 , and 3 4 5 6 R , R , R and R are hydrogen; jj) a compound wherein R 1 is -NHR 49 wherein R 49 is ethanol, methylpiperidinylbenzyl, ethylpiperidinyl, ethylpiperidinylbenzyl, or butylpiperidinylbenzyl, R 2 is hydrogen, methyl, or -C(CH 3

)

2 , and R 3 , R 4 , R 5 30 and R 6 are hydrogen; 23 WO 2008/109437 PCT/US2008/055495 kk) a compound wherein R is -NHR wherein R is hydrogen, and R , R 4 , R 5 and R6 are hydrogen; 11) a compound wherein R is -NHR56 wherein R56 is -CH 2

CH

2

N(CH

2

CH

3

)

2 or 3 4 5 6 ethylmorpholinyl, R is ethyl, and R , R and R are hydrogen; 5 mm) a compound wherein RI is -NHNH 2 , R 3 is hydrogen, alkyl, or phenyl, and R , R 4 , R and R 6 are hydrogen; nn) a compound wherein R is -NHR 5 7 wherein R 57 is NH 2 , -CH 2

CH

2 OH,

CH

2

CH(OH)(CH

3 ), ethylmorpholinyl, ethylmorpholinyl substituted with =0, ethylphenyl, -CH 2

CH

2

NHCH

3 , -CH 2

CH

2

N(-CH

2

CH

2

CH

3

)

2 , 10 ethylpiperidinyl, or ethylpiperidinylbenzyl, R 2 is methyl, and R , R 4 , R 5 and R6 are hydrogen; oo) a compound wherein R1 is morpholinyl, R2 is -C(F) 3 , -C(=O), -CH 2 OH, 3 4 5 6 -C(=O)H, -COOH, chloro, -NO 2 , or cyano, and R , R , R and R are hydrogen; 15 pp) a compound wherein R is -NHR wherein R is heptyl, phenyl, benzyl, or ethylphenyl, R 2 is hydrogen, methyl, or chlorophenyl, R 4 , R 5 and R 6 are hydrogen; 1 9 92 3 4 5 qq) a compound wherein R is -NR wherein R9 is phenyl and R , R , R , R and R6 are hydrogen; 1 2 3 4 5 6 20 rr) a compound wherein R is morpholinyl and R2, R , R , R and R are hydrogen; 1 2 3 4 5 6 ss) a compound wherein R is methylpiperazinyl and R , R , R , R and R are hydrogen; tt) a compound wherein R is -NHCH 2

CH

2 OH or NHCH 2

CH

2

OCH

3 , R2 is 3 4 5 6 25 phenyl and R , R , R and R are hydrogen; uu) a compound wherein R is -NHR 5 9 wherein R 5 9 is ethylamino, butylamino, 2 3 4 ethylaminomethyl, and R is hydrogen, methyl, or -C(=O)NH 2 , and R , R , R and R6 are hydrogen; vv) a compound wherein R is -NHR60 wherein R is ethylpiperidinyl, 30 methylpiperidinylbenzyl, piperidinylbenzyl, ethylpiperidinylbenzyl, methylpyrrolidinylmethyl, ethylpiperazinylbenzyl, -CH 2

C(=O)

24 WO 2008/109437 PCT/US2008/055495 piperazinylbenzyl, -C(=O)-methylnaphthyl,

-CH

2

CH

2

CH

2

CH

2

CH

2

N(CH

3

)(C

7

H

7 ), -CH 2 C(=O)-piperidinylbenzyl, 3 4 5 6 -C(=O)-methylpiperidinylbenzyl, or -CH(CH 3

)

2 , and R , R , R and R are hydrogen; 5 ww) a compound wherein R is -CHCH 2

CH

2 -isoquinolinyl,

-NHCH

2

CH

2

N(CH

2

CH

2

CH

3

)

2 , propyl substituted with piperidinyl fused to phenyl, -NHCH 2

CH

2 , or -NHCH 2

CH

2

CH

2

CH

2

CH

2 substituted with a piperidinyl fused to two adjacent carbon atoms of a phenyl moiety; xx) a compound wherein R is -NH substituted with two pyrrolidinyl groups; R3 2 4 5 6 10 is methyl, and R , R , R and R 6 are hydrogen; 1 3 2 4 5 6 yy) a compound wherein R is -COOCH 3 , R is methyl, and R , R , R and R are hydrogen; zz) a compound wherein R is hydrogen, R2 is methyl, R 7 is oxygen; aaa) a compound wherein R is methyl or oxygen, and R1, R 2, R 4, R and R6 are 15 hydrogen; 1 3 2 bbb) a compound wherein R is -NHCH 2

CH

2

N(CH

2

CH

3

)

2 , R is ethyl, and R,

R

4 , R and R 6 are hydrogen; and ccc) a compound wherein R is -NHCH 2

CH(OH)(CH

3 ) or

-NHCH

2

CH

2

NHCH

2

CH

2 OH, R2 is methyl, and R3, R4, R and R6 are 20 hydrogen. In aspects of the invention a compound of the formula Ia or Ib is employed wherein R is a piperazinyl or substituted piperazinyl, in particular a piperazinyl substituted with a pyrimidinyl of Formula A below. N/\/N -N \

N

25 N A Thus, a pyridazine compound for use in the present invention includes compounds of the Formula II: 25 WO 2008/109437 PCT/US2008/055495

R

1 0

R

11 N N N ' N-N II wherein R 10 and R 11 are independently substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, 5 cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, phosphonate, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof. 10 In an aspect of the invention, a compound of the Formula II is employed wherein

R

1 0 is hydrogen; hydroxyl; alkyl; aryl [e.g. phenyl which is optionally substituted (e.g., halide)]; piperazinyl which may be substituted (e.g. substituted with a pyrimidinyl);

-NR

36 R" wherein R is hydrogen or alkyl, and R 37 is phenyl which may be substituted or alkyl which may be substituted (e.g. amino, in particular -CH 2

CH

2

NH

2 ; 15 CH 2

CH

2

NHCOOC(CH

3

)

3 ); morpholinyl which may be substituted; or -SR wherein R2 is phenyl which may be substituted; and R 11 is hydrogen, or aryl (e.g. phenyl) which may be substituted. In a particular aspect of the invention a compound of the Formula II is employed wherein R 1 0 is hydrogen, halo, optionally substituted hydroxyl, alkyl, pyridinyl, phenyl, 20 benzyl, piperazinyl, amino, morpholinyl, or -SR24 wherein R24 is alkyl or aryl. In an embodiment, R1U is -NH[CH 2 ]mNR61R62 wherein m is 1 to 6, in particular 2 to 4, R61 is hydrogen, R62 is a carboxyl, in particular -COOC(CH 3

)

3 . In an aspect of the invention, a compound of the Formula II is employed wherein R" is hydrogen, halo, optionally substituted alkyl, pyridinyl, piperidinyl, morpholinyl, 25 piperazinyl, or phenyl. In another aspect of the invention, a compound of the Formula II is employed wherein both of R 1 0 and R 11 are not hydrogen. 26 WO 2008/109437 PCT/US2008/055495 In particular embodiments of the invention, one or more of R 10 and R 11 are alkyl, in particular C 1

-C

6 alkyl and the other of RiU and RII is hydrogen. In particular embodiments of the invention, one or more of R 1 0 and R 11 are aryl in particular phenyl or benzyl and the other of R 1 0 and RII is hydrogen. 5 In particular embodiments of the invention, a compound of the Formula II is a compound in Table 3, more particularly a compound designated MWO1-2-065LKM, MWO1-2-069SRM, MWO1-2-151SRM, MWO1-5-188WH, MWO1-6-127WH, MWO1-6 189WH, or MWO1-7-107WH, and pharmaceutically acceptable salts, and derivatives thereof. 10 In aspects, the invention employs a compound of the Formula III:

R

15 R' 1 wherein R and R are independently substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, 15 cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof. 20 In other aspects, the invention employs a compound of the Formula IV: 27 WO 2008/109437 PCT/US2008/055495 R 70 N -- N R 71 I , )~ N IV wherein R 70 and R 71 are independently substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, 5 cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silyalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, or carbamoyl, or an isomer or pharmaceutically acceptable salt thereof. 10 In other aspects, a compound of the formula IV is employed wherein R 70 is substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, 15 silylthio, =0, =S, carboxyl, carbonyl, carbamoyl, or carboxamide, especially heterocyclic, heteroaryl, amino, and substituted amino and R 71 is aryl or substituted aryl; or an isomer or a pharmaceutically acceptable salt thereof. In another aspect, a compound of the Formula IV is employed wherein R 70 is a heterocylic, in particular a saturated 3 to 6-membered heteromonocylic group containing 1 20 to 4 nitrogen atoms more particularly, pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl, especially piperazinyl or piperidinyl, which may be substituted with alkyl especially methyl, dimethyl, cycloalkyl especially cyclohexyl, aryl especially phenyl, a substituted or unsubstituted unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, in particular, indolyl, isoindolyl, indolizinyl, indazolyl, quinazolinyl, 25 pteridinyl, quinolizidinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, cinnolinyl, 28 WO 2008/109437 PCT/US2008/055495 phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, carbazolyl, purinyl, benzimidazolyl, quinolyl, isoquinolyl, quinolinyl, isoquinolinyl, or indazolyl, especially benzimidazolyl substituted with oxy. In other aspects, a compound of the Formula IV is employed wherein R 70 is amino 5 or substituted amino, and optionally R 7 1 is aryl, in particular phenyl. In an aspect R 70 is -N R 6 wherein R is hydrogen or alkyl, in particular C 1

-C

6 alkyl, more particularly methyl or dimethyl, or -N-R4U R wherein R is hydrogen or alkyl, in particular C 1

-C

6 alkyl, more particularly methyl and R is alkyl substituted with amino or substituted amino, heterocyclic, substituted heterocylic, or cycloalkyl. In an embodiment, R is -N-R 42R43 10 wherein R42 is hydrogen or alkyl, in particular C 1

-C

6 alkyl, more particularly methyl and

R

43 is C1-C 6 alkyl, especially methyl or ethyl substituted with a cycloalkyl especially cyclopropyl, a heterocyclic especially piperidinyl, pyrrolidinyl, or morpholinyl which may be substituted in particular substituted with aryl, especially benzyl. A compound of the Formula IV may comprise a structure designated as compound 15 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, or 139 in Table 5 or pharmaceutically acceptable salts, isomers, or derivatives thereof. In further aspects, the invention employs a compound of the Formula V: N N CN N

R

50 . N

R

51

R

52 V 50 51 52 wherein RU, R , and R are independently substituted or unsubstituted hydrogen, 20 hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, 29 WO 2008/109437 PCT/US2008/055495 silyloxy, silylalkyl, silylthio, =0, =S, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof. In aspects of the invention a compound of the Formula V is employed wherein R5U is substituted or unsubstituted hydrogen, alkyl, aryl, or heterocyclic; R is substituted or 5 unsubstituted hydrogen or alkyl, and R is substituted or unsubstituted hydrogen, alkyl, cycloalkyl, heteroaryl or halo. In an aspect, a compound of the Formula V is employed wherein R is hydrogen, C 1

-C

6 alkyl which may be substituted with alkyl, especially methyl or trimethyl, phenyl, or a 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms more particularly, piperidinyl or morpholinyl, R 5 1 is hydrogen or alkyl 10 especially methyl, and R is hydrogen, alkyl especially methyl, dimethyl, ethyl, or propyl, cyclohexyl, chloro, or an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, especially pyridinyl. In an embodiment, R is aryl, R is hydrogen, and R is C 1

-C

6 alkyl. 15 A compound of the Formula V may comprise compound MW01-7-057WH, or structure 32, 34, 36, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 49, 63, 69, 70, 71, 75, 76, 77, 78, 79, 80, 81, or 82 in Table 5 or pharmaceutically acceptable salts, isomers or derivatives thereof In aspects of the invention the pyridazine compound is an isolated and pure, in 20 particular, substantially pure, compound of the Formula 1, 11, 111, IV, or V, or an isomer or a pharmaceutically acceptable salt thereof. As used herein, the term "pure" in general means better than 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure, and "substantially pure" means a compound synthesized such that the compound, as made or as available for consideration into a composition or dosage form described herein, has only 25 those impurities that can not readily nor reasonably be removed by conventional purification processes. A pyridazine compound employed in the invention includes derivatives, in particular derivatives of a compound of the Formula I, II, III, IV, or V. The term "derivative" of a compound, as used herein, refers to a chemically modified compound 30 wherein the chemical modification takes place either at a functional group of the compound or on the aromatic ring. Non-limiting examples of derivatives of compounds of 30 WO 2008/109437 PCT/US2008/055495 the Formula 1, 11, 111, IV, or V (e.g., pyridazine derivatives of the present invention) may include N-acetyl, N-methyl, N-hydroxy groups at any of the available nitrogens in the compound. Derivative groups that may be used to modify the compounds of the Formula I, II, III, IV, or V can be found in U.S. Patent Application No. 20030176437 (herein 5 incorporated by reference in its entirety for all purposes). In some embodiments, the organic compounds, and/or heterocyclic derivatives thereof depicted in Tables 1, 2, 3, 4 or 5 are employed, in particular Tables 2, 3, 4, or 5. In particular aspects the invention employs a compound of the Formula 1, 11, 111, IV, or V as defined herein, with the proviso that compounds depicted in Table 1 are excluded. 10 In other particular aspects the invention employs a compound of the Formula II with the proviso that the compounds depicted in Table 1 are excluded. In further particular aspects the invention employs a compound of the Formula III with the proviso that compounds depicted in Table 1 are excluded. In further particular aspects the invention employs compounds of the Formula IV 15 with the proviso that compounds depicted in Table 1 are excluded. In still further particular aspects the invention employs compounds of the Formula V with the proviso that compounds depicted in Table 1 are excluded. In accordance with aspects of the invention pyridazine compounds and/or related heterocyclic derivatives thereof (see, for example, the Tables herein, in particular Table 2, 20 3, 4 and/or 5 or heterocyclic derivatives thereof), are employed in the treatment or prevention of disorders disclosed herein. In some embodiments, the compounds employed are those depicted in Table 2, 3, 4, and/or 5 or derivatives thereof. In some embodiments, the invention employs one or more of the compounds designated herein as MWO1-3 183WH, MWO1-5-188WH, MWO1-2-065LKM, MWO1-2-184WH, MWO1-2-189WH and 25 MWO1-2-151SRM, or isomers or pharmaceutically acceptable salts thereof. In some embodiments, the invention employs one or more of the compounds designated herein as MWO1-3-183WH, MWO1-5-188WH, MWO1-2-065LKM, MWO1-2 184WH, MWO1-2-189WH and MWO1-2-151SRM, or isomers or pharmaceutically acceptable salts thereof. 30 In some embodiments, the invention employs one or more of the compounds designated MWO1-3-183WH, MWO1-5-188WH, MWO1-2-065LKM, MWO1-2-184WH, 31 WO 2008/109437 PCT/US2008/055495 MWO1-2-151SRM, MW01-2-189WH, and MW01-1-01-L-D07, and/or related derivatives, in particular, heterocyclic derivatives, of these compounds. In another particular embodiment of the invention, MWO1-2-151SRM, an isomer, a pharmaceutically acceptable salt, or derivative thereof is employed in the invention. In a particular embodiment of the 5 invention, MWO1-5-188WH, an isomer, a pharmaceutically acceptable salt, or derivative thereof is employed in the invention. A pyridazine compound also includes "pharmaceutically acceptable salt(s)". By pharmaceutically acceptable salts is meant those salts which are suitable for use in contact with the tissues of a subject or patient without undue toxicity, irritation, allergic response 10 and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are described for example, in S. M. Berge, et al., J. Pharmaceutical Sciences, 1977, 66:1. Examples of salts include the compounds designated herein as MWO1-1-01-L-D1O, MWO1-1-01-L-E02, MWO1-1-01-L-E08, MWO1-1-03-L-A05, MWO1-1-16-L-D09, and MWO1-1-17-L-G04. 15 In aspects of the invention, an acid addition salt, in particular a halide salt, more particularly a chloride salt, most particularly a hydrochloride salt of a compound of the formula II is employed. In a particular embodiment, a pharmaceutically acceptable halide salt of the pyridazine compound 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1 yl)pyridazine(5) shown in Figure 10 is employed. 20 In an embodiment, a pharmaceutically acceptable salt employed in the invention is a chloride salt of 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine(5) shown in Figure 10. In a particular embodiment, a pharmaceutically acceptable salt is a hydrochloride salt of 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine (5) shown in Figure 10, more particularly the di-hydrochloride hydrate salt shown below (i.e., 25 MW01-9-034WH)(16)(i.e., 2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl) pyrimidine dihydrochloride salt)(6). 32 WO 2008/109437 PCT/US2008/055495 N N N N | -2HCl-H20 In aspects of the invention a di-hydrochloride hydrate salt of a compound of the Formula V, in particular 2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine dihydrochloride salt (6) shown in Figure 10, characterized by enhanced solubility is 5 utilized in the present invention. The di-hydrochloride hydrate salt may be further characterized by one or more of the following: a yellow powder, having a purity of greater than about 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, molecular weight of 423.3395, soluble in DMSO, melting point of greater than 488K, acid dissociation constants (pKa) of 2.55, 1.46, 0.84 and -4.31 (calculated), logP of 2.29 determined from 10 octanol/water partition coefficient, logS of 2.5 (experimental)/4.08 (calculated), and/or having an aqueous solubility at 37'C of about 100 to 400 mg/ml, about 100 to 350 mg/ml, about 150 to 350 mg/ml, about 200 to 350 mg/ml, or about 300 to 350 mg/ml, in particular a solubility of greater than 322 mg/ml in water (2HCLe H 2 O) salt). In aspects, a compound of the Formula V in amorphous or crystalline form that has 15 an enhanced resorption rate is utilized. In particular aspects the resorption rate is increased by a factor of at least 2, 3, 4 or 5. A pyridazine compound, in particular a compound of the Formula 1, 11, 111, IV, or V, may contain one or more asymmetric centers and may give rise to enantiomers, diasteriomers, and other stereoisomeric forms which may be defined in terms of absolute 20 stereochemistry as (R)- or (S)-. Thus, pyridazine compounds include all possible diasteriomers and enantiomers as well as their racemic and optically pure forms. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When a pyridazine compound contains centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds 25 include both E and A geometric isomers. All tautomeric forms are also included within the scope of a pyridazine compound employed in the present invention. 33 WO 2008/109437 PCT/US2008/055495 A compound of the formula 1, 11, 111, IV or V includes crystalline forms which may exist as polymorphs. Solvates of the compounds formed with water or common organic solvents are also intended to be encompassed within the term. Thus, a pyridazine compound, in particular a compound of the Formula I, II, III, IV, or V, can exist in 5 unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms may be considered equivalent to the unsolvated forms for the purposes of the present invention. In addition, hydrate forms of the compounds and their salts are encompassed within this invention. Further prodrugs of compounds of the formula 1, 11, 111, IV or V are encompassed within the term. 10 The term "solvate" means a physical association of a compound with one or more solvent molecules or a complex of variable stoichiometry formed by a solute (for example, a compound of the invention) and a solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, 15 for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. In general, the solvents selected do not interfere with the biological activity of the solute. Solvates encompass both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like. Dehydrate, co-crystals, anhydrous, or amorphous forms of the compounds of the 20 invention are also included. The term "hydrate" means a solvate wherein the solvent molecule(s) is/are H 2 0, including, mono-, di-, and various poly-hydrates thereof. Solvates can be formed using various methods known in the art. Crystalline compounds of the formula 1, 11, 111, IV or V can be in the form of a free base, a salt, or a co-crystal. Free base compounds can be crystallized in the presence of an 25 appropriate solvent in order to form a solvate. Acid salt compounds of the formula I, II, III, IV or V (e.g. HCl, HBr, benzoic acid) can also be used in the preparation of solvates. For example, solvates can be formed by the use of acetic acid or ethyl acetate. The solvate molecules can form crystal structures via hydrogen bonding, van der Waals forces, or dispersion forces, or a combination of any two or all three forces. 30 The amount of solvent used to make solvates can be determined by routine testing. For example, a monohydrate of a compound of the formula I, II, III, IV or V would have 34 WO 2008/109437 PCT/US2008/055495 about 1 equivalent of solvent (H 2 0) for each equivalent of a compound of the invention. However, more or less solvent may be used depending on the choice of solvate desired. Compounds of the formula I, II, III, IV or V may be amorphous or may have different crystalline polymorphs, possibly existing in different solvation or hydration 5 states. By varying the form of a drug, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapor pressure, density, color, 10 and compressibility. A compound of the Formula 1, 11, 111, IV, or V may be in the form of a prodrug that is converted in vivo to an active compound. In a compound of the Formula I one or more 1 2 3 4 5 6 7 of R , R , R , R , R , R , and R may comprise a cleavable group that is cleaved after administration to a subject to provide an active (e.g., therapeutically active) compound, or 15 an intermediate compound that subsequently yields the active compound. A cleavable group can be an ester that is removed either enzymatically or non-enzymatically. The term "prodrug" means a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s). In general, such prodrugs have metabolically 20 cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds. The prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased 25 hydrosolubility), and/or decreased side effects (e.g., toxicity). In general, prodrugs themselves have weak or no biological activity and are stable under ordinary conditions. Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: "Design 30 and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; 35 WO 2008/109437 PCT/US2008/055495 Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985, particularly pp. 309 396; Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172 178 and pp. 949 982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. 5 Soc., 1975; and Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g. N,N-dimethylaminocarbonyl) of hydroxy functional groups on compounds of the formula 1, 11, 111, IV or V, and the like. A compound of the formula I, II, III, IV or V compound can include a 10 pharmaceutically acceptable co-crystal or a co-crystal salt. A pharmaceutically acceptable co-crystal includes a co-crystal that is suitable for use in contact with the tissues of a subject or patient without undue toxicity, irritation, allergic response and has the desired pharmacokinetic properties. The term "co-crystal" as used herein means a crystalline material comprised of two 15 or more unique solids at room temperature, each containing distinctive physical characteristics, such as structure, melting point, and heats of fusion. Co-crystals can be formed by an active pharmaceutical ingredient (API) and a co-crystal former either by hydrogen bonding or other non-covalent interactions, such as pi stacking and van der Waals interactions. An aspect of the invention provides for a co-crystal wherein the co 20 crystal former is a second API. In another aspect, the co-crystal former is not an API. In another aspect, the co-crystal comprises more than one co-crystal former. For example, two, three, four, five, or more co-crystal formers can be incorporated in a co-crystal with an API. Pharmaceutically acceptable co-crystals are described, for example, in "Pharmaceutical co-crystals," Journal of Pharmaceutical Sciences, Volume 95 (3) Pages 25 499 - 516, 2006. Methods for producing co-crystals are discussed in the United States Patent Application 20070026078. A co-crystal former which is generally a pharmaceutically acceptable compound, may be, for example, benzoquinone, terephthalaldehyde, saccharin, nicotinamide, acetic acid, formic acid, butyric acid, trimesic acid, 5-nitroisophthalic acid, adamantane-1,3,5,7 30 tetracarboxylic acid, formamide, succinic acid, fumaric acid, tartaric acid, malic acid, malonic acid, benzamide, mandelic acid, glycolic acid, fumaric acid, maleic acid, urea, 36 WO 2008/109437 PCT/US2008/055495 nicotinic acid, piperazine, p-phthalaldehyde, 2,6-pyridinecarboxylic acid, 5-nitroisophthalic acid, citric acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benezenesulfonic acid. In general, all physical forms of compounds of the formula 1, 11, 111, IV or V are 5 intended to be within the scope of the present invention. A pyridazine compound, in particular a compound of the Formula 1, 11, 111, IV, or V, may optionally comprise a carrier interacting with one or more radicals in the compound, 1 2 3 4 5 6 7 for example R , R , R , R , R , R or R in Formula I. A carrier may be a polymer, carbohydrate, or peptide, or derivatives or combinations thereof, and it may be optionally 10 substituted, for example, with one or more alkyl, halo, hydroxyl, halo, or amino. A carrier may be directly or indirectly covalently attached to a pyridazine compound. A carrier may be substituted with substituents described herein including without limitation one or more alkyl, amino, nitro, halogen, thiol, thioalkyl, sulfate, sulfonyl, sulfinyl, sulfoxide and hydroxyl groups. In aspects of the invention the carrier is an amino acid including alanine, 15 glycine, praline, methionine, serine, threonine, asparagine, alanyl-alanyl, prolyl-methionyl, or glycyl-glycyl. A carrier can also include a molecule that targets a pyridazine compound, in particular a compound of the Formula 1, 11, 111, IV, or V, to a particular tissue or organ. Thus, a carrier may facilitate or enhance transport of a pyridazine compound, in particular a compound of the Formula I, II, III, IV or V, to a target therapeutic site, for example the 20 brain. A "polymer" refers to molecules comprising two or more monomer subunits that may be identical repeating subunits or different repeating subunits. A monomer generally comprises a simple structure, low-molecular weight molecule containing carbon. Polymers may optionally be substituted. Polymers that can be used in the present invention include 25 without limitation vinyl, acryl, styrene, carbohydrate derived polymers, polyethylene glycol (PEG), polyoxyethylene, polymethylene glycol, poly-trimethylene glycols, polyvinylpyrrolidone, polyoxyethylene-polyoxypropylene block polymers, and copolymers, salts, and derivatives thereof. In aspects of the invention, the polymer is poly(2-acrylamido-2-methyl- 1 -propanesulfonic acid); poly(2-acrylamido-2-methyl,- 1 30 propanesulfonic acid-coacrylonitrile, poly(2-acrylamido-2-methyl-1-propanesulfonic acid co-styrene), poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); and sulfates and 37 WO 2008/109437 PCT/US2008/055495 sulfonates derived therefrom; poly(acrylic acid), poly(methylacrylate), poly(methyl methacrylate), and poly(vinyl alcohol). A "carbohydrate" as used herein refers to a polyhydroxyaldehyde, or polyhydroxyketone and derivatives thereof. The term includes monosaccharides such as 5 erythrose, arabinose, allose, altrose, glucose, mannose, threose, xylose, gulose, idose, galactose, talose, aldohexose, fructose, ketohexose, ribose, and aldopentose. The term also includes carbohydrates composed of monosaccharide units, including disaccharides, ogliosaccharides, or polysaccharides. Examples of disaccharides are sucrose, lactose, and maltose. Oligosaccharides generally contain between 3 and 9 monosaccharide units and 10 polysaccharides contain greater than 10 monosaccharide units. A carbohydrate group may be substituted at one two, three or four positions, other than the position of linkage to a pyridazine compound. For example, a carbohydrate may be substituted with one or more alkyl, amino, nitro, halo, thiol, carboxyl, or hydroxyl groups, which are optionally substituted. Illustrative substituted carbohydrates are glucosamine, or galactosamine. In 15 aspects of the invention, the carbohydrate is a sugar, in particular a hexose or pentose and may be an aldose or a ketose. A sugar may be a member of the D or L series and can include amino sugars, deoxy sugars, and their uronic acid derivatives. In embodiments of the invention where the carbohydrate is a hexose, the hexose is glucose, galactose, or mannose, or substituted hexose sugar residues such as an amino sugar residue such as 20 hexosamine, galactosamine, glucosamine, in particular D-glucosamine (2-amino-2-doexy D-glucose) or D-galactosamine (2-amino-2-deoxy-D-galactose). Illustrative pentose sugars include arabinose, fucose, and ribose. A sugar residue may be linked to a pyridazine compound from a 1,1 linkage, 1,2 linkage, 1,3 linkage, 1,4 linkage, 1,5 linkage, or 1,6 linkage. A linkage may be via an 25 oxygen atom of a pyridazine compound. An oxygen atom can be replaced one or more times by -CH 2 - or -S- groups. The term "carbohydrate" also includes glycoproteins such as lectins (e.g. concanavalin A, wheat germ agglutinin, peanutagglutinin, seromucoid, and orosomucoid) and glycolipids such as cerebroside and ganglioside. 30 A "peptide" carrier includes one, two, three, four, or five or more amino acids covalently linked through a peptide bond. A peptide can comprise one or more naturally 38 WO 2008/109437 PCT/US2008/055495 occurring amino acids, and analogs, derivatives, and congeners thereof. A peptide can be modified to increase its stability, bioavailability, solubility, etc. "Peptide analogue" and "peptide derivative" as used herein include molecules which mimic the chemical structure of a peptide and retain the functional properties of the peptide. A carrier can be an amino 5 acid such as alanine, glycine, proline, methionine, serine, threonine, histidine, asparagine, alanyl-alanyl, prolyl-methionyl, or glycyl-glycyl. A carrier can be a polypeptide such as albumin, antitrypsin, macroglobulin, haptoglobin, caeruloplasm, transferring, a- or P- lipoprotein, P- or y- globulin or fibrinogen. A peptide can be attached to a pyridazine compound through a functional group on the side chain of certain amino acids (e.g. serine) 10 or other suitable functional groups. A carrier may comprise four or more amino acids with groups attached to three or more of the amino acids through functional groups on side chains. In an aspect, the carrier is one amino acid, in particular a sulfonate derivative of an amino acid, for example cysteic acid. Approaches to designing peptide analogues, derivatives and mimetics are known in 15 the art. For example, see Farmer, P. S. in Drug Design (E. J. Ariens, ed.) Academic Press, New York, 1980, vol. 10, pp. 119-143; Ball. J. B. and Alewood, P. F. (1990) J Mol. Recognition 3:55; Morgan, B. A. and Gainor, J. A. (1989) Ann. Rep. Med. Chem. 24:243; and Freidinger, R. M. (1989) Trends Pharmacol. Sci. 10:270. See also Sawyer, T. K. (1995) "Peptidomimetic Design and Chemical Approaches to Peptide Metabolism" in 20 Taylor, M. D. and Amidon, G. L. (eds.) Peptide-Based Drug Design: Controlling Transport and Metabolism, Chapter 17; Smith, A. B. 3rd, et al. (1995) J. Am. Chem. Soc. 117:11113 11123; Smith, A. B. 3rd, et al. (1994) J. Am. Chem. Soc. 116:9947-9962; and Hirschman, R., et al. (1993) J. Am. Chem. Soc. 115:12550-12568. The term "alkyl", either alone or within other terms such as "thioalkyl" and 25 "arylalkyl", means a monovalent, saturated hydrocarbon radical which may be a straight chain (i.e. linear) or a branched chain. An alkyl radical for use in the present invention generally comprises from about 1 to 20 carbon atoms, particularly from about 1 to 10, 1 to 8 or 1 to 7, more particularly about 1 to 6 carbon atoms, or 3 to 6 carbon atoms. Illustrative alkyl radicals include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, 30 isobutyl, isopentyl, amyl, sec-butyl, tert-butyl, tert-pentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, n-dodecyl, n-tetradecyl, pentadecyl, n-hexadecyl, heptadecyl, n 39 WO 2008/109437 PCT/US2008/055495 octadecyl, nonadecyl, eicosyl, dosyl, n-tetracosyl, and the like, along with branched variations thereof. In certain aspects of the invention an alkyl radical is a C 1

-C

6 lower alkyl comprising or selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, isopentyl, amyl, tributyl, sec-butyl, tert-butyl, 5 tert-pentyl, and n-hexyl. An alkyl radical may be optionally substituted with substituents as defined herein at positions that do not significantly interfere with the preparation of compounds of the Formula 1, 11, 111, IV, or V and do not significantly reduce the efficacy of the compounds. In certain aspects of the invention, an alkyl radical is substituted with substituents, in particular one to five substituents, including halo, lower alkoxy, lower 10 aliphatic, a substituted lower aliphatic, hydroxy, cyano, nitro, thio, amino, keto, aldehyde, ester, amide, substituted amino, carboxyl, sulfonyl, sulfinyl, sulfenyl, sulfate, sulfoxide, substituted carboxyl, halogenated lower alkyl (e.g. CF 3 ), halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, cycloaliphatic, substituted cycloaliphatic, or aryl (e.g., phenylmethyl 15 (i.e. benzyl)). Substituents on an alkyl group may themselves be substituted. As used herein in respect to certain aspects of the invention, the term "substituted aliphatic" refers to an alkyl or an alkane possessing less than 10 carbons where at least one of the aliphatic hydrogen atoms has been replaced by a halogen, an amino, a hydroxy, a nitro, a thio, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted 20 lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic, etc.). Examples of such groups include, but are not limited to, 1-chloroethyl and the like. As used herein in respect to certain aspects of the invention, the term "lower-alkyl substituted-amino" refers to any alkyl unit containing up to and including eight carbon 25 atoms where one of the aliphatic hydrogen atoms is replaced by an amino group. Examples of such groups include, but are not limited to, ethylamino and the like. As used herein in respect to certain aspects of the invention, the term "lower-alkyl substituted-halogen" refers to any alkyl chain containing up to and including eight carbon atoms where one of the aliphatic hydrogen atoms is replaced by a halogen. Examples of 30 such groups include, but are not limited to, chlorethyl and the like. 40 WO 2008/109437 PCT/US2008/055495 As used herein, the term "acetylamino" shall mean any primary or secondary amino that is acetylated. Examples of such groups include, but are not limited to, acetamide and the like. As used herein the term "alkenyl" refers to an unsaturated, acyclic branched or 5 straight-chain hydrocarbon radical comprising at least one double bond. An alkenyl radical may contain from about 2 to 24, 2 to 15, or 2 to 10 carbon atoms, in particular from about 3 to 8 carbon atoms and more particularly about 3 to 6 or 2 to 6 carbon atoms. Suitable alkenyl radicals include without limitation ethenyl, propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), and prop-2-en-2-yl), buten-1-yl, but-1-en-2-yl, 10 2-methyl-prop-I-en-i -yl, but-2-en- I -yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, hexen-1-yl, 3-hydroxyhexen-1-yl, hepten-1-yl, and octen-1-yl, and the like. An alkenyl radical may be optionally substituted similar to alkyl. In aspects of the invention, "substituted alkenyl" includes an alkenyl group substituted by, for example, one to three substituents, preferably one to two substituents, 15 such as alkyl, alkoxy, haloalkoxy, alkylalkoxy, haloalkoxyalkyl, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, amino, alkylamino, alkanoylamino, aminoacyl, aminoacyloxy, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, carbamyl, keto, thioketo, thiol, alkylthio, sulfonyl, sulfonamido, thioalkoxy, aryl, nitro, and the like. As used herein, the term "alkynyl" refers to an unsaturated, branched or straight 20 chain hydrocarbon radical comprising one or more triple bonds. An alkynyl radical may contain about I to 20, 1 to 15, or 2-10 carbon atoms, particularly about 3 to 8 carbon atoms and more particularly about 3 to 6 carbon atoms. Suitable alkynyl radicals include without limitation ethynyl, such as prop-1-yn-1-yl and prop-2-yn-1-yl, butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, and but-3-yn-1-yl, pentynyls such as pentyn-1-yl, 25 pentyn-2-yl, 4-methoxypentyn-2-yl, and 3-methylbutyn-1-yl, hexynyls such as hexyn-1-yl, hexyn-2-yl, hexyn-3-yl, and 3,3-dimethylbutyn-1-yl radicals and the like. An alkynyl may be optionally substituted similar to alkyl. The term "cycloalkynyl" refers to cyclic alkynyl groups. In aspects of the invention, "substituted alkynyl" includes an alkynyl group 30 substituted by, for example, a substituent, such as, alkyl, alkoxy, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, amino, alkylamino, alkanoylamino, 41 WO 2008/109437 PCT/US2008/055495 aminoacyl, aminoacyloxy, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, carbamyl, keto, thioketo, thiol, alkylthio, sulfonyl, sulfonamido, thioalkoxy, aryl, nitro, and the like. As used herein the term "alkylene" refers to a linear or branched radical having from about 1 to 10, 1 to 8, 1 to 6, or 2 to 6 carbon atoms and having attachment points for two or 5 more covalent bonds. Examples of such radicals are methylene, ethylene, propylene, butylene, pentylene, hexylene, ethylidene, methylethylene, and isopropylidene. When an alkenylene radical is present as a substituent on another radical it is typically considered to be a single substituent rather than a radical formed by two substituents. As used herein the term "alkenylene" refers to a linear or branched radical having 10 from about 2 to 10, 2 to 8, or 2 to 6 carbon atoms, at least one double bond, and having attachment points for two or more covalent bonds. Examples of alkenylene radicals include 1,1-vinylidene (-CH 2 =C-), 1,2-vinylidene (-CH=CH-), and 1,4-butadienyl (-CH=CH CH=CH-). As used herein the term "halo" refers to a halogen such as fluorine, chlorine, 15 bromine or iodine atoms. As used herein the term "hydroxyl" or "hydroxy" refers to an -OH group. As used herein the term "cyano" refers to a carbon radical having three of four covalent bonds shared by a nitrogen atom, in particular -C=N. A cyano group may be substituted with substituents described herein. 20 As used herein the term "alkoxy" refers to a linear or branched oxy-containing radical having an alkyl portion of one to about ten carbon atoms, such as a methoxy radical, which may be substituted. In aspects of the invention an alkoxy radical may comprise about 1-10, 1-8, 1-6, or 1-3 carbon atoms. In embodiments of the invention, an alkoxy radical comprises about 1-6 carbon atoms and includes a CI-C 6 alkyl-O-radical 25 wherein C 1

-C

6 alkyl has the meaning set out herein. Examples of alkoxy radicals include without limitation methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy alkyls. An "alkoxy" radical may optionally be substituted with one or more substitutents disclosed herein including alkyl atoms to provide "alkylalkoxy" radicals; halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals (e.g. fluoromethoxy, chloromethoxy, 30 trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropox) and "haloalkoxyalkyl" radicals (e.g. 42 WO 2008/109437 PCT/US2008/055495 fluoromethoxymethyl, chloromethoxyethyl, trifluoromethoxymethyl, difluoromethoxyethyl, and trifluoroethoxymethyl). As used herein the term "alkenyloxy" refers to linear or branched oxy-containing radicals having an alkenyl portion of about 2 to 10 carbon atoms, such as an ethenyloxy or 5 propenyloxy radical. An alkenyloxy radical may be a "lower alkenyloxy" radical having about 2 to 6 carbon atoms. Examples of alkenyloxy radicals include without limitation ethenyloxy, propenyloxy, butenyloxy, and isopropenyloxy alkyls. An "alkenyloxy" radical may be substituted with one or more substitutents disclosed herein including halo atoms, such as fluoro, chloro or bromo, to provide "haloalkenyloxy" radicals (e.g. 10 trifluoroethenyloxy, fluoroethenyloxy, difluoroethenyloxy, and fluoropropenyloxy). A "carbocylic" includes radicals derived from a saturated or unstaturated, substituted or unsubstituted 5 to 14, 5 to 12, or 5 to 10 member organic nucleus whose ring forming atoms (other than hydrogen) are solely carbon. Examples of carbocyclic radicals are cycloalkyl, cycloalkenyl, aryl, in particular phenyl, naphthyl, norbornanyl, 15 bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenylcyclohexyl, acenapththylenyl, anthracenyl, biphenyl, bibenzylyl, and related bibenzylyl homologs, octahydronaphthyl, tetrahydronaphthyl, octahydroquinolinyl, dimethoxytetrahydronaphthyl and the like. As used herein, the term "cycloalkyl" refers to radicals having from about 3 to 15, 3 20 to 10, 3 to 8, or 3 to 6 carbon atoms and containing one, two, three, or four rings wherein such rings may be attached in a pendant manner or may be fused. In aspects of the invention, "cycloalkyl" refers to an optionally substituted, saturated hydrocarbon ring system containing 1 to 2 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C 3

-C

7 carbocylic ring. Examples of cycloalkyl groups include single ring 25 structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclododecyl, and the like, or multiple ring structures such as adamantanyl, and the like. In certain aspects of the invention the cycloalkyl radicals are "lower cycloalkyl" radicals having from about 3 to 10, 3 to 8, 3 to 6, or 3 to 4 carbon atoms, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 30 cycloheptyl. The term "cycloalkyl" also embraces radicals where cycloalkyl radicals are 43 WO 2008/109437 PCT/US2008/055495 fused with aryl radicals or heterocyclyl radicals. A cycloalkyl radical may be optionally substituted with groups as disclosed herein. In aspects of the invention, "substituted cycloalkyl" includes cycloalkyl groups having from 1 to 5 (in particular 1 to 3) substituents including without limitation alkyl, 5 alkenyl, alkoxy, cycloalkyl, substituted cycloalkyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, keto, thioketo, thiol, thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, hydroxyamino, alkoxyamino, and nitro. As used herein in respect to certain aspects of the invention, the term 10 "cycloaliphatic" refers to a cycloalkane possessing less than 8 carbons or a fused ring system consisting of no more than three fused cycloaliphatic rings. Examples of such groups include, but are not limited to, decalin and the like. As used herein in respect to certain aspects of the invention, the term "substituted cycloaliphatic" refers to a cycloalkane possessing less than 8 carbons or a fused ring 15 system consisting of no more than three fused rings, and where at least one of the aliphatic hydrogen atoms has been replaced by a halogen, a nitro, a thio, an amino, a hydroxy, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic). Examples of such groups include, but are not limited to, 1-chlorodecalyl and the like. 20 A used herein, the term "cycloalkenyl" refers to radicals comprising about 4 to 16, 2 to 15, 2 to 10, 2 to 8, 4 to 10, 3 to 8, 3 to 7, 3 to 6, or 4 to 6 carbon atoms, one or more carbon-carbon double bonds, and one, two, three, or four rings wherein such rings may be attached in a pendant manner or may be fused. In certain aspects of the invention the cycloalkenyl radicals are "lower cycloalkenyl" radicals having three to seven carbon atoms. 25 Examples of cycloalkenyl radicals include without limitation cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. A cycloalkenyl radical may be optionally substituted with groups as disclosed herein, in particular 1, 2, or 3 substituents which may be the same or different. As used herein the term "cycloalkoxy" refers to cycloalkyl radicals (in particular, 30 cycloalkyl radicals having 3 to 15, 3 to 8 or 3 to 6 carbon atoms) attached to an oxy radical. 44 WO 2008/109437 PCT/US2008/055495 Examples of cycloalkoxy radicals include cyclohexoxy and cyclopentoxy. A cycloalkoxy radical may be optionally substituted with groups as disclosed herein. As used herein, the term "aryl", alone or in combination, refers to a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached 5 together in a pendant manner or may be fused. In aspects of the invention an aryl radical comprises 4 to 24 carbon atoms, in particular 4 to 10, 4 to 8, or 4 to 6 carbon atoms. Illustrative "aryl" radicals includes without limitation aromatic radicals such as phenyl, benzyl, naphthyl, indenyl, benzocyclooctenyl, benzocycloheptenyl, pentalenyl, azulenyl, tetrahydronaphthyl, indanyl, biphenyl, acephthylenyl, fluorenyl, phenalenyl, 10 phenanthrenyl, and anthracenyl. An aryl radical may be optionally subsitituted with groups as disclosed herein, in particular hydroxyl, alkyl ("arylalkyl"), carbonyl, carboxyl, thiol ("thioalkyl"), amino, and/or halo, in particular a substituted aryl includes without limitation arylamine and arylalkylamine. As used herein in respect to certain aspects of the invention, the term "substituted 15 aryl" includes an aromatic ring, or fused aromatic ring system consisting of no more than three fused rings at least one of which is aromatic, and where at least one of the hydrogen atoms on a ring carbon has been replaced by a halogen, an amino, a hydroxy, a nitro, a thio, an alkyl, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted 20 cycloaliphatic). Examples of such groups include, but are not limited to, hydroxyphenyl, chlorophenyl and the like. In aspects of the invention, an aryl radical may be optionally subsitituted with one to four substituents such as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, halo, trifluoromethoxy, trifluoromethyl, 25 hydroxy, alkoxy, alkanoyl, alkanoyloxy, aryloxy, aralkyloxy, amino, alkylamino, arylamino, aralkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, sulfonic acid, alkysulfonyl, sulfonamido, aryloxy and the like. A substituent may be further substituted by hydroxy, halo, alkyl, alkoxy, alkenyl, alkynyl, 30 aryl or aralkyl. In aspects of the invention an aryl radical is substituted with hydroxyl, alkyl, carbonyl, carboxyl, thiol, amino, and/or halo. The term "aralkyl" refers to an aryl or 45 WO 2008/109437 PCT/US2008/055495 a substituted aryl group bonded directly through an alkyl group, such as benzyl. Other particular examples of substituted aryl radicals include chlorobenyzl, and amino benzyl. As used herein, the term "aryloxy" refers to aryl radicals, as defined above, attached to an oxygen atom. Exemplary aryloxy groups include napthyloxy, quinolyloxy, 5 isoquinolizinyloxy, and the like. As used herein the term "arylalkoxy," refers to an aryl group attached to an alkoxy group. Representative examples of arylalkoxy groups include, but are not limited to, 2-phenylethoxy, 3-naphth-2-ylpropoxy, and 5-phenylpentyloxy. As used herein, the term "aroyl" refers to aryl radicals, as defined above, attached to 10 a carbonyl radical as defined herein, including without limitation benzoyl and toluoyl. An aroyl radical may be optionally substituted with groups as disclosed herein. As used herein the term "heteroaryl" refers to fully unsaturated heteroatom containing ring-shaped aromatic radicals having at least one heteroatom selected from carbon, nitrogen, sulfur and oxygen. A heteroaryl radical may contain one, two or three 15 rings and the rings may be attached in a pendant manner or may be fused. In aspects of the invention the term refers to fully unsaturated heteroatom-containing ring-shaped aromatic radicals having from 3 to 15, 3 to 10, 3 to 8, 5 to 15, 5 to 10, or 5 to 8 ring members selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom. Examples of "heteroaryl" radicals, include without limitation, an unsaturated 5 20 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl and the like; an unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, in particular, indolyl, isoindolyl, indolizinyl, indazolyl, quinazolinyl, pteridinyl, quinolizidinyl, phthalazinyl, 25 naphthyridinyl, quinoxalinyl, cinnolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, carbazolyl, purinyl, benzimidazolyl, quinolyl, isoquinolyl, quinolinyl, isoquinolinyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl and the like; an unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, in particular, 2-furyl, 3-furyl, pyranyl, and the like; an unsaturated 5 to 6-membered heteromonocyclic group 30 containing a sulfur atom, in particular, thienyl, 2-thienyl, 3-thienyl, and the like; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 46 WO 2008/109437 PCT/US2008/055495 1 to 3 nitrogen atoms, in particular, furazanyl, benzofurazanyl, oxazolyl, isoxazolyl, and oxadiazolyl; an unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, in particular benzoxazolyl, benzoxadiazolyl and the like; an unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 5 to 3 nitrogen atoms, for example, thiazolyl, isothiazolyl, thiadiazolyl and the like; an unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as benzothiazolyl, benzothiadiazolyl and the like. The term also includes radicals where heterocyclic radicals are fused with aryl radicals, in particular bicyclic radicals such as benzofuranyl, benzothiophenyl, phthalazinyl, chromenyl, 10 xanthenyl, and the like. A heteroaryl radical may be optionally substituted with groups as disclosed herein, for example with an alkyl, amino, halogen, etc., in particular a heteroarylamine. In aspects of the invention, the term refers to an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, 15 pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl and the like. A heteroaryl radical may be optionally substituted with groups disclosed herein, for example with an alkyl, amino, halogen, etc., in particular a substituted heteroaryl radical is a heteroarylamine. 20 The term "heterocyclic" refers to saturated and partially saturated heteroatom containing ring-shaped radicals having at least one heteroatom selected from carbon, nitrogen, sulfur and oxygen. A heterocylic radical may contain one, two or three rings wherein such rings may be attached in a pendant manner or may be fused. In an aspect, the term refers to a saturated and partially saturated heteroatom-containing ring-shaped 25 radicals having from about 3 to 15, 3 to 10, 5 to 15, 5 to 10, or 3 to 8 ring members selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom. Examplary saturated heterocyclic radicals include without limitation a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl]; a saturated 3 to 6-membered 30 heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl]; and, a saturated 3 to 6-membered heteromonocyclic group 47 WO 2008/109437 PCT/US2008/055495 containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl] etc. Examples of partially saturated heterocyclyl radicals include without limitation dihydrothiophene, dihydropyranyl, dihydrofuranyl and dihydrothiazolyl. Illustrative heterocyclic radicals include without limitation aziridinyl, azetidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 5 azepinyl, 1,3-dioxolanyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, pyrazolinyl, 1,4-dithianyl, thiomorpholinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, thioxanyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, 10 imidazolidinyl, 3H-indolyl, quinuclidinyl, quinolizinyl, and the like. As used herein in respect to certain aspects of the invention, the term "heterocyclic" refers to a cycloalkane and/or an aryl ring system, possessing less than 8 carbons, or a fused ring system consisting of no more than three fused rings, where at least one of the ring carbon atoms is replaced by oxygen, nitrogen or sulfur. Examples of such groups 15 include, but are not limited to, morpholino and the like. As used herein in respect to certain aspects of the invention, the term "substituted heterocyclic" refers to a cycloalkane and/or an aryl ring system, possessing less than 8 carbons, or a fused ring system consisting of no more than three fused rings, where at least one of the ring carbon atoms is replaced by oxygen, nitrogen or sulfur, and where at least 20 one of the aliphatic hydrogen atoms has been replaced by a halogen, hydroxy, a thio, nitro, an amino, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic). Examples of such groups include, but are not limited to 2-chloropyranyl. The foregoing heteroaryl and heterocyclic groups may be C-attached or N-attached 25 (where such is possible). As used herein the term "sulfonyl", used alone or linked to other terms such as alkylsulfonyl or arylsulfonyl, refers to the divalent radicals -SO 2 -. In aspects of the invention, the sulfonyl group may be attached to a substituted or unsubstituted hydroxyl, alkyl group, ether group, alkenyl group, alkynyl group, aryl group, cycloalkyl group, 30 cycloalkenyl group, cycloalkynyl group, heterocyclic group, carbohydrate, peptide, or peptide derivative. 48 WO 2008/109437 PCT/US2008/055495 The term "sulfinyl", used alone or linked to other terms such as alkylsulfinyl (i.e. -S(O)-alkyl) or arylsulfinyl, refers to the divalent radicals -S(O)-. The term "sulfonate" is art recognized and includes a group represented by the formula: 5 - - -- O R 18 0 wherein R 1 is an electron pair, hydrogen, alkyl, cycloalkyl, aryl, alkenyl, alkynyl, cycloalkenyl, cycloalkynyl, heterocyclic, carbohydrate, peptide, or peptide derivative. 10 The term "sulfate", used alone or linked to other terms, is art recognized and includes a group that can be represented by the formula: -- O---OF.19 OOFJ 0 wherein R19 is an electron pair, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, carbohydrate, peptide or peptide derivative. 15 The term "sulfoxide" refers to the radical -S=O. As used herein the term "amino", alone or in combination, refers to a radical where a nitrogen atom (N) is bonded to three substituents being any combination of hydrogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, silyl, heterocyclic, or heteroaryl with the general chemical formula -NR3 R 3 9 where R and R39 can be any combination of 20 hydrogen, hydroxyl, alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, aryl, carbonyl carboxyl, amino, silyl, heteroaryl, or heterocyclic which may or may not be substituted. Optionally one substituent on the nitrogen atom may be a hydroxyl group (-OH) to provide an amine known as a hydroxylamine. Illustrative examples of amino groups are amino (-NH 2 ), alkylamino, acylamino, cycloamino, acycloalkylamino, arylamino, arylalkylamino, and 25 lower alkylsilylamino, in particular methylamino, ethylamino, dimethylamino, 2-propylamino, butylamino, isobutylamino, cyclopropylamino, benzylamino, allylamino, hydroxylamino, cyclohexylamino, piperidinyl, hydrazinyl, benzylamino, 49 WO 2008/109437 PCT/US2008/055495 diphenylmethylamino, tritylamino, trimethylsilylamino, and dimethyl-tert.-butylsilylamino, which may or may not be substituted. As used herein the term "thiol" means -SH. A thiol may be substituted with a substituent disclosed herein, in particular alkyl (thioalkyl), aryl (thioaryl), alkoxy 5 (thioalkoxy) or carboxyl. The term "sulfenyl" used alone or linked to other terms such as alkylsulfenyl, refers to the radical -SR wherein R is not hydrogen. In aspects of the invention R2 is substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, silyl, silylalkyl, heterocyclic, heteroaryl, carbonyl, carbamoyl, alkoxy, or carboxyl. 10 As used herein, the term "thioalkyl", alone or in combination, refers to a chemical functional group where a sulfur atom (S) is bonded to an alkyl, which may be substituted. Examples of thioalkyl groups are thiomethyl, thioethyl, and thiopropyl. A thioalkyl may be substituted with a substituted or unsubstitute carboxyl, aryl, heterocylic, carbonyl, or heterocyclic. 15 As used herein the term "thioaryl", alone or in combination, refers to a chemical functional group where a sulfur atom (S) is bonded to an aryl group with the general chemical formula -SR26 where R26 is aryl which may be substituted. Illustrative examples of thioaryl groups and substituted thioaryl groups are thiophenyl, chlorothiophenyl, para-chlorothiophenyl, thiobenzyl, 4-methoxy-thiophenyl, 4-nitro-thiophenyl, and 20 para-nitrothiobenzyl. As used herein the term "thioalkoxy", alone or in combination, refers to a chemical functional group where a sulfur atom (S) is bonded to an alkoxy group with the general chemical formula -SR where R is an alkoxy group which may be substituted. A "thioalkoxy group" may have 1-6 carbon atoms i.e. a -S-(O)-C 1

-C

6 alkyl group wherein C 1 25 -C 6 alkyl have the meaning as defined above. Illustrative examples of a straight or branched thioalkoxy group or radical having from 1 to 6 carbon atoms, also known as a C 1

-C

6 thioalkoxy, include thiomethoxy and thioethoxy. A thiol may be substituted with a substituted or unsubstituted heteroaryl or heterocyclic, in particular a substituted or unsubstituted saturated 3 to 6-membered 30 heteromonocylic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl] or a saturated 3 to 6-membered heteromonocyclic group 50 WO 2008/109437 PCT/US2008/055495 containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl; sydnonyl], especially a substituted morpholinyl or piperidinyl. As used herein, the term "carbonyl" refers to a carbon radical having two of the four covalent bonds shared with an oxygen atom. 14 5 As used herein, the term "carboxyl", alone or in combination, refers to -C(O)OR or -C(=O)OR14 wherein R14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, a heteroaryl, or a heterocyclic, which may optionally be substituted. In particular aspects of the invention, -C(O)OR 4 provides an ester or an amino acid derivative. An esterified form is also particularly 10 referred to herein as a "carboxylic ester". In aspects of the invention a "carboxyl" may be substituted, in particular substituted with alkyl which is optionally substituted with one or more of amino, amino, halo, alkylamino, aryl, carboxyl or a heterocyclic. Examples of carboxyl groups are methoxycarbonyl, butoxycarbonyl, tert.alkoxycarbonyl such as tert.butoxycarbonyl, arylmethyoxycarbonyl having one or two aryl radicals including 15 without limitation phenyl optionally substituted by for example lower alkyl, lower alkoxy, hydroxyl, halo, and/or nitro, such as benzyloxycarbonyl, methoxybenxyloxycarbonyl, diphenylmethoxycarbonyl, 2-bromoethoxycarbonyl, 2-iodoethoxycarbonyltert.butylcarbonyl, 4-nitrobenzyloxycarbonyl, diphenylmethoxy carbonyl, benzhydroxycarbonyl, di-(4-methoxyphenyl-methoxycarbonyl, 20 2-bromoethoxycarbonyl, 2-iodoethoxycarbonyl, 2-trimethylsilylethoxycarbonyl, or 2-triphenylsilylethoxycarbonyl. Additional carboxyl groups in esterified form are silyloxycarbonyl groups including organic silyloxycarbonyl. The silicon substituent in such compounds may be substituted with lower alkyl (e.g. methyl), alkoxy (e.g. methoxy), and/or halo (e.g. chlorine). Examples of silicon substituents include trimethylsilyl and 25 dimethyltert.butylsilyl. In aspects of the invention, the carboxyl group may be an alkoxy carbonyl, in particular methoxy carbonyl, ethoxy carbonyl, isopropoxy carbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, or heptyloxy carbonyl, especially methoxy carbonyl or ethoxy carbonyl. As used herein, the term "carbamoyl", alone or in combination, refers to amino, 30 monoalkylamino, dialkylamino, monocycloalkylamino, alkylcycloalkylamino, and dicycloalkylamino radicals, attached to one of two unshared bonds in a carbonyl group. 51 WO 2008/109437 PCT/US2008/055495 As used herein, the term "carboxamide" refers to the group -CONH-. As used herein, the term "nitro" means -NO 2 -. As used herein, the term "acyl", alone or in combination, means a carbonyl or thiocarbonyl group bonded to a radical selected from, for example, optionally substituted, 5 hydrido, alkyl (e.g. haloalkyl), alkenyl, alkynyl, alkoxy ("acyloxy" including acetyloxy, butyryloxy, iso-valeryloxy, phenylacetyloxy, benzoyloxy, p-methoxybenzoyloxy, and substituted acyloxy such as alkoxyalkyl and haloalkoxy), aryl, halo, heterocyclyl, heteroaryl, sulfinyl (e.g. alkylsulfinylalkyl), sulfonyl (e.g. alkylsulfonylalkyl), cycloalkyl, cycloalkenyl, thioalkyl, thioaryl, amino (e.g alkylamino or dialkylamino), and aralkoxy. 10 Illustrative examples of "acyl" radicals are formyl, acetyl, 2-chloroacetyl, 2-bromacetyl, benzoyl, trifluoroacetyl, phthaloyl, malonyl, nicotinyl, and the like. In aspects of the invention, "acyl" refers to a group -C(O)R 64, where R64 is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl. Examples include, but are not limited to formyl, acetyl, 15 cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like. As used herein the term "phosphonate" refers to a C-PO(OH) 2 or C-PO(OR 65)2 group wherein R65 is alkyl or aryl which may be substituted. As used herein, "ureido" refers to the group "-NHCONH-". A ureido radical includes an alkylureido comprising a ureido substituted with an alkyl, in particular a lower 20 alkyl attached to the terminal nitrogen of the ureido group. Examples of an alkylureido include without limitation N'-methylureido, N'-ethylureido, N'-n-propylureido, N'-i propylureido and the like. A ureido radical also includes a N',N'-dialkylureido group containing a radical -NHCON where the terminal nitrogen is attached to two optionally substituted radicals including alkyl, aryl, heterocylic, and heteroaryl. 25 The terms used herein for radicals including "alkyl", "alkoxy", "alkenyl", "alkynyl", "hydroxyl" etc. refer to both unsubstituted and substituted radicals. The term "substituted," as used herein, means that any one or more moiety on a designated atom (e.g., hydrogen) is replaced with a selection from a group disclosed herein, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable 30 compound. Combinations of substituents and/or radicals are permissible only if such combinations result in stable compounds. "Stable compound" refers to a compound that is 52 WO 2008/109437 PCT/US2008/055495 sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. A radical in a pyridazine compound may be substituted with one or more substituents apparent to a person skilled in the art including without limitation alkyl, 5 alkoxy, alkenyl, alkynyl, alkanoyl, alkylene, alkenylene, hydroxyalkyl, haloalkyl, haloalkylene, haloalkenyl, alkoxy, alkenyloxy, alkenyloxyalkyl, alkoxyalkyl, aryl, alkylaryl, haloalkoxy, haloalkenyloxy, heterocyclic, heteroaryl, alkylsulfonyl, sulfinyl, sulfonyl, sulfenyl, alkylsulfinyl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, amino, oxy, halo, azido, thio, =0, =S, cyano, hydroxyl, 10 phosphonato, phosphinato, thioalkyl, alkylamino, arylamino, arylsulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, heteroarylsulfinyl, heteroarylsulfony, heteroarylamino, heteroaryloxy, heteroaryloxylalkyl, arylacetamidoyl, aryloxy, aroyl, aralkanoyl, aralkoxy, aryloxyalkyl, haloaryloxyalkyl, heteroaroyl, heteroaralkanoyl, heteroaralkoxy, heteroaralkoxyalkyl, thioaryl, arylthioalkyl, alkoxyalkyl, and acyl groups. These 15 substitutents may themselves be substituted. A chemical substituent is "pendant" from a radical if it is bound to an atom of the radical. In this context, the substituent can be pending from a carbon atom of a radical, a carbon atom connected to a carbon atom of the radical by a chain extender, or a heteroatom of the radical. The term "fused" means that a second ring is present (i.e, attached or 20 formed) by having two adjacent atoms in common or shared with the first ring. Pyridazine compounds, in particular compounds of the Formula I, II, III, IV, or V can be prepared using reactions and methods generally known to the person of ordinary skill in the art, having regard to that knowledge and the disclosure of this application including the Examples. The reactions are performed in a solvent appropriate to the 25 reagents and materials used and suitable for the reactions being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the compounds should be consistent with the proposed reaction steps. This will sometimes require modification of the order of the synthetic steps or selection of one particular process scheme over another in order to obtain a desired compound of the invention. It 30 will also be recognized that another major consideration in the development of a synthetic route is the selection of the protecting group used for protection of the reactive functional 53 WO 2008/109437 PCT/US2008/055495 groups present in the compounds. An authoritative account describing the many alternatives to the skilled artisan is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991). The starting materials and reagents used in preparing the pyridazine compounds are 5 either available from commercial suppliers or are prepared by methods well known to a person of ordinary skill in the art, following procedures described in such references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons, New York, 10 N.Y., 1991; March J.: Advanced Organic Chemistry, 4th ed., John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive Organic Transformations, VCH Publishers, New York, 1989. The starting materials, intermediates, and pyridazine compounds may be isolated and purified using conventional techniques, such as precipitation, filtration, distillation, 15 crystallization, chromatography, and the like. The pyridazine compounds may be characterized using conventional methods, including physical constants and spectroscopic methods, in particular HPLC. Pyridazine compounds which are basic in nature can form a wide variety of different salts with various inorganic and organic acids. In practice is it desirable to first 20 isolate a pyridazine compound from the reaction mixture as a pharmaceutically unacceptable salt and then convert the latter to the free base compound by treatment with an alkaline reagent and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of the pyridazine compounds are readily prepared by treating the base compound with a substantially 25 equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained. Pyridazine compounds which are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. These salts may be prepared by 30 conventional techniques by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations and then evaporating 54 WO 2008/109437 PCT/US2008/055495 the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents 5 are typically employed to ensure completeness of reaction and maximum product yields. In particular aspects, a compound of the formula II wherein R" is hydrogen and R 10 is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more 10 particularly pyridinyl, may be prepared by reacting a compound with a structure of formula II wherein R 1 0 is halo, in particular chloro, and R 11 is hydrogen, with boronic acid substituted with an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, 15 more particularly pyridinyl, under suitable conditions to prepare a compound of the formula II wherein R 11 is hydrogen and R 10 is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl. In an 20 embodiment, R 1 0 is phenyl substituted with halo. In another aspect, a compound of the formula II wherein R 11 is hydrogen and R 1 0 is a substituted aryl is prepared by reacting a compound with the structure of formula II wherein R 10 is halo, in particular chloro, and R 11 is hydrogen, with a substituted aryl boronic acid under suitable conditions. 25 In another aspect, a compound of the formula II wherein R 10 is hydrogen and R 1 1 is alkyl is prepared by reacting a compound with the structures of formula II wherein R 11 is halo, in particular chloro, and R 1 0 is hydrogen, with an alkyl boronic acid under suitable conditions. In an embodiment, R is lower alkyl, in particular methyl or ethyl, and a compound of the formula II wherein R 11 is chloro is reacted with lower alkyl boronic acid, 30 in particular methyl or ethyl boronic acid under suitable conditions. 55 WO 2008/109437 PCT/US2008/055495 In another aspect, a compound of the formula II is prepared wherein R 10 is hydrogen and R 11 is an alkyl by reacting a pyridazine substituted at the C3 position with halo (e.g., chloro), at the C4 position with alkyl, and at the 6 position with phenyl, with 2-(piperidin 4-yloxy)pyrimidine under suitable conditions to prepare a compound of the formula II 5 wherein R 1 0 is hydrogen and R 11 is an alkyl. In an embodiment, R 11 is methyl or ethyl. In another aspect, a compound of the formula II wherein R 10 is hydrogen and R" is aryl is prepared by reacting a compound with the structure of formula II wherein R 1 0 is hydrogen and R 11 is halo (e.g., chloro), with pyridazine substituted at the C3 position with halo (e.g., chloro), at the C4 position with aryl, and at the 6 position with phenyl, with 2 10 (piperidin-4-yloxy)pyrimidine under suitable conditions. In an embodiment, R 11 is phenyl. In another aspect, a compound of the formula II is prepared wherein R 10 is hydrogen and R" is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3 pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, 15 more particularly pyridinyl by reacting a compound of the formula II wherein R 11 is halo, in particular chloro, and R U is hydrogen, with a boronic acid substituted with an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly 20 pyridinyl, under suitable conditions. In an embodiment, a compound of the formula II is prepared wherein R 1 0 is hydrogen and R 11 is pyridinyl by reacting a compound of the formula II wherein R 1 1 is halo, in particular chloro, and R 1 0 is hydrogen, with a pyridinyl boronic acid under suitable conditions. 25 In another aspect, a compound of the formula II is prepared wherein R 10 is hydrogen and R 11 is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl by reacting a pyridazine substituted at the C3 position with 30 halo, at the C4 position with an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 56 WO 2008/109437 PCT/US2008/055495 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl, and at the 6 position with phenyl, with 2-(piperidin 4-yloxy)pyrimidine under suitable conditions. In an embodiment, a compound of the formula II is prepared wherein R 1 0 is 5 hydrogen and R 11 is pyridinyl by reacting a pyridazine substituted at the C3 position with halo, at the C4 position with pyridinyl, and at the 6 position with phenyl, with 2-(piperidin 4-yloxy)pyrimidine under suitable conditions to prepare a compound of the formula II wherein R 1 0 is hydrogen and R 11 is pyridinyl. In another aspect, a compound of the formula II is prepared wherein R 10 is hydrogen 10 and R 11 is piperidinyl or substituted piperidinyl by reacting a compound of the formula II wherein R 1 1 is halo, in particular chloro, and R 10 is hydrogen with piperazinyl or substituted piperazinyl under suitable conditions. In another aspect, a compound of the formula I is prepared wherein R Iis piperazinyl or piperazinyl substituted with alkyl, aryl, or cycloalkyl, R 2 is aryl, R', R 4 , R 5 and R 6 are 15 hydrogen and R is absent, by reacting a pyridazine substituted at the C3 position with halo and at the C4 position with aryl, with a piperazinyl or piperazinyl substituted with alkyl, aryl, or cycloalkyl under suitable conditions. In another aspect, a compound of the formula I is prepared wherein R Iis piperazinyl or piperazinyl substituted with alkyl, aryl, or cycloalkyl, R2 is an unsaturated 5 to 6 20 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl, R , 4 5 6 7 R , R and R are hydrogen and R is absent, by reacting a pyridazine substituted at the C3 position with halo and at the C4 position with an unsaturated 5 to 6 membered 25 heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl, with piperazinyl or piperazinyl substituted with alkyl, aryl, or cycloalkyl under suitable conditions. In another aspect, a compound of the formula I is prepared wherein R is substituted 30 amino in particular amino substituted with substituted morpholinyl, in particular morpholinoethyl, R 2 is aryl or an unsaturated 5 to 6 membered heteromonocyclyl group 57 WO 2008/109437 PCT/US2008/055495 containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or 3 4 5 6 7 tetrazolyl, in particular pyridinyl, R , R , R and R are hydrogen and R is absent, by reacting a pyridazine substituted at the C3 position with halo, at the C4 position with aryl 5 or an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4 pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, more particularly pyridinyl, with substituted amino in particular amino substituted with substituted morpholinyl, in particular morpholinoethyl, under suitable conditions. 10 In another aspect, a compound of the formula V is prepared wherein R 50 is aryl, R 51 is hydrogen, and R is alkyl by reacting a pyridazine substituted at position C 3 with halo, at position C 4 with aryl and at position 6 with alkyl, with 1-(2-pyrimidyl)piperazine under suitable conditions. In another aspect, a compound of the formula I is prepared wherein R 1 is substituted 15 amino, R2 is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3 pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, in 3 4 5 6 7 particular pyridinyl, R , R , R and R are hydrogen and R is absent by reacting a pyridazine substituted at the C 3 position with halo, at the C 4 position with an unsaturated 5 20 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, or tetrazolyl, in particular pyridinyl, and at the C 6 position with phenyl, and a substituted amino under suitable conditions. In the preparation of compounds of the Formula II, a precursor (see, for example, 25 Figure 10, compound (15)) that may be utilized can be obtained commercially and used directly for the synthesis of the illustrated compound MWO1-3-183WH without further purification. Compounds may be synthesized with yields of 81 - 96%. All purified compounds may be characterized by HPLC, mass spectrometry and NMR in order to confirm syntheses. In Figure 10, a synthetic scheme is shown, for synthesis of MWO1-3 30 183 WH. 58 WO 2008/109437 PCT/US2008/055495 Thus, in an aspect, a compound of the Formula II is prepared wherein a substituted 6-phenylpyridazine is reacted with 2-(piperazin-lyl)pyridmidine to produce a compound of the Formula II wherein R 1 0 and R 11 are hydrogen. A compound of the formula II wherein R 1 0 and R 11 are hydrogen can be reacted under suitable conditions and with suitable 5 reagents to introduce the radicals R 1 0 and RII which are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, carboxyl, carbonyl, carbamoyl, or 10 carboxamide. The term "disorder" refers to disorders involving disruptions to normal neural electrical activity and/or function including without limitation conduction disturbances of the central nervous system (CNS), more particularly Seizure-Related Disorders. A disorder may be either or both of an acute or chronic nature of unknown origin, hereditary origin or 15 it may be secondary to, for example, manipulation of the brain such as by surgery or radiation; alcohol, benzodiazepine, barbiturates or other drugs or chemical withdrawal; exposure to epileptogenic drugs; injury or trauma, stroke, cerebrovascular accident, fever, CNS inflammation or infection (e.g. meningitis), metabolic disturbance, or electroconvulsive therapy. The term also includes the emotional, cognitive, and motor 20 symptoms resulting from these disorders. The term "Seizure-Related Disorders" refers to a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular recurrent and/or excessive seizures. A "seizure" is a sudden disruption of the brain's normal electrical activity accompanied by altered consciousness and/or other neurological and behavioral 25 manifestations. A seizure may be partial or generalized. In some aspects of the invention, a Seizure-Related Disorder includes Epilepsy, Ictogenesis, epileptogenesis, non-epileptic convulsions, eclampsia and convulsions due to administration of a convulsive agent or trauma to a subject. Ictogenesis refers to the rapid and definitive electrical/chemical event which occurs 30 over seconds or minutes. Epileptogenesis refers to a slow biochemical or histological process occurring over months to years involving transformation of the normal brain to a 59 WO 2008/109437 PCT/US2008/055495 state susceptible to spontaneous, episodic, time-limited, recurrent seizures. Epileptogenesis involves a first initiation phase which occurs prior to the first seizure and often results from stroke, disease, trauma (e.g. caused by head injury or surgery). In the second phase of epileptogenesis, the brain, which is already susceptible to seizures, becomes more 5 susceptible to more frequent and severe seizures. The term "Epilepsy" refers to a chronic disorder of the brain characterized by transient but recurrent, excessive, or abnormal, disturbances to the electrical functions of the brain that may or may not associate with impairment or loss of consciousness and abnormal movements, sensation or behavior, in particular seizures. The term encompasses 10 epileptic syndromes that are characterized by specific symptoms that include epileptic seizures. Such syndromes include but are not limited to, absence epilepsy, psychomotor epilepsy, temporal lobe epilepsy, frontal lobe epilepsy, occipital lobe epilepsy, parietal lobe epilepsy, Lennox-Gastaut syndrome, Rasmussen's encephalitis, childhood absence epilepsy, Ramsay Hunt Syndrome type II, benign epilepsy syndrome, benign infantile 15 encephalopathy, benign neonatal convulsions, early myoclonic encephalopathy, progressive epilepsy and infantile epilepsy, mesial temporal lobe epilepsy, benign myoclonic epilepsy in infants, juvenile myoclonic epilepsy, juvenile absence epilepsy, epilepsy with generalized tonic clonic seizures in childhood, infantile spasms (West syndrome), epilepsy with continuous spike and waves in slow wave sleep (ESES), Laudau 20 Kleffner syndrome, and Rasmussen's syndrome. A subject may suffer from any combination of these syndromes. In aspects of the invention, a subject suffers from partial seizures. In other aspects of the invention, a subject suffers from generalized seizures. In aspects of the invention, a disorder is epileptogenesis. In other aspects of the invention, the disorder is epilepsy. In other aspects of the invention, the disorder is early 25 life seizures or pediatric epilepsy. COMPOSITIONS AND KITS One or more pyridazine compound, in particular a compound of the Formula I, II, III, IV, or V, may be formulated into a pharmaceutical composition for administration to a subject. Therefore, the invention provides formulations including without limitation pills, 30 tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid 60 WO 2008/109437 PCT/US2008/055495 medium) suppositories, sterile injectable solutions, and/or sterile packaged powders, which contain a pyridazine compound in particular a pure or substantially pure pyridazine compound. Pharmaceutical compositions of the present invention or fractions thereof comprise 5 suitable pharmaceutically acceptable carriers, excipients, and vehicles selected based on the intended form of administration, and consistent with conventional pharmaceutical practices. Particular compositions of the invention may contain a pyridazine compound that is pure or substantially pure. Suitable pharmaceutical carriers, excipients, and vehicles are described in the standard text, Remington: The Science and Practice of Pharmacy (21st 10 Edition. 2005, University of the Sciences in Philadelphia (Editor), Mack Publishing Company), and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. A composition of the invention may include at least one buffering agent or solution. Suitable buffering agents include, but are not limited to hydrochloric, hydrobromic, 15 hydroiodic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, glucoronic, maleic, furoic, citric, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic, pamoic, methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, galacturonic acid and mixtures thereof. Additional agents that may be included are one or more of pregelatinized maize starch, polyvinyl pyrrolidone, 20 hydroxypropyl methylcellulose, lactose, microcrystalline cellulose, calcium hydrogen phosphate, magnesium stearate, talc, silica, potato starch, sodium starch glycolate, sodium lauryl sulfate, sorbitol syrup, cellulose derivatives, hydrogenated edible fats, lecithin, acacia, almond oil, oily esters, ethyl alcohol, fractionated vegetable oils, methyl, propyl-p-hydroxybenzoates, sorbic acid and mixtures thereof. Buffering agents may 25 additionally comprise one or more of dichlorodifluoromethane, trichloro fluoromethane, dichlorotetra fluoroethane, carbon dioxide, poly (N-vinyl pyrrolidone), poly (methylmethacrylate), polyactide, polyglycolide and mixtures thereof. In some aspects, a buffering agent may be formulated as at least one medium including without limitation a suspension, solution, or emulsion. In other aspects, a buffering agent may additionally 30 comprise a formulatory agent including without limitation a pharmaceutically acceptable carrier, excipient, suspending agent, stabilizing agent or dispersing agent. 61 WO 2008/109437 PCT/US2008/055495 In aspects of the invention, a pharmaceutical composition is provided for oral administration of one or more pyridazine compounds for treatment of a disorder. By way of example for oral administration in the form of a capsule or tablet, the active component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as 5 lactose, starch, sucrose, methyl cellulose, magnesium stearate, glucose, calcium sulfate, dicalcium phosphate, mannitol, sorbital, and the like. For oral administration in a liquid form, the drug component may be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Suitable binders (e.g. gelatin, starch, corn sweeteners, natural sugars including glucose; natural and synthetic 10 gums, and waxes), lubricants (e.g. sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride), disintegrating agents (e.g. starch, methyl cellulose, agar, bentonite, and xanthan gum), flavoring agents, and coloring agents may also be combined in the compositions. Compositions as described herein can further comprise wetting or emulsifying agents, or pH buffering agents. 15 In aspects of the invention, a composition of the invention is a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The compositions can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, 20 magnesium carbonate, etc. Various delivery systems are known and can be used to administer a composition of the invention, e.g. encapsulation in liposomes, microparticles, microcapsules, and the like. Formulations for parenteral administration may include aqueous solutions, syrups, aqueous or oil suspensions and emulsions with edible oil such as cottonseed oil, coconut 25 oil or peanut oil. Dispersing or suspending agents that can be used for aqueous suspensions include synthetic or natural gums, such as tragacanth, alginate, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose, and polyvinylpyrrolidone. Compositions for parenteral administration may include sterile aqueous or non aqueous solvents, such as water, isotonic saline, isotonic glucose solution, buffer solution, 30 or other solvents conveniently used for parenteral administration of therapeutically active agents. A composition intended for parenteral administration may also include 62 WO 2008/109437 PCT/US2008/055495 conventional additives such as stabilizers, buffers, or preservatives, e.g. antioxidants such as methylhydroxybenzoate or similar additives. Compositions of the invention can be formulated as pharmaceutically acceptable salts as described herein. 5 A compound of the formula 1, 11, 111, IV or V or a composition of the invention may be sterilized by, for example, filtration through a bacteria retaining filter, addition of sterilizing agents to the compounds or composition, irradiation of the compounds or composition, or heating the compounds or composition. Alternatively, the compounds or compositions of the present invention may be provided as sterile solid preparations e.g. 10 lyophilized powder, which are readily dissolved in sterile solvent immediately prior to use. After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of a composition of the invention, such labeling would include amount, frequency, and method of administration. 15 According to the invention, a kit is provided. In an aspect, the kit comprises a compound of the formula I, II, III, IV or V or a formulation of the invention in kit form. The kit can be a package which houses a container which contains compounds of the formula 1, 11, 111, IV or V or formulations of the invention and also houses instructions for administering the compounds or formulations to a subject. The invention further relates to 20 a commercial package comprising compounds of the formula I, II, III, IV or V or formulations of the invention together with instructions for their use. In particular a label may include amount, frequency, and method of administration. The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of a composition of the invention to 25 provide a beneficial effect including a therapeutic effect. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the labeling, manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration. 30 The invention also relates to articles of manufacture and kits containing materials useful for treating a disorder disclosed herein. An article of manufacture may comprise a 63 WO 2008/109437 PCT/US2008/055495 container with a label. Examples of suitable containers include bottles, vials, and test tubes which may be formed from a variety of materials including glass and plastic. A container holds compounds of the formula 1, 11, 111, IV or V or formulations of the invention which are effective for treating a disorder disclosed herein. The label on the container indicates 5 that the compounds of the formula 1, 11, 111, IV or V or formulations of the invention are used for treating a disorder disclosed herein and may also indicate directions for use. In aspects of the invention, a medicament or formulation in a container may comprise any of the medicaments or formulations disclosed herein. In aspects of the invention, a kit of the invention comprises a container described 10 herein. In particular aspects, a kit of the invention comprises a container described herein and a second container comprising a buffer. A kit may additionally include other materials desirable from a commercial and user standpoint, including, without limitation, buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods disclosed herein (e.g., methods for treating a disorder disclosed herein). A 15 medicament or formulation in a kit of the invention may comprise any of the formulations or compositions disclosed herein. In aspects of the invention, the kits may be useful for any of the methods disclosed herein, including, without limitation treating a subject suffering from Epilepsy. Kits of the invention may contain instructions for practicing any of the methods described herein. 20 ADMINISTRATION A pyridazine compound and composition of the present invention can be administered by any means that produces contact of the active agent(s) with the agent's sites of action in the body of a subject or patient to produce a therapeutic effect, in particular a beneficial effect, in particular a sustained beneficial effect. A pyridazine 25 compound or composition of the invention can be formulated for sustained release, for delivery locally or systemically. It lies within the capability of a skilled physician or veterinarian to select a form and route of administration that optimizes the effects of the compositions and treatments of the present invention to provide therapeutic effects, in particular beneficial effects, more particularly sustained beneficial effects. 30 Pyridazine compounds and compositions may be administered in oral dosage forms such as tablets, capsules (each of which includes sustained release or timed release 64 WO 2008/109437 PCT/US2008/055495 formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular forms, all utilizing dosage forms well known to those of ordinary skill in the pharmaceutical arts. Pyridazine compounds and 5 compositions of the invention may be administered by intranasal route via topical use of suitable intranasal vehicles, or via a transdermal route, for example using conventional transdermal skin patches. A dosage protocol for administration using a transdermal delivery system may be continuous rather than intermittent throughout the dosage regimen. A sustained release formulation can also be used for the therapeutic agents. 10 In aspects of the invention the pyridazine compounds or compositions of the invention are administered by peripheral administration, in particular by intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, or pulmonary administration. 15 A therapeutically effective dose of a pyridazine compound or composition of the invention for the treatment of a particular disorder or condition to provide effects, in particular beneficial effects, more particularly sustained beneficial effects, will depend on the nature of the disorder, and can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of 20 administration, and the seriousness of the disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Suitable dosage ranges for administration are particularly selected to provide therapeutic effects, in particular beneficial effects, more particularly sustained beneficial effects. A dosage range is generally effective for triggering the desired biological 25 responses. The dosage ranges for a pyridazine compound are generally about 0.01 mg to about 3 g per kg, 0.01 mg to about 2 g per kg, 0.5 mg to about 2 g per kg, about 1 mg to about 1 g per kg, about 1mg to about 500 mg per kg, about 1 mg to about 200 mg per kg, about 1 mg to about 100 mg per kg, about 1 mg to about 50 mg per kg, about 10 mg to about 100 mg per kg, or about 30 mg to 70 mg per kg of the weight of a subject, once, 30 twice, or more per day, preferably once daily. 65 WO 2008/109437 PCT/US2008/055495 In aspects of the invention the dosages ranges are about 0.01 to 3000 mg/kg, 0.01 to 2000 mg/kg, 0.5 to 2000 mg/kg, about 0.5 to 1000 mg/kg, 0.1 to 1000 mg/kg, 0.1 to 500 mg/kg, 0.1 to 400 mg/kg, 0.1 to 300 mg/kg, 0.1 to 200 mg/kg, 0.1 to 100 mg/kg, 0.1 to 50mg/kg, 0.1 to 20 mg/kg, 0.1 to 10 mg/kg, 0.1 to 6 mg/kg, 0.1 to 5 mg/kg, 0.1 to 3 mg/kg, 5 0.1 to 2 mg/kg, 0.1 to 1 mg/kg, I to 1000 mg/kg, I to 500 mg/kg, I to 400 mg/kg, I to 300 mg/kg, 1 to 200 mg/kg, 1 to 100 mg/kg, 1 to 50mg/kg, 1 to 20 mg/kg, 1 to 10 mg/kg, 1 to 6 mg/kg, 1 to 5 mg/kg, or 1 to 3 mg/kg, or 1 to 2.5 mg/kg, or less than or about 10mg/kg, 5mg/kg, 2.5mg/kg, 1mg/kg, or 0.5 mg/kg twice daily or less. In embodiments of the invention, the dosages ranges are about 0.1 to 1000 mg/kg, 10 0.1 to 500 mg/kg, 0.1 to 400 mg/kg, 0.1 to 300 mg/kg, 0.1 to 200 mg/kg, 0.1 to 100 mg/kg, 0.1 to 75 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 20 mg/kg, 0.1 to 15 mg/kg, 0.1 to 10 mg/kg, 0.1 to 9 mg/kg, 0.1 to 8 mg/kg, 0.1 to 7 mg/kg, 0.1 to 6 mg/kg, 0.1 to 5 mg/kg, 0.1 to 4 mg/kg, 0.1 to 3 mg/kg, 0.1 to 2 mg/kg, or 0.1 to 1 mg/kg. A composition or treatment of the invention may comprise a unit dosage of a 15 pyridazine compound to provide beneficial effects, in particular one or more of the beneficial effects set out herein. A "unit dosage" or "dosage unit" refers to a unitary i.e., a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising the active agent as such or a mixture with one or more solid or liquid pharmaceutical 20 excipients, carriers, or vehicles. A pyridazine compound can be provided once daily, twice daily, in a single dosage unit or multiple dosage units (i.e., tablets or capsules) having about 50 to about 10000 mg, 50 to about 2000 mg, 70 to about 7000 mg, 70 to about 6000 mg, 70 to about 5500 mg, 70 to about 5000 mg, 70 to about 4500 mg, 70 to about 4000 mg, 70 to about 3500 mg, 70 to 25 about 3000 mg, 150 to about 2500 mg, 150 to about 2000 mg, 200 to about 2500, 200 to about 2000 mg, 200 to about 1500 mg, 700 to about 1200 mg, 70 mg to 1000 mg, 70 mg to 500 mg, in particular 200 to 2000 mg, 70 to 1200 mg, or 1000 mg. The dosage regimen of the invention will vary depending upon known factors such as the pharmacodynamic characteristics of the agents and their mode and route of 30 administration; the species, age, sex, health, medical condition, and weight of the patient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of 66 WO 2008/109437 PCT/US2008/055495 treatment, the route of administration, the renal and hepatic function of the patient, and the desired effect. Thus, a subject may be treated with a pyridazine compound or a composition of the invention on substantially any desired schedule. A pyridazine compound or composition of 5 the invention may be administered one or more times per day, in particular 1 or 2 times per day, once per week, once a month, twice a month or continuously. However, a subject may be treated less frequently, such as every other day or once a week, or more frequently. A pyridazine compound or a composition of the invention may be administered to a subject for about or at least about 24 hours, 2 days, 3 days, 1 week, 2 weeks to 4 weeks, 2 weeks to 10 6 weeks, 2 weeks to 8 weeks, 2 weeks to 10 weeks, 2 weeks to 12 weeks, 2 weeks to 14 weeks, 2 weeks to 16 weeks, 2 weeks to 6 months, 2 weeks to 12 months, 2 weeks to 18 months, or 2 weeks to 24 months, periodically or continuously. Pyridazine compounds, compositions and treatment methods described herein are indicated as therapeutic agents or methods either alone or in conjunction with other 15 therapeutic agents or other forms of treatment. They may be combined or formulated with one or more therapies or agents used to treat a condition described herein. Compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies. Therefore, compounds of the formula 1, 11, 111, IV or V may be co-administered with one or more additional therapeutic agents for treating disorders 20 disclosed herein as well as agents that are used for the treatment of complications resulting from or associated with a disorder disclosed herein, or general medications that treat or prevent side effects. In aspects, the additional therapeutic agents comprise phenobarbital, valproate, levetiracetam, tiagabine, N-methyl-D-aspartate, alpha-amino-3-hydroxy-5 25 methylisoxazole-4-propionic acid (AMPA) antagonists, and neuotrophins and their receptors. The invention will be described in greater detail by way of a specific example. The following example is offered for illustrative purposes, and is not intended to limit the invention in any manner. 30 EXAMPLES Summary 67 WO 2008/109437 PCT/US2008/055495 Early-life seizures increase vulnerability to subsequent neurologic insult. The hypothesis that early-life seizures increase susceptibility to later neurologic injury by causing chronic glial activation was tested. To determine the mechanisms by which glial activation may modulate neurologic injury, both acute changes in pro-inflammatory 5 cytokines and long-term changes in astrocyte and microglial activation and astrocyte glutamate transporters in a 'two-hit' model of kainic acid (KA)-induced seizures were examined. Methods: Postnatal day (P) 15 male rats were administered KA or phosphate buffered saline (PBS). On P45 animals either received a second treatment of KA or PBS. On P55, control (PBS-PBS), early-life seizure (KA-PBS), adult seizure (PBS-KA), and 10 'two-hit' (KA-KA) groups were examined for astrocyte and microglial activation, alteration in glutamate transporters and expression of the glial protein, clusterin. Results: P15 seizures resulted in an acute increase in hippocampal levels of IL-10 and S100B, followed by behavioral impairment and long-term increases in GFAP and S 100B. Animals in the 'two-hit' group showed greater microglial activation, neurologic injury and susceptibility to 15 seizures compared to the adult seizure group. Glutamate transporters increased following seizures but did not differ between these two groups. Treatment with Minozac, a small molecule inhibitor of proinflammatory cytokine up-regulation, following early-life seizures prevented both the long-term increase in activated glia and the associated behavioral impairment. Conclusions: These data suggest that glial activation following early-life 20 seizures results in increased susceptibility to seizures in adulthood, in part through priming microglia and enhanced microglial activation. Glial activation may be a novel therapeutic target in pediatric epilepsy. The following materials and methods were used in the study described in this example. 25 Materials and Methods: Animal use A total of 195 male Sprague-Dawley rats (Charles River Laboratories, Cambridge, MA) were used in these experiments. Animals were divided into experimental groups as summarized in Tables 6 and 7. Within each group, where multiple outcome measures were 30 required, surviving animals were randomly selected for each endpoint. All procedures were approved by the Institutional Animal Care and Use Committee of Children's Memorial 68 WO 2008/109437 PCT/US2008/055495 Research Center, Chicago, IL. Kainic acid-mediated induction of seizures On either postnatal day (P)15 or 45, rats were administered either KA (Ocean Produce International, Nova Scotia) or equivalent volume of vehicle, phosphate-buffered 5 saline (PBS, pH 7.4) (2). The dose of KA on P 15 (5 mg/kg) and P45 (15 mg/kg) was based on the age-dependent difference in threshold for KA-induced seizures (22). All injections were intraperitoneal (ip). 'Two-hit' model of kainic acid-induced seizures To determine the long-term effects of early-life seizures occurring on P15, animals 10 were allowed to recover for 30 days. On P45, rats were administered KA as previously described for the 'twohit' model of KA-induced neurologic injury (2). Control animals were administered PBS, and all animals were allowed to recover for a further 10 days before sacrifice on P55. Four experimental groups, including controls (PBS-PBS), newborn seizures (KA-PBS), adult seizures (PBS-KA), and 'two-hit' animals (KA-KA) were 15 studied. Rats were perfused transcardially with PBS and fixed with 4% paraformaldehyde (PFA) in 0.1 M PBS, pH 7.4. Brains were excised and post-fixed in 4% PFA overnight. Brains were paraffin-embedded and sectioned for immunohistochemistry. For each outcome measure, two axial sections representing the hippocampus (sections between Bregma -7.34 mm, Paxinos plate 99, and Bregma -5.60 mm, Paxinos plate 106) were 20 selected (23). Determination of seizure onset and grading severity of seizures Following administration of KA or PBS, all animals were monitored continuously for three hours. Time of latency to onset of first seizure (defined as onset of forelimb clonus) and severity of seizures were quantified as previously described (2). Only animals 25 with grade IV seizures were included in this study. Assessment of neuronal injury Neuronal injury was measured on five pm paraffin-embedded sections using Fluoro-Jade B (FJB) (Chemicon International, Temecula, CA) (24,25). The nuclear dye 4, 6-diamidino-2-phenyllindole (DAPI, Sigma, St. Louis, Missouri) was used to counterstain 30 and to identify cell nuclei. CA1, CA2, CA3, dentate gyrus (DG) and polymorph dentate gyrus (PoDG) of the hippocampus were photographed at 10x magnification, and images 69 WO 2008/109437 PCT/US2008/055495 were converted to grayscale for quantification of FJB-positive cells. The percentage of positive cells in the hippocampal regions specified was measured by thresholding for lightly stained, or FJB-positive cells (Metamorph, Universal Imaging Corporation, Sunnyvale, CA). The total FJB-positive cells in the hippocampus as well as hippocampal 5 region-specific staining were obtained for each sample. Brain homogenate preparation and protein concentration determination Hippocampal homogenates were prepared by sonication in protease inhibitor cocktail (1 tg leupeptin (Sigma, St. Louis, MO), 0.001 M 4-dithio-L-threitol (DTT, Sigma), 0.002 M sodium orthovanadate (Sigma) and 0.001 M phenylmethanesulfonyl 10 fluorid (PMSF, FLUKA, Switzerland) in I ml PBS). Total protein concentration was measured using commercially available reagents (BCA, Pierce, Rockford, IL). Measurement of pro-inflammatory cytokines Levels of IL-1r, IL-6, and TNF-a, were measured in hippocampal homogenates by enzyme linked immunosorbent assay using commercially available plates and reagents 15 (ELISA; MesoScale Discovery, MSD, Gaithersburg, Maryland). S1OOB levels were measured as described (26). Samples were analyzed in duplicates and compared with known concentrations of protein. Plates were analyzed using the SECTOR Imager 2400 (MSD). Hippocampal-linked task testing 20 The Y-maze test of spontaneous alternation was used to evaluate hippocampus dependent spatial learning (26, 27). Testing began on P27 when animals were first able to decide between the left or right arm of the maze. Testing was performed by a blinded observer on alternate days until P55. Each animal started in the vertical arm of the Y-maze. If the animal selected a different arm on the second run in the maze, it was scored as 25 alternating. The percent alternation over the duration of testing was calculated for each animal. Western blot analysis of factor H and clusterin levels following kainate-induced seizures Changes in FH and clusterin levels in the hippocampus 24 hr following KA induced seizures were quantified by Western blot using commercially available antibodies 30 (1:2000 goat polyclonal anti-FH antibody, Quidel Corporation, San Diego, CA; 1:1000 goat polyclonal anti clusterin antibody, Santa Cruz Biotech, Santa Cruz, CA). Proteins 70 WO 2008/109437 PCT/US2008/055495 were separated by conventional methods using polyacrylamide electrophoresis gels. Following incubation in secondary antibody (1:1000 anti-goat IgG-HRP for FH; 1:2000 anti-goat IgG-HRP for clusterin), protein bands were visualized by electrochemiluminescent detection (ECL Western Blotting Detection Reagents, Amersham 5 Biosciences, Piscataway, NJ). Bands of the appropriate size were quantified by relative densitometry using digitized images and OpenLab software (Improvision line, Lexington, MA). Values for FH and clusterin were normalized to GAPDH and p-tubulin respectively, and the data expressed as a ratio of the two bands (1:4000 GAPDH, Ambion, Austin, Tx; 1: 1000 B-tubulin. The E7 anti-p-tubulin antibody developed by Michael Klymkowsky was 10 obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242). Immunohistochemistry Immunohistochemical detection of hippocampal markers of glial activation and 15 astrocyte glutamate transporters was performed in five Pm paraffin-embedded sections using Vectastain Elite ABC immunodetection kits and diaminobenzidine substrate (DAB) (Vector Laboratories, Burlingame CA). The following primary antibodies were used: GFAP (1:1500, mouse monoclonal, Sigma); S1OOB (1:1500, rabbit polyclonal, DAKO Cytomation, Carpinteria, CA); Ibal (1:400, goat polyclonal, Abcam, Cambridge, MA); FH 20 (1: 400, goat polyclonal, Quidel); -clusterin (1:100, goat polyclonal, Santa Cruz); GLAST (1:5000 guinea pig polyclonal, Chemicon International, Temecula, CA) and GLT-1 (1:5000, guinea pig polyclonal, Chemicon). Control sections were incubated in normal serum or PBS in place of primary antibody. In order to determine the specificity of the antibodies, selected slides were incubated with preadsorbed IgG in place of primary 25 antibody (Rabbit IgG for S 100B; Mouse IgG for GFAP). For clusterin, GLAST and GLT 1, control peptides were used instead of the primary antibodies to determine specific immunoreactivity. Sections were incubated for one hour at 38'C with the appropriate biotinylated secondary antibody at 1:400 dilution (Vector). Immunofluorescent double-labeling of clusterin-positive cells 30 Double-labeling of clusterin-immunoreactive cells was performed with either the astrocyte marker, GFAP (1:1000) or the neuronal marker, NeuN (1:50, Chemicon). After 71 WO 2008/109437 PCT/US2008/055495 rehydration and incubation in normal horse serum (NHS) for 20 min, sections were incubated with either primary antibody for 1 hr at room temperature. After a 30 min incubation with biotinylated secondary antibody (anti-mouse IgG, 1:400) tissues were incubated with Fluorescent Avidin D for 45 min (Vector), then blocked with Avidin and 5 Biotin solutions and 10% NHS. Tissues were then incubated with the second primary antibody (clusterin, 1:50 dilution) for 1 hr. Sections were incubated with biotinylated anti goat IgG secondary antibody (1:400) for 20 min, followed by Texas Red Avidin for 45 min (Vector). After washing with PBS, coverslips were mounted with Vectashield mounting media with DAPI (Vector). 10 Peroxidase double-labeling of clusterin -immunoreactive cells Double-labeling of clusterin-immunoreactive cells was also performed with the microglial marker, Ibal or with the neuronal marker, NeuN. Standard immunohistochemical methods were followed but VIP (Vector) instead of DAB was used as the substrate for visualization. Following development with VIP, tissues were blocked 15 and then incubated with Ibal antibody (1:400 dilution) overnight at 4'C. After incubation with biotinylated anti-goat IgG for 1 hr, tissues were treated with ABC solution (Vector) and developed with SG substrate (Vector) before mounting. A similar approach was used for double labeling of clusterin with NeuN (1:50). Image acquisition and quantification of immunoreactive cells 20 Sections were examined under brightfield microscopy by two blinded observers (Nikon Eclipse E800). For GFAP, S100B, Ibal, FH, clusterin, GLAST and GLT-1 sections, the CAI, CA2, CA3, DG and PoDG were photographed at lOx magnification, and images were converted to grayscale for quantification of immunoreactive cells. The percentage of positive cells in the hippocampal regions specified was measured by thresholding for dark 25 objects indicative of immunoreactive cells (Metamorph, Universal Imaging Corporation, Sunnyvale, CA). The total hippocampal immunoreactivity as well as hippocampal region specific immunoreactivity was obtained for each sample. Changes in the morphology of immunoreactive cells were not assessed. Attenuation of pro-inflammatory cytokine increase following kainate administration 30 To determine whether suppression of early cytokine increases would prevent long term glial activation and improve neurobehavioral outcome after early-life seizures, P15 72 WO 2008/109437 PCT/US2008/055495 rats were administered Minozac (Mzc). Mzc, 2-(4-(4-methyl-6-phenylpyridazin-3 yl)piperazin-1-yl)pyrimidine dihydrochloride monohydrate, is a bioavailable and CNS penetrant, small molecule suppressor of brain pro-inflammatory cytokine up-regulation (19). Mzc was refined from a lead compound synthesized by chemical diversification of an 5 inactive pyridazine fragment (26). Mzc (5 mg/kg) or diluent (saline) was administered via ip injection at 3 and 9 hr following KA injection on P15 (Figure 7). Control animals were injected an equal volume of saline (Sal). At 12 hr, animals were sacrificed, and tissues were processed for analysis of pro-inflammatory cytokines by ELISA as above. A separate group of animals was allowed to recover for 30 d for Y-maze testing and 10 immunohistochemical analysis of glial activation. Details of experimental groups and outcome measures are summarized in Table 7. Statistical analysis Values are expressed as mean ± SEM for each group. Test for normality was performed for each data set. Student's t-test was used to compare two groups, and One-way 15 analysis of variance (ANOVA) was performed to compare three or more groups. Tukey's Multiple Comparison Test was used for parametric measures and Dunn's post-test was applied for non-parametric data. Fisher's Exact Test was used to determine differences in seizure severity. Kaplan-Meier Survival Analysis and log rank test was performed to analyze differences in mortality between groups. Significance was defined as p < 0.05 for 20 all tests. Prism 4.0 (GraphPad Software, Inc., San Diego, CA) was used for statistical analyses. RESULTS Comparison of kainate-induced seizures on P15 and P45 Seizure latency (data expressed as minutes ± SEM; n) was significantly reduced in 25 rats exposed to KA on P15 (P15 KA and KA-PBS; 16.7 ± 1.2; n=30) compared to P45 (P45 KA and PBS-KA; 34.3 ± 3.3; n=32) (Figure 1 A). There were no differences in severity of seizures between age groups. On P15, the majority of animals (P15 KA and KA-PBS; 27/31, 87%) experienced Grade IV seizures, which was not significantly different from the frequency of Grade IV seizures in the P45 treatment group (P45 KA and 30 PBS-KA; 28/32, 88%). Survival in the immature rats exposed to KA (KA-P13S, 16/19, 84%) was not significantly different from the P45 group (PBS-KA, 13/20, 65%) (Figure 1 73 WO 2008/109437 PCT/US2008/055495 B). Early life seizures increase susceptibility to seizures in adulthood Seizure susceptibility (Figure 1) were first compared in the 'two-hit' group exposed to KA on both P15 and P45 (KA-KA) with rats first exposed to KA on P45 (PBS-KA). 5 Seizure latency was significantly reduced in the 'two-hit' group (KA-KA, 18.8 3.8; n=12), compared to rats first administered KA on P45 (P45 KA and PBS-KA; 34.3 3.3; n=32) (Figure IA). Survival (Figure 1B) was significantly decreased in the 'two-hit' group (6/12, 50%) compared to the PBS-KA animals (13/20, 65%). There were no significant inter-group differences in seizure severity. Grade IV seizures occurred in 88% (28/32) of 10 animals exposed to KA on P45 (P45 KA and PBS-KA) and in 100% (12/12) of the 'two hit' KA-KA animals. There were no significant differences in weight (g ± SEM) between groups at the time of sacrifice on P55 (PBS-PBS, 316.7 ± 6.1; KA-PBS, 327.7 ± 8.4; PBS KA, 292.6 ± 9.0; KA-KA, 326.0 ± 21.2). Neuronal injury resulting from seizures is greater following a 'second-hit' 15 The degree of hippocampal neuronal injury (Figures 1 C and D) in the adult seizure (PBS-KA) was compared to the 'two-hit' (KA-KA) groups using the fluorescent dye FJB (data expressed as % FJB-positive cells ± SEM). A summary of the regions of interest for FJB and other immunohistochemical outcome measures is shown in Figure lE. No neuronal injury was detected either in controls (PBS-PBS; n=9) or the immature seizure 20 group (KA-PBS; n=5). The 'two-hit' group had significantly greater neuronal injury (29.2 ± 3.6; n=5) compared to littermates who first received KA as adults (PBS-KA, 6.4 ± 0.8; n=7). The majority of FJB-positive cells in both groups were in the CA3 layer of the hippocampus. CAI, CA2 and DG also showed significant increases in labeled cells compared to controls. FJG-positive cells were also observed in the entorhinal and frontal 25 cortex, lateral septal nuclei, piriform cortex, perirhinal cortex of these groups. Values in these regions were not different between groups. Seizures result in an acute increase in hippocampal IL-flp and SJOOB levels To determine whether seizures resulted in increases in pro-inflammatory cytokine levels and glial activation (data expressed as pg/ml ± SEM; n), changes in levels of pro 30 inflammatory cytokines (IL-13, IL-6, TNF-a, and S100), in hippocampal brain homogenates 24 hr following KA administration were measured (Figure 2). This response 74 WO 2008/109437 PCT/US2008/055495 in the immature (P15) and adult (P45) brain was compared. In the newborn, KA exposure resulted in a significant increase in IL-13 (37.0 ± 4.0; n=7) compared to PBS-treated controls (20.5 ± 3.0; n=6) (Figure 2A). A similar increase was observed in the P45 animals treated with KA (45.8 ± 9.3; n=9) compared to age matched controls (21.1 ± 4.8; n=4). 5 There were no significant differences between the immature and adult levels of IL- I. IL-6 also showed a similar trend of changes as IL-3 but did not reach statistical significance (Figure 2B). There was no change in the level of TNF-a in the four groups (Figure 2C). In contrast, S100B levels (Figure 2D) significantly increased in KA-treated newborns (2664.0 ± 225.8, n=7) compared to PBS-treated controls (1123 ± 130.7, n=4). A similar increase 10 was observed in P45 animals treated with KA (5508 ± 304.3, n=10) compared to PBS treated P45 controls (3678.0 ± 529.3, n=4). S1OOB levels were significantly higher in adults compared to newborns both in KA-treated and PBS-treated groups. Early-life seizures result in neurobehavioral impairment To determine whether the acute increase in IL-1 and S1OOB following KA 15 induced seizures in the newborn was accompanied by abnormal neurobehavioral outcome, animals were tested for the ability to perform in the Y-maze, a test for hippocampal-linked behavior (data expressed as % alternation ± SEM; n) (Figure 3A). Despite the absence of neuronal injury, animals in the early life seizure group showed significant impairment (KA-PBS, 25.4 ± 3.4, n=12) compared to controls (PBS-1PBS, 73.4 ± 5.3, n=8) after a 40 20 day recovery period. Seizures in the newborn brain result in prolonged glial activation To determine whether seizures in the immature brain resulted in glial activation despite the absence of neuronal injury, immunohistochemical methods were used to quantify changes in astrocyte-specific markers, GFAP and S1OOB (Figures 3B-K) and the 25 microglial marker, Ibal (Figure 4) in the hippocampus. Immunostaining (data expressed as % of immuno-positive cells ± SEM; n) in the four long-term (P55) recovery groups, control (PBS-PBS), immature seizures (KA-PBS), adult seizures (PBS-KA) and 'two-hit' (KA-KA) groups were compared. A single administration of KA on P15 resulted in a significant increase in GFAP 30 immunoreactivity in the hippocampus (Figures 3B-F), which persisted after 40 days recovery (KA- PBS, 59.9 ± 4.8, n=10) compared to controls (PBS-PBS, 25.8 ± 3.4, n=13). 75 WO 2008/109437 PCT/US2008/055495 Animals in the 'two-hit' group showed significant increases in GFAP (KA-KA, 72.0 ±15.5, n=5) compared to controls but were not significantly different from the adult seizure group (PBS-KA, 50.3 ± 6.5, n=10). GFAP-positive astrocytes in the KA-PBS, PBS-KA and KA KA groups had thicker processes and enhanced staining compared to controls. These cells 5 also tended to surround neurons. For every hippocampal region examined (CA1, CA2, CA3, DG and PoDG), all three KA-treated groups had significantly increased GFAP positive cells compared to the PBS-PBS group. No individual region showed a higher percentage of GFAP-positive cells compared to other regions examined. A similar response was observed for the glial-derived protein, S1OOB (Figures 3G 10 K). S1OOB immunoreactive astrocytes in the hippocampus were significantly increased 40 days after a single exposure to KA on P15 (KA-PBS, 35.0 ± 7.3, n=10) compared to controls (PBS-PBS, 10.8 ± 1.7, n=113). Again, animals in the 'two-hit' group showed significant increases in S1OOB (KA-KA, 39.6 ± 1.9, n=6) compared to controls but were not significantly different from the adult seizure group (PBS-KA, 31.0 ± 2.6, n=8). In the 15 KA-exposed animals, the morphology of these cells was typically that of an activated astrocyte (Figures 3H-J). Microglial activation is transient and is increased by a 'second hit' Notably, animals in the 'two-hit' group showed a significant increase (Figure 4) in Ibal-immunoreactive microglia (KA-KA, 34.0 ± 5.0, n=6) compared to the adult seizure 20 group (PBSKA, 17.4 ± 4.3, n=5). Ibal expression in both these groups (Figures 4C, D) was also significantly increased compared to controls (PBS-PBS, 4.0 ± 0.6, n=6) (Figure 4A). In contrast to the persistent increase in GFAP and S1OOB, activated microglia were not increased in the long-term recovery group (KA-PBS, 8.7 ± 0.8, n=8) after early-life seizures (Figure 4B). 25 Increased clusterin levels implicate microglial activation in the 'two-hit' model FH and clusterin modulate microglial activation and astrocyte-dependent cell death following brain injury (16-18, 28). Changes were measured in both proteins in the hippocampus 24-hr following seizures in the newborn (Figures 5A, D) using Western blotting (data expressed as relative density ± SEM; n). There was no difference in FH 30 levels between controls and KA-treated groups at P15 or P45 (Figure 5A). Next, immunohistochemical methods were used to determine whether early-life seizures resulted 76 WO 2008/109437 PCT/US2008/055495 in persistent changes in FH (Figures 5B, C) in the hippocampus in adulthood. There were no significant differences in values for FH in the long-term recovery groups. FH immunoreactive cells had the morphology of astrocytes, and were also present in the frontal cortex, striatum, and periventricular areas. 5 After 24-hr recovery from KA-induced seizures, clusterin levels in the hippocampus were significantly higher both on P15 (4.5 ± 0.36, n = 8), and P45 (4.3 ± 0.33, n = 5) compared to age-matched controls (3.0 ± 0.30, n = 6) and (2.7 ± 0.31, n = 6) (Figure 5D). Early-life seizures did not result in persistent changes in clusterin (Figures 7 E) in the hippocampus (data expressed as % of immuno-positive cells ± SEM). Animals 10 exposed to KA in adulthood (Figure 5F) showed a significant increase in clusterin (PBS KA, 18.9 ± 3.7, n=7) compared to controls. Clusterin levels were significantly increased in the 'two-hit' group (KA-KA, 32.9 3.1, n=6) compared to both adult seizures (PBS-KA, 18.9 ± 3.7, n=7), early-life seizures (KA-PBS, 2.1± 0.8, n=7) and controls (PBS-PBS, 1.6 ± 1.1, n=8) (Figures 5G, H). To 15 identify the cellular origin of clusterin, double-labeling studies were carried out in all 4 experimental groups (n = 4 per group) (Figures 51-L). Qualitative assessment of clusterin immunostaining showed clusterin positive cells in the entorhinal cortex, cerebral cortex, midbrain and hippocampal layers CAl, CA2, CA3 dentate gyrus and PoDG. Clusterin positive cells did not co-label with NeuN (Figures 51, J), or GFAP (Figure 5K), but did co 20 label with Ibal (Figure 5L), identifying them as microglia. Glial glutamate transporters GLAST and GLT-1 increase following seizures To determine one potential mechanism by which glial activation may result in neuronal dysfunction following early-life seizures, immunohistochemical methods were used to measure changes in astrocyte glutamate transporters GLAST and GLT-1 in the 25 hippocampus (Figure 6) (13). Expression of these proteins was compared in the four long term experimental groups after exposure to KA or PBS on P15 (data expressed as % of immuno-positive cells ± SEM; n). GLAST and GLT-1 immunoreactive cells showed a similar pericellular staining pattern and distribution in the brain (Figures 6A-C). The majority of labeled cells were distributed in the hippocampus, entorhinal cortex and frontal 30 cortex. Neither GLAST nor GLT-1 expression was significantly increased over long-term recovery in the hippocampus following early-life seizures (Figure 6D). In contrast, animals 77 WO 2008/109437 PCT/US2008/055495 exposed to KA in adulthood showed a significant increase in GLAST (PBS-KA, 16.3 3.8, n=7) compared to controls (PBS-PBS; 3.4 ± 0.6, n=7). GLAST levels were also significantly increased in the 'two-hit' group (KA-KA, 22.4 ± 5.0, n=6) compared to controls. Similar results were observed for GLT-1. Values for GLT-1 in the early-life 5 seizure group (KA-PBS, 5.9 ± 1.9, n=6) were not significantly different compared to controls (PBS-PBS, 7.2 ± 1.1, n=6), while animals exposed to KA in adulthood did show a significant increase in GLT-1 (PBS-KA, 19.4 ± 3.5, n=10) compared to controls. GLT-1 levels were significantly increased in the 'two-hit' group (KA-KA, 25.0 ± 4.2, n=5) compared to controls. 10 Delayed administration of Minozac prevents hippocampal-dependent behavioral deficit following KA-induced seizures Remarkably, treatment with the small molecule compound Mzc after KA-induced seizures on P15 (Figure 7A), prevented the compromise of behavioral function seen in the KA-exposed group (Figure 7B). After 30 days recovery, the percent alternation in KA 15 exposed animals treated with saline (KA-Sal, 53.3 ± 3.1, n=21) was significantly reduced compared to controls (PBS-Sal, 83.0 ± 3.4, n=10). Animals treated with Mzc following KA-induced seizures (KA-Mzc, 79.5 ± 2.5, n=20) showed significantly improved performance in this test compared to KA-Saline animals (P < 0.001). Delayed administration of Minozac suppresses kainate-induced acute increase in pro 20 inflammatory cytokines Determination as to whether the prevention by Mzc of neurobehavioral impairment after early-life seizures was the result of suppression of the acute cytokine, and long-term glial activation responses was sought next. Treatment with Mzc after KA-induced seizures on P15 also prevented the acute increase in pro-inflammatory cytokines (Figures 8A-D) in 25 hippocampal brain homogenates (data expressed as % control SEM, n). In the Mzc treated group at 12 hr recovery after KA exposure, levels of IL-1 (103.7 ± 4.6, n=12), IL 6 (103.2 ± 3.8, n=12), TNF-a (98.5 ± 3.9, n=12) and S1OOB (89.1 ± 9.7, n=8) were not significantly different from controls and were significantly suppressed in comparison to the animals exposed to KA and treated with saline alone. 30 Delayed administration of Minozac prevents KA -induced prolonged increase in glial activation 78 WO 2008/109437 PCT/US2008/055495 Treatment with Mzc after KA exposure on P15 also prevented the long-term increase in astrocyte activation (Figures 8E-L). After 30 days recovery, glial activation was quantified by immunohistochemical methods. Levels of GFAP immunoreactive cells (Figures 8E-H) were significantly increased in KA-exposed animals (KA-Sal, 47.8 ± 7.6, 5 n=8), and this increase was prevented by treatment with Mzc (KA-Mzc, 20.9 ± 1.8, n=9), (Figure 8H). A similar result was seen for S 1008 for both groups (KA-Sal, 15.6 ± 2.0, n=12; KA-Mzc, 8.1 ± 0.9, n=13), (Figures 8 I-L). DISCUSSION This study addressed two questions, the dichotomy between neurobehavioral 10 impairment in animals following early-life seizures despite the absence of neuronal injury and second, the mechanisms by which seizures in the immature brain may increase vulnerability to seizures later in life (4, 6, 29, 30). The key findings of this study are; (a) increased susceptibility to seizures in the 'two-hit' animals exposed to a 'second-hit' of KA following early-life seizures; (b) the longterm increase in glial activation and impairment 15 of hippocampal-dependent behavior following early-life seizures; (c) enhanced microglial activation in the 'two-hit' animals exposed to KA on P15 and P45 and; (d) prevention of both outcomes by delayed administration of a small-molecule inhibitor of pro inflammatory cytokine upregulation. The lack of neuronal injury in the early-life seizure group and the increased injury 20 in the 'two-hit' group are consistent with previous studies (2). The impairment in neurobehavioral function seen in this and other studies (31) following early-life seizures suggests a compromise of hippocampal neuronal function, although other limbic areas may also be injured (32). The prevention of this impairment by treatment with Mzc implicates pro-inflammatory cytokines in the initiation of the process. The lack of difference in the 25 cytokine response in the early-life and adult seizure groups does not rule out age-dependent differences in this initial cytokine response as such differences have been reported (22) and these data reflect only a single time point. The prevention of the long-term increase in glial activation in the Mzc-treated animals demonstrates that glial activation can contribute to neuronal dysfunction (8). 30 The threshold for generation of seizures is lower in the immature than the adult brain (6) but the immature hippocampus is resistant to SE-induced structural damage (29). 79 WO 2008/109437 PCT/US2008/055495 This discrepancy implies that the mechanisms by which early life seizures increase the vulnerability of the adult to seizures and neurologic injury occur at the molecular or subcellular level. Previous studies have implicated changes in AMPA receptors (33), glutamate receptor subunits (34), and the neuronal glutamate transporter, EAAC1 (15). The 5 data showing enhanced microglial activation in the 'two-hit' group implicates glial (astrocytes and microglial) activation in the mechanisms leading to increased susceptibility to seizures and neurologic injury following early life seizures. This hypothesis is supported by the improved behavioral function and prevention of long-term glial activation in the Mzc-treated animals. The precise mechanisms by which activated astrocytes and microglia 10 cause neurologic injury remain obscure (35, 36). Neuroinflammation is a well-established response to central nervous system injury (36) including epilepsy (37) although the potential of this response as a therapeutic target in epilepsy has not been explored in detail. Precedent from human pathologic, in vitro, and in vivo studies of Alzheimer's disease have implicated a glia-mediated neuroinflammatory 15 response both in the pathophysiology of the disease (8) and as treatment target (19, 26, 38). Microglial activation leading to overexpression of IL-1 has been proposed as the pivotal step in initiating a self propagating cytokine cycle culminating in neurodegeneration (8, 39). The data showing an early increase in IL- 1 is consistent with previous studies of pro inflammatory cytokine mRNA changes in response to KA on P15 (22) and P21 (40). The 20 pivotal role of pro-inflammatory cytokines in the initiation of this cycle is supported by the therapeutic benefit afforded in the Mzc-treated early-life seizure group in which the acute cytokine response was suppressed. IL-1 and pro-inflammatory cytokines may also function in epilepsy as pro-convulsant signaling molecules independent of such a cycle (41). 25 Evidence has been found of long-term glial activation in the hippocampi of rats exposed to KA on P15, manifest as increases in GFAP and SlOOB (42, 43) expression after 40 days recovery. The astrocyte-derived cytokine SlOOB was increased both acutely and during long-term recovery in this study. Together with the long-term increase in GFAP, this finding implies that astrocytes remain activated following early-life seizures. While the 30 mechanisms by which SlOOB increases vulnerability to neurologic injury remain to be determined, studies of mice overexpressing S1OB demonstrate both an increase in glial 80 WO 2008/109437 PCT/US2008/055495 activation and increased susceptibility to neurologic insults (10, 44). Increased S1OOB levels found in the adult control animals is consistent with the rise in S1OOB associated with aging (45). There was no long-term change in the expression of the astrocyte glutamate 5 transporters, which are responsible for the majority of glutamate uptake in the central nervous system (13, 14). The increase in both transporters in the 'two-hit' group was comparable to that found in the adult (PBS-KA) seizure group, and may be a protective response (46). These data imply that, either the astrocyte glutamate transporters do not contribute to the increase in seizure susceptibility following early life seizures, or the 10 functional properties of these transporters are altered. Clusterin expression is upregulated in astrocytes following seizures (18). The increase in clusterin in the KA-exposed animals is of microglial origin. This result supports the finding that microglial activation is potentiated in the 'two-hit' group and may be a mechanism by which activated microglia can lead to cell injury (17). The complement 15 inhibitory protein, Factor H (28), acts as a chemotactic factor for activated microglia in amyloid-p-induced brain injury (16). Lack of change in Factor H levels in response to KA suggests that this signaling pathway is not involved in microglial recruitment after seizures. The small molecule used in these studies, Mzc (19), is a bioavailable, water soluble, CNS-penetrant, non-toxic compound that inhibits hippocampal pro-inflammatory 20 cytokine upregulation, suppresses synaptic dysfunction, and attenuates hippocampal dependent behavioral deficits in an Alzheimer's disease mouse model. The results presented here and the ability to produce Mzc in large scale under FDA guidelines (19) indicates the need to investigate the potential of this compound as a novel therapeutic in pediatric epilepsy. Efficacy in the present study lends further support to the hypothesis that 25 targeting neuroinflammation may alter progression of central nervous system disorders (19, 20, 38). These data implicate neuroinflammation both in the chronic neurologic sequelae of early-life seizures, and the increased susceptibility to further neurologic injury following seizures in the newborn period. A model (Figure 9) is proposed in which an initial rise in 30 pro-inflammatory cytokines following early life seizures, particularly IL-13 and S1OOB, results in further activation of microglia. This activation is also transient, but is followed 81 WO 2008/109437 PCT/US2008/055495 by a persistent increase in astrocyte activation. Activated astrocytes result in neurobehavioral impairment, and may increase the susceptibility to a second neurologic insult in part through enhanced microglial activation after the insult. Early-life seizures prime microglia for an exaggerated response to a second neurologic insult (20). These 5 hypotheses are supported by the effects of suppression of the initial pro-inflammatory cytokine response, the regional specificity of the glial activation response to the hippocampus, previous data showing increased susceptibility to neurologic injury in transgenic mice overexpressing S1OOB (10, 44), and a similar model proposed for neurodegeneration in Alzheimer's disease (7, 8, 19, 20). 10 The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown 15 and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or 20 patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the methods etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not 25 entitled to antedate such disclosure by virtue of prior invention. 82 WO 2008/109437 PCT/US2008/055495 Table 1 Compound Compound Synthetic Number Structure Code 1 MWO1-ES1 I I N O 0 4 O MWO1-ES112 H' N 10 0 MWO1-ES159 O N N-~ 0 Z,I |O 11 0 MWO1-ES21 H,N O Os N 12 0 MWO1-ES31

H~N

H, N N O SO 13 0 MWOI-ES68 H, N 0" 01 N ~ 0 83 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 14 MWO1-ES61 H, N 0 0 N O 16 0 MWO1-ES75 H'N IN I | O 17 0 MWO1-ES81 H' N N 0 18 0 MWO1-ES91 HN CI NN / OH 20 CH 3 MWO1-1-04 L-D04 NN CI 23 MWO1-1-15 L-H07 NN 24 MWO1-1-16 L-F05 N,N NO'l0'CH3 84 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 25 MWO1-1-18 L-B09 N,N N' N H 31 Br MW01-1 NN 035LKM Br 40 O-CH 3 MWO1-1-09 L-G07 \/ \ NH 2 N-N HO4 0 41 H 3 C MWO1-2-03 0 L-C02 0 \ C z \/NH N N-N 43 MWO1-1-15 L-E09 x NH -- N-N NH 2 44 H 3 C MWO1-1-16 L-B11 N-N

NH

2 47 MWO1-4

H

2 N \ / CI 198B-Z N-N 85 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 48 MWO1-5 0 144A-Z

H

2 N 0 N-N 49 MWO1-4 198C-Z H2N N-N 50 CI MWO1-5 144C-Z

H

2 N / N-N 51 -O MWO1-5 144D-Z

H

2 N -/ N-N 52 MWO1-5 145A-Z

H

2 N / / N-N 54 MWO1-5 189Z N-N 55 MWO1-5

H

2 N 202B-Z N-N 86 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 61 OH MWO1-1-01 L-D06 NH N N 65 H2N NH MWO1-1-01 L-E1O N N 66 H3C s MWO1-1-02 L-E08 NH I '- 0 N 70 CH3 MWO1-1-03 L-D03 N 71 SH MW01-1-03 N L-F03 N 73 CH3 MW01-1-03 0 L-G10 N N 87 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 74 O - MWO1-1-03 I L-H06 N 75 MWO1-1-04 N L-C03 O N N 76 CH 3 MWO1-1-07 L-H04 S N N 88 MWO1-1-100 L-A04 N O 0 N 'N 88 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 89 MWO1-1-100 N L-A05 HN N I CIH CIH 90 MWO1-1-100 N L-A08 HN NCIH CIH 91 N'CH3 MWO1-1-100 L-A09 HN CIH N N CIH 89 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 92 MWO1-1-11 L-E08 HN 0 N IN 94 N MWO1-1-15 L-G09 97 MWO1-1-16 L-G03 N HN 0 N N 106 -N --- \ -MWO1-9 N N \ 039Z 1 0 7 N -N 107 -\MWO1-9 2N 1 04/Z / "'-i N-N/ -00 108 - MWO1-9 N-N -041Z 109 - /\MWO1-9 C -I-104A-Z 110 /MWO9-9 / __ 105A-Z 90 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 111 OH MWO1-9 CI 11OA-Z N-N 112 NH 2 MWO1-9 H2N \133A-Z

H

2 N- I N-N 113 MWO1-9 149A-Z CI N-N 114 CI MWO1-9 CI \159A-Z C 171Zz N-N 115 MWO1-9 CI - 171Z N-N 116 MWO1-9 / CI 172Z N- N 118 MWO1-9 ,-N CI 204Z C~ NN 120 MWO1-1-16 N L-G08 HN N N 91 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 122 MWO1-1-17 L-G05 N HN N N 123 MWO1-1-17 L-G11 N N "N 125 MW01-1-17 L-H03 N H N N N 92 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 127 MWO1-1-17 L-H11 N N HN N N 130 MW01-1-18 L-A08 N' ,N ' o HN N N 137 C O MWO1-2 N 020SRM N 143 CI MWO1-2 CI 056WH N-N 93 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 149 MWO1-1-18 L-A1 1 H NN N

H

3 0~ 150 - MWO1-1-18 L-B03 N N\H N-N 151 -- --- / MWO1-1 N NH -- N 18-L-B09 158 H 2 N MWO1-3 CI 033WH 159 Br MWO1-3 N N 173 - - MWO1-2-03 \ / N-/ NH L-D02 N-N 94 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 175 MWO1-2-06 L-F04 N 175A H N N N 179 H3C, s MWO1-2-33 L-B02 N 180 MWO1-3-01 L-G07 OH N 183 -- MWO1-5 _ N-/ N O 160WH N- N 184 MWO-5 - \ /N N-161 WEI N-N 189 MWO1-6 / 041WH HN - O. N N N 95 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 190 H 2 N MWO1-6 044WH NH N 192 H 2 N MWO1-6 050WH NH N 197 OH MWO1-1-01 L-A1O N N 198 CH 3 MWO1-1-01 0 L-B03 N N 96 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 199 OH MWO1-1-01 L-B09 NH NH

H

3 C N 201 CH 3 CI MWO1-1-01 NN L-E03 202 0

CH

3 MW01-1-01

H

3 C L-E04 205 MW01-1-18 L-B07 N

H

3 C

CH

3 N5 N' N 97 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 208 MW01-1-03 L-G03 N CI N L-C0

-

N /' 210 0 MW01-1-04 CO L-C03 HN 0' N 217 H3 MW01-1-02 o DL-E03 HN

H

3 C N ' 218 OH 3 MWO1-1-02 L-E06 HN

H

3 0 9 98 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 221 MWO1-1-02 N N c L-F02 223 OH MWO1-1-02 L-F08 HN

H

3 C N N 225 YH 3 MWO1-1-02 N L-G05 N

H

3 C N 226 YH 3 MWO1-1-02 N CH3 L-G06 0

H

3 C N N 99 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 227 CH 3 MWO1-1-03 O L-A02 NH N N 229 CI MWO1-1-03

H

3 C L-B09 N 230 OH MWO1-1-03 L-B10 NHH H3C N N 231 Br MWO1-1-03

H

3 C L-C03 N 233 CI MWO1-1-03 L-C08 CI N N 100 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 235 H2NNH MWO1-1-03 H3C N L-E08

H

3 ' N 236 NH 2 CI MWO1-1-03 0 NL-E09 N 240 HO CH 3 MWO1-1-04 L-A06 N

H

3 CN 242 HO MWO1-1-04 L-D1O N 250 MWO1-1-05 N L-B11 0

H

3 C N N 101 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 251 MWO1-1-05 N L-C02 O

H

3 C N N 254 MWO1-1-05 N L-G1 1 HN

H

3 C N N 255 - CH3 MW01-1-05 H3C N'CH3L-5 N 266 MWO1-1-08 L-D09 HN

H

3 C N N 102 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 268 MWO1-1-09 L-C06

CH

3 HN N N 270 NH 2 MWO1-1-09 OH L-G05 N 0 271 CH 3 MWO1-1-09 O N H 2 L-G07 OH N 0 272 CH 3

NH

2 MWO1-1-09 H3C OH L-G09 N O 274 CI MW01-1-09 L-H07 N 103 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 275 OH MWO1-1-15

H

3 C L-A04 N 276 CI MWO1-1-15 I IL-B02 N 278 H 3 C CH 5 MWO1-1-15 L-B1O N N 280 H 3 C OH MWO1-1-15 L-C04 N N 282 CH 3 Cl MWO1-1-15

H

3 C N L-D03 N 284 H 3 C N MW01-1-15 L-G1O N 104 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 292 MWO1-1-17 N L-A09 o N,.

H

3 C 293 0 MWO1-1-17 L-A1 1 CH3H N N'N 294 CH 3 H MWO1-1-17 IN "' OH L-B02 N' N 295 CH 3 H MWO1-1-17 N N'CH3 L-B10 N'IN H 296 CH 3 H MWO1-1-17 N N CH3 L-E11 N N

CH

3 297 CH 3 H MWO1-1-17 N'INN N ) L-F03 298 O MWO1-1-17 OHl H L-H05 CH3 H N N 105 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 299 MWO1-1-18 L-A09 N

CH

3 H Nq N' N 308 0 MWO1-2-03 F F F C) L-B08 H N N'N 310 0 MW01-2-03 L-C05 0 N NN 313 0 MWO1-2-03 OH N) L-G07 H N'N 318 O MW0I-2-101 H O NO L-H08 HN I N N'N 106 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 319 0 MWO1-2-10 L-E05 COOH N N N 320 0 MWO1-2-10 C) L-E06 CI H N N 321 0 NH 2 MWO1-2-20 H L-B02 N NH 2 N' 323 NO 2 H MWO1-2-20 NIN N N L-D05 N'N 324 N MWO1-2-20 H L-E09 N N'N 326 CI MWO1-2-25 L-H06 H N N' 107 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 328 CH MWO1-3-01 CH3 CH 3 L-G03 N' N 329 CH 3 N MWO1-3-01 0 L-G04 N' N 331 CH 3 MWO1-3-01

K

0 L-G08

CH

3 0O

CH

3 N'N 332 H3C MWO1-3-01 CH3 Si CH3 L-G09

CH

3 N' N 335 MWO1-3-06

CH

3 L-E09 Si ,CH 3 O CH 3 CH3X / \ N'N 337 MWO1-1-07 01 L-G07 N -N 1N' 108 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 339 CH 3 MW01-1-15 CI L-C11 N'N 340 MW01-1-15 N H L-E09 NNH2 N'N N 341 H H MW01-1-16 3 N NH2 L-B11 346 CH 3 MW01-1-17

CH

3 H N CH 3 L-F10 N N'N 347 MW01-1-17 K0) L-F11

CH

3 H N N N'N 350 MW01-2-20

H

3 C N NL-B N'N 352 0 MW01-3-01

H

3 C O'CH 3 L-F09 N N 109 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 359 CI MWO1-1-03 NL-E05 N CI CI 360 S MWO1-1-03 N L-A08 N 361 H 3 C, MWO1-1-03 o L-H08 O O 362 0 MWO1-1-01 s NH L-H04 N 363 MWO1-1-01 L-H06 NH N 110 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 366 S MWO1-1-03

H

3 C NH L-E07 N CI 367 NO 2 MWO1-1-05 L-E05 S HN 4 368 0 MWO1-1-03

H

3 C NH L-B03 N 371 H 2 N MWO1-1-05 L-E07 N

NO

2 372 0 MWO1-1-03

H

3 C NH L-A03 CN CI 111 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 373 CI MWO1-1-03

H

3 C N L-E03 N OH 374 S MWO1-1-01

H

3 C -CH 3 L-H1O N 375 CI MWO1-1-04 L-H08 ,N N' 376 CH 3 MWO1-1-01 0 L-G1O N' NH HO 377 CI MWO1-1-03 ' L-G1 1 N CIN Cl 380 MWO1-1-04 CIH L-B07 N N N Is, 0 381 MWO1-1-04 0 CIH L-C09 N NN N~ 0 Br 112 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 382 MWO1-1-10 L-G05 0 0- N--N HO C COOH N HOOCA N 113 WO 2008/109437 PCT/US2008/055495 Table 2 Compound Compound Synthetic Number Structure Code 22 ,CH 3 MWO1-1-15 N ' L-E08 \ / \ /N CH 3 C/N -N 26 MWO1-2-02 \ / N -L-H09 N- ' OH 29 MW01-1 N N 030A-LKM N N N N N N NJ N ' 30 Br MW01-1 030B-LKM N N N O N N N 114 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 33 MWO1-2 N N 65LKM N N N N F 34 MWO1-2 N N 127LKM N C) N C I N H 35 MWO1-2 N "N 134LKM N N N N N 115 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 36 MWO1-2 N N 146LKM N (N) N N N N 37 MWO1-2 N N 147LKM N N

H

2 N N H 38 CH 3 MWO1-1-02 /---\L-B11 N NH N-N V 39 H 3 C-O OH 3 MWO1-1-04 0 L-F1O D / CI N-N 42 H 3 C CH 3 0 MWO1-2-33 )O/ L-A11

H

3 C N-N 116 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 45 MWO1-1-17 L-E06 N H N-N N 46 MW01-1 045MAS N N N N S 53 MWO1-5 0 145B-Z 0 NH

H

2 N N-N_ 117 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 56 MWO1-7 127AB-Z O HN N N N N N N 60 OH MWO1-1-01 L-B04 N H NH N N 62 MWO1-1-01 N L-D0 CICI 63 r oMW01-1-01 H ClfN" L-E02 HN H N 118 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 64 MWO1-1-01 BrCH3 L-E08 N Br 67 N MWO1-1-02 L-H1O NN N 68 H 3 C s MWO1-1-03 L-A05 N N Br 69 OH MWO1-1-03 L-B08 NH N 72 Br Br MWO1-1-03 L-G09 N N 119 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 87 Br MWO1-1-08 L-E11 S O N N 93 HO MWO1-1-13 HO L-G06 0 HO N N NH HN N N N 95 NH 2 0 MWO1-1-16 N OH L-D09 CI 120 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 96 MWO1-1-16 N L-E02 CIH HN CIH N N 105 N MWO1-9 //\-/ / N N038Z N N-N 121 MWO1-1-17 L-G04 N HN N CIH N CIH 124 MWO1-1-17 L-H02 N O HN N N 121 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 126 H3C MWO1-1-17 L-H07

H

3 C N HN N N 128 MWO1-1-18 L-A02 (N) N N N 129 MW01-1-18 L-A03 H N N N N 122 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 136 O MWO1-2 N O'O018SRM N N N 138 MWO1-2 NN 023SRM N N 'O N N N 147 MWO1-2 N N 177A-WH N N N N N N N 148 N MWO1-2 177B-WH N N CI N N N 123 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 153 0 CI MWO1-2 N N 184WH 155 MWO1-2 N N 191A-WH N H ONN 156 MWO1-2 193B-WH HN NH H O N "N N 0 H 157 HO MWO1-3 \/N N N-N N 160 MWO1-3 - -N019A-WH N N N-N 124 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 161 CI MWO1-3 060A-WH NN N NN 162 NH 2 MWO1-3 'N 072WH N N N N 163 CI MWO1-3 NN 117WH N N N 164 CI MWO1-3 11 8WH NH CI N N N H 166 N MWO1-3 N N 183WH N N-N 171 MWO1-2-03 N-/N L-G03 N-N \ OH 172 O MWO1-2-03 - N L-C04 NH N N-N 125 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 174 MWO1-2-03 L-G03 N r-"O N-NN 0 176 - - MWO1-2 \/ N/-H 3 102-L-C1 1 O>0 177 NH 2 MWO1-2-21 NN L-F04 178 OH MWO1-2-24 N L-G09 0 N 181A H N N 126 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 186 \MWO1-5 188WH \ /N N \ - N-N N 188 OH MWO1-6 ~N 003WH N N N N !5N 191 H 2 N MWO1-6 046WH NH N ~N 200 HO CH 3 MW01-1-01 L-C06 NH N 203 MWO1-2-03

CH

3 H L-D09 IN N N N H N 127 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 204 MWO1-1-01 L-B02 NN NH OH N 206 OH O MW01-2-03 N L-D09 HN N N H N 207 MW01-2-03 L-G04 NH H3C N N 209 MW01-1-17 L-E05 H N' NN 128 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 211 MWO1-1-04 HC L-C03 NNH N N 212 MWO1-1-01 N NH L-E11 HNNH

H

3 C N N N ,-r 213 CH 3 O MWO1-1-01

K

0 HN N L-F02

H

3 C 0 N N 214 0 Q MWO1-1-01 N L-F03 N

H

3 C N 129 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 215 MWO1-1-01 L-G08 N

H

3 CN 216 OH MWO1-1-02 L-D11 N OH 0 HN

H

3 C N N 219 CH 3 MWO1-1-02 L-E04 NH r

H

3 C N N 220 N4 MWO1-1-02 L-E11 N N 130 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 222 N MWO1-1-02 L-F04 HN'O

H

3 C N N 224 MWO1-1-02 L-F09

H

3 C2 N IN 228 MWO1-1-03 L-A04

H

3 C N N 232 H3CO O MWO1-1-03 L-C04

H

3 C N C N' N 234 MW01-1-03 H3C ClL-E04 '-N N 131 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 237 CH 3 MWO1-1-03 L-E1O N

H

3 C N N 238 H 3 Cs 0 MWO1-1-03 L-G02 N

H

3 C N 239 C H3 MW01-1-03 K L-H04 0 0 N

H

3 C N N 132 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 241 OH MWO1-1-04 L-D08 HN N H3C N N 243 H3 MWO1-1-04 0/ CI L-E03 N N 244 N0 MWO1-1-04 L-E04 H3C N N 245 O OH MW01-1-04 L-E09 N

H

3 C N N 133 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 246 CH 3 MWO1-1-04

K

0 L-F06 0 HN

H

3 C N 247 Br CI MWO1-1-04 Br NN L-G06 N 248 CH 3 MWO1-1-04 S L-H06

H

3 C N N 249 CH 3 MWO1-1-04 L-H07 CI N N 134 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 252 MWO1-1-05 L-F05

H

3 C HN HN

H

3 C N N 253 COOH MWO1-1-05 L-G1O HN HOOC IN 256 OH MWO1-1-05 O=S=O L-H07

NH

2

H

3 C N N 257 HN'NH2 MWO1-1-05 Ns L-H09 N N 135 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 258 NH 2 MWO1-1-05 H3C -CH3 L-H11 N 259 MWO1-1-07 L-E07

H

3 C N N 260 CI MWO1-1-07 L-G09 SN

H

3 C N N 261 CI MWO1-1-07 L-H03

H

3 C N N 262 0 -- CH 3 MWO1-1-07 N L-H05

H

3 C N N 136 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 263 MWO1-1-07 L-H06 N N

H

3 C' HN H3C N N 264 OH MWO1-1-08 I L-C07 N 265 MWO1-1-08 L-C09 0 N N 267 H3C O O MWO1-1-08 N,, L-E04 N N N3 137 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 269 MWO1-1-09 L-G04

NH

2 N 0 273 NH MWO1-1-09 L-G11 N07O N N I I N 277 CI CI MWO1-1-15 CI N L-B07 N 279 CH 3 MWO1-1-15

H

3 C OH L-B11 N IN 281 Cl MWO1-1-15 SN L-D02 H3C0 N 138 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 282 CH 3 CI MWO1-1-15

H

3 C L-D03 N 283 H3C, N' CH3 MW01-1-15 L-E1O

H

3 C N N 285 0 CI MWO1-1-15 11 HC N L-H09 N 286 MWO1-1-16 H3C ,N L-E05 HN HN ) N N 287 H MWO1-1-01 0 NN C L-F11 N CI 139 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 288 N MWO1-1-17 L-B05 H N N 290 CH 3

CH

3 MWO1-1-16

NH

2 L-E08 'N CI 291 H 3 C CH 3 MW01-1-16

H

3 C L-G07 CH O

CH

3 N'N 297 CH 3 H MW01-1-17 NIN N_-,N ) L-F03 N'N 300 MW01-1-18 L-B04 CH3 N N'N 301 CH 3 MW01-1-18 L-B10 H N N'N H 3 C 140 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 302 MWO1-1-18 L-B11

H

3 C CH 3 N H N N N'N 303 CI MWO1-1-18 N L-C05 S N HO N'NH O 304 CH 3 MWO1-1-18 L-C06 H N 'N

H

3 C 305 CH 3 O MWO1-1-18 S N L-C08 306 0 MWO1-1-18

CH

3 NC OH L-C1O N4 141 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 307 H 3 C MWO1-1-18 L-D04 H N N'

H

3 C 309 MWO1-2-03 L-C03

CH

3 N -'N N IN 0 311 0 MWO1-2-03

NH

2 CN L-D07 H N N' N 312 0 MWO1-2-03 L-D08 CH3H N I N N'' N 0 314 CH 3 MWO1-2-03

NH

2 L-G1O N'N _,- Sl 315 CH 3 H MWO1-2-06 N L-F06 N'N / 142 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 316 ---^'O MWO1-2-09 N N L-B08 CI N'N 317 CH 3 MWO1-2-09 N L-E1O 0'N' OH 322 N MWO1-2-20 H L-B10 N H NH N'N 325 CH 3 MWO1-2-24

K

0 L-A05 . OICH 3 N' 327 CH3 MWO1-3-01 L-G02 N 330 CHH MWO1-3-01

CH

3

SH

3 L-G05 C H 3 N' N 333 CH 3 MWO1-3-06

NH

2 L-B07 OH N P OH 143 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 334 CH 3 MWO1-3-06

NH

2 L-B08 OH 336 MWO1-1-07 N L-G07 H3C 338 H MWO1-1-08

H

3 0 N

CH

3 L-D03 N N 1~ 342 MWO1-1-16 L-E09 N H N N 343 MWO1-1-17 L-C09 N

CH

3 N N'N 144 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 344 MWO1-1-17 L-E07

H

3 C N H N N' N 345 MWO1-1-17 L-E08

CH

3 N H N N' N 348 MWO1-1-18 L-A04

H

3 C'N H

H

3 C N N'N 349 MWO1-1-18 L-B05 H N N H3 N' 145 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 351 0 MWO1-2-33 11 HO'N S CH 3 L-A1O N'N 356 CH MWO1-1-01 0 COH 3 L-E06 HN kO N NH 0 357 CI 0 MWO1-1-01 NH L-H09 CI N 358 Cl MWO1-1-05 S N L-D07 N N N 365 CH 3 MWO1-1-03 OH Br L-D04 I I ON N' N 146 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code 369 S MWO1-1-04

H

3 C NH L-G02 CN CH3 379 MWO1-2-24 L-E07 H N N N 0 H2C MWO1-01-1 L-B07 NHN -NH N N MWO1-7 084WH N HN N 147 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code MWO1-7 085WH N Y N N MWO1-7 r-' s 091WH N N N N CH MWO1-10-12 N L-G05 N N 148 WO 2008/109437 PCT/US2008/055495 Compound Compound Synthetic Number Structure Code MWO1-7 057WH 149 WO 2008/109437 PCT/US2008/055495 Table 3 Compounds of the Formula II 2-(4-(6-phenylpyridazin-3-yl)piperazine-1-yl) pyrimidine and Derivatives No Compound Table NU24020 Structure C1C Final Code MWO1-2-069A SRM MWO1-6 127WH MWO1-6 189WH 150 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code MWO1-7 107WH SN WH 151SRM MWO1-2-069A N N SRM N N N N F 151 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code 29 MW01-1-030A N N LKM N N N N N N, N N 65K N N N F 34 MWO1-2 Nr -N 127LKM N N N CIN N H 152 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code 35 MWO1-2 N N 134LKM N CN) N N N N 36 MWO1-2 N N 146LKM N N N N N N 37 MWO1-2 N -N 147LKM (N) N

H

2 N N H 153 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code 46 MW01-1 045MAS N N N N S 105 N /--\\/MWO1-9-038Z /)N N \ N N-N 138 MWO1-2 N N 023SRM N C) N 'O N N N 147 MWO1-2-177A WH N N NN N N N 154 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code 155 MWO1-2-191A N N WH TI N 0 N O N NN H 157 HO MWO1-3 N- ND 003WH N N - \ /OW N NN 160 MWO1-3-019A N N N-N N 186 MWO1-5 188WH S N NNN N-N N 252 MWO1-1-05-L F05 N

H

3 C HN HN

H

3 C N N 155 WO 2008/109437 PCT/US2008/055495 No Compound Table NU24020 Structure C1C Final Code 263 MWO1-1-07-L H06 N N

H

3 CN HN

H

3 C N N 156 WO 2008/109437 PCT/US2008/055495 Table 4 Compound Code MWO1-01-02-L-G05 CH, N N N MWO1-01-03-L-E1O N 157 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-01-04-L-D08 OH N N HL MW01-01-18-L-A02 N N 158 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-01-18-L-C02 H MWO1 -02-03-L-G04 H N N N..1,9 MWO1-2-18SRM 159 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1.-2-23SRM N N N i N MWO1-2-13SRM N 1 NN N MWO1 -2-1 63MAS I 1I N1 N N 160 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-2-177A-WH N N tN N->N N N N N N MWO1-2-191A-WH N N: N : N N MWO1-3-024SRM N N16 161 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-3-027SRM N N J N N IN I-N MWO1-3-057SRM N MWO1-3-O65SRM 216

N

N N MWO1 -3-O66SRM N-N ,' MSO1-3-183-WH - -' N NN N. 162 WO 2008/109437 PCT/US2008/055495 Compound Code MWO-4-179LKM N MWO1-4-179LKM N 16N MWO01-4-18 8LKM N N N N MWO1 -7-029BWH N IN163 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-7-031WH N: I/ HN N MWO1-7-100WVH N YN N MWO1-7-102WH N N N(N N NN 164--12W WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-7-133WH "N N N MWO1-9-039MZ N N - / ) MWO1-9-040MZ N rN ) ...... ... N-N2 MWO1-21OLPI N .N N N 165 WO 2008/109437 PCT/US2008/055495 Compound Code MWO1-2103LPI 1N 166 WO 2008/109437 PCT/US2008/055495 Table 5 y N "N N N N St atu 5 S uctreaStoc Srt7 8 meta NN I ILIue1 S'trucl re12S ute3 N N Stoture1 Strueare17 Structure1 -16r 5 tucue SJs.JcJare21 stibe ure 2 a m 2 167I WO 2008/109437 PCT/US2008/055495 N N N N C Y CN CN) 14 N N N N N NN Cr~ N N N NNN N' NN - N. .. N N rStructure38So ue9Srutr4 Structuure3& NeN N N NY N!N

N

168 WO 2008/109437 PCT/US2008/055495 it C KNN HO C CID N Nf two IN" CN 16 WO 2008/109437 PCT/US2008/055495 HNHN N HN HN ciA N . IN N'JN N < N Y . N N N- I Q: N~ NN ~N;~ N -,eY- N Nt,4e.8 Stiu~t~c e7 NWmlii. .- U N170 TTSi1.r, WO 2008/109437 PCT/US2008/055495 Km UN N5 ( I. Srtue3Srcue4Si ucture45 Simctu o86 NNN N N N F-1 N N N Stmcture~iStructure 14 N AlH\ S rer87 Stutr142 S trS N-N N KI 9 IN CN HN -NH Cs StrctWe S rtc &5 SNr Jt C Stoctue 143 N NN N : N NH C NyN I N' C1C Stiucture&7 I. Strctrre9& Sru~cture C9 Srcture30 171 WO 2008/109437 PCT/US2008/055495 N N NN N N .N HN HNH

HN

0 NN HNN Strucure10 Stucture W2 [Strutr1:13 N N Stri&.~re01Structure 020-'StrucLure1J7 CrC NIHD Cr C Strutur113Strctueil4Strctue113Siucture 116E 'N> F1" 72 'J" NN [ I 172 WO 2008/109437 PCT/US2008/055495 N S"Cr CC WW21~trctr 22tu Aue;23 NHN N NI N Structur127 N Scu 2S St3 ISructure123

K

7HN T CCC -N % HN SirsStr cre-GLr322 Structiem14 -NH -~ 1 '-" NA C-r Suctu 4 4 173 WO 2008/109437 PCT/US2008/055495 Table 6 Summary of experimental groups and outcome measures Treatment Age at Endpoints sacrifice Group (n) P15 P45 ELISA or Immunohistochemistry Behavior Western P15 PBS (6) PBS P16 Cyt; FH; Cl P15 KA (12) KA P16 Cyt; FH; Cl P45 PBS (6) PBS P46 Cyt; FH; Cl P45 KA (12) KA P46 Cyt; FH; Cl PBS-PBS (20) PBS PBS P55 FJB; GFAP; S1OOB; lbal; Y maze FH; Cl; GLAST; GLT-I KA-PBS (19) KA PBS P55 FJB; GFAP; S1OOB; lbal; Latency FH; Cl; GLAST; GLT-1 Severity Y maze PBS-KA (20) PBS KA P55 FJB; GFAP; S1OOB; lbal; Latency FH; Cl; GLAST; GLT-1 Severity KA-KA (12) KA KA P55 FJB; GFAP; S1OOB; lbal; Latency FH; Cl; GLAST; GLT-I Severity Total (107) 5 P, postnatal day; KA, Kainic acid; Cyt, cytokines (IL-1p; IL6; TNFa, S1OOB); FJB, Fluoro-JadeB; FH, Factor H; Cl, Clusterin; GLAST and GLT-I, Glutamate transporters; Latency, time to seizure onset; Severity, seizure severity following KA. 174 WO 2008/109437 PCT/US2008/055495 Table 7 Suppression of glial activation: summary of experimental groups, and outcome measures Treatment Recovery Endpoints (P15) Group (n) ELISA Immunohistochemistry Behavior PBS (12) Sal 12 hr Cyt KA (9) Sal 12 hr Cyt KA (13) Mzc 12 hr Cyt PBS (10) Sal 30 d GFAP; S1OOB Y maze KA (22) Sal 30 d GFAP; S1OOB Y maze KA (22) Mzc 30 d GFAP; S1OOB Y maze Total (88) 5 P, postnatal day; KA, Kainic acid; Mzc, Minozac; Cyt, cytokines (IL-13; 1L6; TNFa, S1OOB) 10 175 WO 2008/109437 PCT/US2008/055495 References The following are references used by the publication included in Example 1. 1. Giorgi F, Malhotra S, Hasson H, Veliskova J, Rosenbaum D, Mosh6 S. Effects of status epilepticus early in life on susceptibility to ischemic injury in adulthood. 5 Epilepsia 2005; 46:490-498. 2. Koh S, Storey T, Santos T, Mian A, Cole A. Early-life seizures increase susceptibility to seizure-induced brain injury in adulthood. Neurology 1999; 53:915-921. 3. Dube C, Chen K, Eghbal Ahmadi M, Brunson K, Soltesz I, Baram T. Prolonged 10 febrile seizures in the immature rat model enhance hippocampal excitability long term. Ann Neurol 2000; 34:774-780. 4. Schmid R, Tandon P, Stafstrom C, Holmes G. Effects of neonatal seizures on subsequent seizure-induced brain injury. Neurology 1999; 53:1754-1761. 5. French J, Williamson P, Thadani V, et al. Characteristics of medial temporal lobe 15 epilepsy. I. Results of history and physical examination. Ann Neurol 1993; 34:774 780. 6. Haut S, Veliskovi J, Mosh6 S. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol 2004; 3:608-617. 7. 7. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's Disease. 20 Neurobiol Aging 2000; 21:383-421. 8. Mrak R, Griffin W. Glia and cytokines in progression of neurodegeneration. Neurobiol Aging 2005; 26:349-354. 9. Hagberg H, Mallard C. Effect of inflammation on central nervous system development and vulnerability. Curr Opin Neurol 2005; 18:117-123. 25 10. Wainwright M, Craft J, Griffin W, et al. Increased susceptibility of S1OOB transgenic mice to perinatal hypoxia-ischemia. Ann Neurol 2004; 56:61-67. 11. Van Eldik U, Wainwright MS. The Janus face of glial-derived S1OOB: beneficial and detrimental functions in the brain. Restorative Neurol Neurosci 2003; 21:97 108. 30 12. Weiss S, Cataltepe 0, Cole A. Anatomic studies of DNA fragmentation in rat brain after systemic kainic acid administration. Neuroscience 1996; 74:541-551. 176 WO 2008/109437 PCT/US2008/055495 13. Maragakis N, Rothstein J. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 2004; 15:461-473. 14. Huang Y, Bergles D. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 2004; 14:346-352. 5 15. Zhang G, Raol YH, Hsu F, Brooks-Kayal A. Long-term alterations in glutamate receptor and transporter expression following early-life seizures are associated with increased seizure susceptibility. JNeurochem 2004; 88:91-101. 16. Strohmeyer R, Ramirez M, Cole G, Mueller K, Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the 10 Alzheimer's disease brain. JNeuroimmunol 2002; 131:135-146. 17. Han B, DeMattos R, Dugan L, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nature Med 2001; 7:338-343. 18. Dragunow M, Preston K, Dodd J, Young D, Lawlor P, Christie D. Clusterin accumulates in dying neurons following status epilepticus. Mol Brain Res 1995; 15 32:279-290. 19. Hu W, Ralay Ranaivo H, Roy S, et al. Development of a novel therapeutic suppressor of brain pro-inflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorgan Med Chem Lett 2007; 17:414-418. 20 20. Perry V, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; doi: 10.1038/nri2015. 21. Wing L, Behanna H, Van Eldik L, Watterson D, Ralay Ranaivo H. De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res 2006; 3:205-214. 25 22. Rizzi M, Perego C, Aliprandi M, et al. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 2003; 14. 23. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd edition. Sydney: Academic Press, 1986. 30 24. Schmued L, Hopkins K. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000; 874:123-130. 177 WO 2008/109437 PCT/US2008/055495 25. Wainwright M, Kohli R, Whitington P, Chace D. Carnitine treatment inhibits increases in cerebral carnitine esters and glutamate detected by mass spectrometry following hypoxiaischemia in newborn rats. Stroke 2006; 37:524-530. 26. Ralay Ranaivo H, Craft J, Hu W, et al. Glia as a therapeutic target: selective 5 suppression of human amyloid-B-induced up-regulation of brain proinflammatory cytokine production attenuates neurodegeneration. JNeurosci 2006; 26:662-670. 27. Weiss C, Shroff A, Disterhoft J. Spatial learning and memory in aging C57BL/6 mice. Neurosci Res Commun 1998; 23:77-92. 28. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease 10 inflammation. JAlz Dis 2001; 3:131-157. 29. Holmes G. Effects of seizures on brain development: lessons from the laboratory. Pediatr Neurol 2005; 33:1-11. 30. Holmes G, Ben Ari Y. Seizures in the developing brain: perhaps not so benign after all. Neuron 1998; 21:1231-1234. 15 31. Sayin U, Sutula T, Stafstrom C. Seizures in the developing brain cause adverse long-term effects on spatial learning and anxiety. Epilepsia 2004; 45:1539-1548. 32. Letty S, Lerner-Natoli M, Rondouin G. Differential impairments of spatial memory and social behavior in two models of limbic epilepsy. Epilepsia 1995; 36:973-982. 33. Jensen F, Blume H, Alvarado I, Firkusny I, Geary C. NBQX blocks acute and late 20 epileptogenic effects of perinatal hypoxia. Epilepsia 1995; 36:966-972. 34. Sanchez R, Koh S, Rio C, et al. Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia induced seizures. JNeurosci 2001; 21:8154-8163. 35. Cardona A, Pioro E, Sasse M, et al. Control of microglial neurotoxicity by the 25 fractalkine receptor. Nature Neurosci 2006; 9:917-924. 36. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18:315-321. 37. Vezzani A, Granata T. Brain inflammation in epilepsy: Experimental and clinical evidence. Epilepsia 2005; 46:1724-1743. 178 WO 2008/109437 PCT/US2008/055495 38. Craft J, Watterson D, Van Eldik L. Neuroinflammation: a potential therapeutic target in Alzheimer's disease and related disorders. Exp Opin Therap Targets 2005; 9:887-900. 39. Sheng J, Kazuhiro I, Skinner R, et al. In vivo and in vitro evidence supporting a 5 role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996; 17:761-766. 40. Ravizza T, Rizzi M, Perego C, et al. Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 2005; 46:S113-Si17. 41. Vezzani A, Richichi C, Aliprandi M, et al. Functional role of inflammatory 10 cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 2002; 43:S30-S35. 42. Rothermundt M, Peters M, Prehn JH, Arolt V. S1OOB in brain damage and neurodegeneration. Microscopy Research & Technique 2003; 60:614-632. 43. Leviton A, Darnmann 0. Brain damage markers in children. Neurobiological and 15 clinical aspects. Acta Paediatrica 2002; 91:9-13. 44. Craft J, Watterson D, Marks A, Van Eldik L. Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human p-amyloid. GLIA 2005; 51:209-216. 45. Verbitsky M, Yonan A, Malleret G, Kandel E, Giliam T, Pavlidis P. Altered 20 hippocampal transcript profile accompanies an age-related spatial memory deficit in mice. Learining and Memory 2004; 11:253-260. 46. Rao V, Dogan A, Bowen K, Todd K, Dempsey R. Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal damage following traumatic injury to rat brain. Eur J Neurosci 2001; 13:119-128. 25 179

Claims (15)

1. A pharmaceutical composition for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures comprising a pyridazine compound in a therapeutically effective amount for treating the disorder, and a 5 pharmaceutically acceptable carrier, excipient, or vehicle.

2. A pharmaceutical composition according to claim 1 wherein the pyridazine compound comprises a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl.

3. A pharmaceutical composition according to claim 2 wherein the heteroaryl is 10 piperazinyl substituted with pyrimidinyl or pyridinyl.

4. A pharmaceutical composition according to claim 1 wherein the pyridazine compound has the Formula Ta or lb R1 R1 RT3 R 3 R4 R 6 R 4 R 6 R5 R5 Ia or Ib 1 2 3 wherein R , R2, and R are independently hydrogen, hydroxyl, alkyl, alkenyl, 15 alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, 20 carbamoyl, or carboxamide; R 7 is substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, 25 ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, 180 WO 2008/109437 PCT/US2008/055495 carboxyl, carbonyl, carbamoyl, or carboxamide or R may be absent and there is a 4 5 6 double bond between N at position 1 and C at position 6; R , R , and R are 1 2 1 7 independently hydrogen, alkyl, alkoxy, halo, or nitro; or R and R , R and R , or R2 and R 3 may form a heteroaryl or heterocyclic ring; or an isomer or a 5 pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition according to claim 1 wherein the pyridazine compound has the Formula II: R' 0 R 1 1 N II 10 wherein Rio and R 11 are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, phosphonate, cyano, halo, 15 silyl, silyloxy, silylalkyl, silylthio, =0, =S, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition according to claim 1 wherein the pyridazine compound has the Formula III: R 15 R' ... ; N N 181 WO 2008/109437 PCT/US2008/055495 wherein R and R are independently substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, 5 sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 1 wherein the pyridazine 10 compound has the Formula IV: R 7 - N N R ( N IV wherein R 70 is substituted or unsubstituted hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, 15 heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, carboxyl, phosphonate, carbonyl, carbamoyl, or carboxamide, especially heterocyclic, heteroaryl, amino, and substituted amino and R is aryl or substituted aryl; or an isomer or a 20 pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to claim 1 wherein the pyridazine compound has the Formula V: 182 WO 2008/109437 PCT/US2008/055495 N ,'N (N) N R 50 N-'N R 51 Rs52 V 50 51 52 wherein RU, R , and R are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, 5 heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, sulfoxide, sulfate, sulfonate amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof. 10

9. A pharmaceutical composition according to claim 1 wherein the pyridazine compound does not include the compounds depicted in Table 1.

10. A pharmaceutical composition according to claim 1 wherein the pyridazine compound is 2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine dihydrochloride salt. 15

11. A method for treating and/or preventing a disorder characterized by conduction disturbances, electroconvulsions and/or seizures in a subject comprising administering a therapeutically effective amount of a composition according to any preceding claim.

12. A method according to claim 11 wherein the disorder is epilepsy. 20

13. A method according to claim 11 or 12 wherein subject is a pediatric patient. 183 WO 2008/109437 PCT/US2008/055495

14. Use of a composition according to any preceding claim for treating and/or preventing a disorder characterized by conduction disturbances, electroconvulsions and/or seizures.

15. A kit comprising a pyridazine compound or a composition as claimed in any 5 preceding claim for preventing and/or treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, a container, and instructions for its use. 184